Tokushima University / Educator and Researcher Directory --- Muguruma, Naoki

Personal Web Page

https://researchmap.jp/read0088047 (researchmap)

https://orcid.org/0000-0002-4740-4809 (ORCID)

Field of Study

○	Gastroenterology

Subject of Study

○	消化器がんの臨床病理学的研究 (Cancer Biomarker, Endoscopic Molecular Imaging, Hereditary Gastrointestinal Tumors)

Book / Paper

Book:

1.	Tetsuji Takayama, Satoshi Teramae, Kumiko Tanaka and Naoki Muguruma : Cowden症候群/PTEN過誤腫症候群(Ⅱ疾患各論 10)., メディカルドゥ, Osaka, Jan. 2022.
2.	Tetsuji Takayama, Yasushi Sato and Naoki Muguruma : Role of Alcohol and Metabolic Diseases in Colorectal Carcinogenesis., Springer-Verlag, Singapore, 2019.
3.	Koichi Okamoto, Tetsuo Kimura, Naoki Muguruma, Susumu Ito and Tetsuji Takayama : 赤外線蛍光内視鏡を用いた新しい診断法の開発., Technical Information Institute Co., Ltd., Sep. 2017.
4.	Masako Kimura, Naoki Muguruma and Tetsuji Takayama : 大腸憩室疾患., Nakayama-Shoten Co., Ltd., Jul. 2017.
5.	Masako Kimura, Naoki Muguruma and Tetsuji Takayama : 大腸憩室疾患の病態., Nakayama-Shoten Co., Ltd., Jul. 2017.
6.	Naoki Muguruma and Tetsuji Takayama : 家族性大腸腺腫症, 日本医事新報社, May 2017.
7.	藤本大策, Tetsuji Takayama and Naoki Muguruma : SSA/P (sessile serrated adenoma/polyp)3, 日本メディカルセンター, Tokyo, Oct. 2016.
8.	Naoki Muguruma and Tetsuji Takayama : がん診断 6内視鏡診断 A消化器内視鏡検査, Mar. 2015.
9.	Naoki Muguruma and Tetsuji Takayama : 胃・十二指腸潰瘍, Ishiyaku Publishers,Inc., May 2014.
10.	Naoki Muguruma and Tetsuji Takayama : 胃食道逆流症・食道炎, Ishiyaku Publishers,Inc., May 2014.
11.	Naoki Muguruma and Tetsuji Takayama : 天疱瘡, IGAKU-SHOIN Ltd.Tokyo,Japan, May 2014.
12.	森博愛, Ichiro Shimizu, 長瀬教夫, Masahiro Nomura, Akiyoshi Nishikado, 井内新, Susumu Ito, Hirohito Honda, Seisuke Okamura, Tsuneo Ninomiya, Ken Saito, 田村禎通, Yutaka Nakaya, Naoki Muguruma, Toshiaki Hashimoto and 高橋昌江 : メディカルスタッフのための内科学(第4版), 医学出版社, Tokyo, Mar. 2013.
13.	Naoki Muguruma and Tetsuji Takayama : Endoscopic Molecular Imaging in Gastrointestinal Oncology, IntechOpen, Sep. 2011. (Link to Publication Site) ● Publication site (DOI): 10.5772/22100 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.5772/22100 (DOI: 10.5772/22100)
14.	Ichiro Shimizu, Susumu Ito, Hirohito Honda, Seisuke Okamura and Naoki Muguruma : コメディカルのための内科学 (第3版), 医学出版社, Tokyo, Mar. 2006.
15.	Naoki Muguruma, Susumu Ito and 森博愛 : 医学出版社, 2006.
16.	Masahiro Sogabe, Toshiya Okahisa, Koji Tsujigami, Yoshio Okita, Hiroshige Hayashi, Toshikatsu Taniki, Hiroshi Hukuno, Masahiko Nakasono, Naoki Muguruma, Seisuke Okamura and Susumu Ito : Ultrasonographic assesment of gastric motility in diabetic gastroparesis befor and after attaining glycemic control., Springer-Verlag, New York, Feb. 2005.
17.	Ichiro Shimizu, 玉木克佳, Hiroshi Shibata, 浦田真里, 板垣達三, 大塩敦郎, 井本佳孝, Koichi Okamoto, 佐藤康紀, 青木利佳, 福野天, 居和城宏, 村田昌彦, 筒井朱美, Naoki Muguruma, Toshiya Okahisa, Seisuke Okamura, Hirohito Honda and Susumu Ito : 当科におけるラジオ波焼灼療法を用いた肝腫瘍治療, Tokushima Medical Association, Tokushima, 2003. (Tokushima University Institutional Repository) ● Metadata: 36161 (Tokushima University Institutional Repository: 36161)
18.	Toshiya Okahisa, 曽我部正弘, 大喜田義雄, Naoki Muguruma, Seisuke Okamura, Hiroshi Shibata and Susumu Ito : 消化器ポケットマニュアル, 株式会社嵯峨野, Kyoto, 2002.
19.	Naoki Muguruma, Susumu Ito, Hidenori Miyake, 松村敏信 and Seiki Tashiro : 胆嚢癌におけるムチン発現と患者予後に関する検討, The Japanese Society of Gastroenterology, Tokyo, Jan. 2001.
20.	Ichiro Shimizu, Hiroshi Shibata, 筒井朱美, 四宮寛彦, 稲山久美, 中園雅彦, Naoki Muguruma, Toshiya Okahisa, Seisuke Okamura and Susumu Ito : 肝細胞癌に対する経皮的ラジオ波熱焼灼療法(RFA)の検討, 大道学館, Fukuoka, 2001.
21.	加藤寛正, Masahiro Nomura, 越智由恵, Ken Saito, Naoki Muguruma, Toshiya Okahisa, Hiroshi Shibata, Seisuke Okamura, Hirohito Honda, Ichiro Shimizu and Susumu Ito : 慢性消化性潰瘍におけるHelivobactor pylori除菌前後の自律神経活動の検討, 四国消化性潰瘍研究会, 2001.
22.	Ichiro Shimizu, 面家敏宏, Zhou Yajun, 糸永美奈, 豊田敬生, Naoki Muguruma, Hiroshi Shibata, Hirohito Honda and Susumu Ito : 女性ホルモン·エストラジオールの肝発癌抑制作用, メジカルセンス, Tokyo, 2001.
23.	Ichiro Shimizu, 面家敏宏, 劉炎, 日浅亜弥, 豊田敬生, Naoki Muguruma, Hiroshi Shibata, Hirohito Honda, 堀江貴浩 and Susumu Ito : 女性ホルモン·エストラジオールの肝線維化抑制作用, Arcmedium, Tokyo, Oct. 1999.
24.	Ichiro Shimizu, 面家敏宏, 劉炎, 日浅亜弥, 豊田敬生, 多田由恵, Naoki Muguruma, Hiroshi Shibata, Hirohito Honda, Susumu Ito and 庄野正行 : 脂質過酸化反応と肝線維化, Okayama, 1999.
25.	Ichiro Shimizu, Yoshiko Noda, 筒井朱美, 多田津昌也, Naoki Muguruma, 堀江貴浩, Toshiya Okahisa, Hiroshi Shibata, Seisuke Okamura, 西條哲也, Nobuya Sano and Susumu Ito : 良性反復性肝内胆汁うっ滞に胆石を伴わない慢性膵炎を合併した1例, The Japanese Society of Gastroenterology, Tokyo, 1999.
26.	Susumu Ito, Naoki Muguruma and 林重仁 : 赤外線内視鏡を用いた微小癌診断法開発の基礎的検討, 国際医書出版, Tokyo, 1997.

Academic Paper (Judged Full Paper):

1.	Tetsuji Takayama, Naoki Muguruma, Masanori Igarashi, shozo Ohsumi, Shiro Oka, Fumihiko Kakuta, Yoshiaki Kubo, Hideki Kumagai, Mika Sasaki, Tamotsu Sugai, Kokichi Sugao, Yuko Takeda, Hisashi Doyama, Kouji Bannno, Suguru Fukahori, Yoichi Furukawa, Takahiro Horimatsu, Ishikawa Hideki, Takeo Iawama, Yasushi Okazaki, Yutaka Saito, Nariaki Matsuura, Michihiro Mutoh, Naohiro Tomita, Takashi Akiyama, Toshiki Yamamoto, Hideyuki Ishida and Nakayama Yoshiko : Clinical Guidelines for Diagnosis and Management of Cowden Syndrome/PTEN Hamartoma Tumor Syndrome in Children and Adults-Secondary Publication., Journal of the Anus, Rectum and Colon, Vol.7, No.4, 284-300, 2023. (Summary) Cowden syndrome (CS)/ hamartoma tumor syndrome (PHTS) is a rare autosomal dominantly inherited condition caused by germline pathogenesis. It is associated with multiple hamartomatous lesions occurring in various organs and tissues, including the gastrointestinal tract, skin, mucous membranes, breast, thyroid, endometrium, and brain. Macrocephaly or multiple characteristic mucocutaneous lesions commonly develop in individuals in their 20s. This syndrome is occasionally diagnosed in childhood due to the occurrence of multiple gastrointestinal polyps, autism spectrum disorders, and intellectual disability. CS/PHTS can be diagnosed taking the opportunity of multigene panel testing in patients with cancer. Appropriate surveillance for early diagnosis of associated cancers is required because patients have a high risk of cancers including breast, thyroid, colorectal, endometrial, and renal cancers. Under these circumstances, there is growing concern regarding the management of CS/PHTS in Japan, but there are no available practice guidelines. To address this situation, the guideline committee, which included specialists from multiple academic societies, was organized by the Research Group on Rare and Intractable Diseases granted by the Ministry of Health, Labour, and Welfare, Japan. The present clinical guidelines explain the principles in the diagnosis and management of CS/PHTS, together with four clinical questions and the corresponding recommendations, incorporating the concept of the Grading of Recommendations Assessment, Development, and Evaluation system. Herein, we present an English version of the guideline, some of which have been updated, to promote seamless implementation of accurate diagnosis and appropriate management of pediatric, adolescent, and adult patients with CS/PHTS. (Link to Publication Site) ● Publication site (DOI): 10.23922/jarc.2023-028 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37900693 ● CiNii @ National Institute of Informatics (CRID): 1390860852414606720 ● Search Scopus @ Elsevier (PMID): 37900693 ● Search Scopus @ Elsevier (DOI): 10.23922/jarc.2023-028 (DOI: 10.23922/jarc.2023-028, PubMed: 37900693, CiNii: 1390860852414606720)
2.	Daisuke Tsuji, Atsushi Nakayama, RIko Yamamoto, Shuji Nagano, Takashi Taniguchi, Ryota Sato, Sangita Karanjit, Naoki Muguruma, Tetsuji Takayama, Kohji Itoh and Kosuke Namba : 1,3a,6a-Triazapentalene derivatives as photo-induced cytotoxic small fluorescent dyes, Communications Chemistry, Vol.6, No.1, 37, 2023. (Summary) 1,3a,6a-Triazapentalene (TAP) is a compact fluorescent chromophore whose fluorescence properties vary greatly depending on the substituents on the TAP ring. This study investigated the photo-induced cytotoxicities of various TAP derivatives. Among the derivatives, 2-p-nitrophenyl-TAP showed significant cytotoxicity to HeLa cells under UV irradiation but no cytotoxicity without UV. In addition, the photo-induced cytotoxicity of 2-p-nitirophenyl-TAP was found to be cancer cell selective and effective against HeLa cells and HCT 116 cells. Under UV irradiation, 2-p-nitrophenyl-TAP generated reactive oxygen species (ROS) that induced an apoptosis and ferroptosis in cancer cells. Therefore, it was revealed that 2-p-nitrophenyl-TAP is the most compact dye that can generate ROS by photoirradiation. (Tokushima University Institutional Repository) ● Metadata: 118227 (Link to Publication Site) ● Publication site (DOI): 10.1038/s42004-023-00838-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36813913 ● Search Scopus @ Elsevier (PMID): 36813913 ● Search Scopus @ Elsevier (DOI): 10.1038/s42004-023-00838-0 (Tokushima University Institutional Repository: 118227, DOI: 10.1038/s42004-023-00838-0, PubMed: 36813913)
3.	Tetsu Tomonari, Joji Tani, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Akihiro Morishita, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Tsutomu Masaki and Tetsuji Takayama : Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve., Cancer Medicine, Vol.12, No.3, 2646-2657, 2023. (Summary) We analyzed the association between the modified albumin-bilirubin (mALBI) grade and therapeutic efficacy of atezolizumab plus bevacizumab (Atezo+Bev) for the treatment of unresectable hepatocellular carcinoma (u-HCC). In this retrospective observational study, we included 71 u-HCC patients treated with Atezo+Bev between September 2020 and September 2021. Patients were grouped corresponding to the mALBI grade at the start of treatment (mALBI 1+2a or mALBI 2b+3) and analyzed for therapeutic effect and the transition rate to secondary treatment. According to the Response Evaluation Criteria in Solid Tumors, the overall response rate was significantly higher for the mALBI 1+2a group, than for the mALBI 2b+3 group, with 26.2% and 3.4%, respectively. The progression-free survival (PFS) was significantly longer in the mALBI 1+2a group (10.5 months) than in the mALBI 2b+3 group (3.0 months). In the multivariate analysis, an mALBI of 1+2a was found to be an independent factor of PFS. The rate of second-line treatment with multi-targeted agents was also significantly higher in the mALBI 1+2a group. In real-world practice, Atezo+Bev treatment might have higher therapeutic efficacy in u-HCC patients with mALBI 1+2a. (Tokushima University Institutional Repository) ● Metadata: 117987 (Link to Publication Site) ● Publication site (DOI): 10.1002/cam4.5145 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35964253 ● Search Scopus @ Elsevier (PMID): 35964253 ● Search Scopus @ Elsevier (DOI): 10.1002/cam4.5145 (Tokushima University Institutional Repository: 117987, DOI: 10.1002/cam4.5145, PubMed: 35964253)
4.	Hironori Wada, Yasushi Sato, Shota Fujimoto, Koichi Okamoto, Masahiro Bando, Tomoyuki Kawaguchi, Hiroshi Miyamoto, Naoki Muguruma, Katsuhisa Horimoto, Yui Matsuzawa, Michihiro Mutoh and Tetsuji Takayama : Resveratrol inhibits development of colorectal adenoma via suppression of LEF1; comprehensive analysis with connectivity map., Cancer Science, Vol.113, No.12, 4374-4384, 2022. (Summary) Although many chemopreventive studies on colorectal tumors have been reported, no effective and safe preventive agent is currently available. We searched for candidate preventive compounds against colorectal tumor comprehensively from United States Food and Drug Administration (FDA)-approved compounds by using connectivity map (CMAP) analysis coupled with in vitro screening with colorectal adenoma (CRA) patient-derived organoids (PDOs). We generated CRA-specific gene signatures based on the DNA microarray analysis of CRA and normal epithelial specimens, applied them to CMAP analysis with 1309 FDA-approved compounds, and identified 121 candidate compounds that should cancel the gene signatures. We narrowed them down to 15 compounds, and evaluated their inhibitory effects on the growth of CRA-PDOs in vitro. We finally identified resveratrol, one of the polyphenolic phytochemicals, as a compound showing the strongest inhibitory effect on the growth of CRA-PDOs compared with normal epithelial PDOs. When resveratrol was administered to Apc mice at 15 or 30 mg/kg, the number of polyps (adenomas) was significantly reduced in both groups compared with control mice. Similarly, the number of polyps (adenomas) was significantly reduced in azoxymethane-injected rats treated with 10 or 100 mg/resveratrol compared with control rats. Microarray analysis of adenomas from resveratrol-treated rats revealed the highest change (downregulation) in expression of LEF1, a key molecule in the Wnt signaling pathway. Treatment with resveratrol significantly downregulated the Wnt-target gene (MYC) in CRA-PDOs. Our data demonstrated that resveratrol can be the most effective compound for chemoprevention of colorectal tumors, the efficacy of which is mediated through suppression of LEF1 expression in the Wnt signaling pathway. (Keyword) Mice / Rats / Animals / Resveratrol / Adenoma / Colorectal Neoplasms / Wnt Signaling Pathway / Chemoprevention / Lymphoid Enhancer-Binding Factor 1 (Tokushima University Institutional Repository) ● Metadata: 117988 (Link to Publication Site) ● Publication site (DOI): 10.1111/cas.15576 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36082704 ● Search Scopus @ Elsevier (PMID): 36082704 ● Search Scopus @ Elsevier (DOI): 10.1111/cas.15576 (Tokushima University Institutional Repository: 117988, DOI: 10.1111/cas.15576, PubMed: 36082704)
5.	Yasuhiro Mitsui, Mai Yagi, Sho Muraki, Tomomi Matsuura, Yoshimi Bando, Shota Fujimoto, Shinji Kitamura, Koichi Okamoto, Naoki Muguruma, Masataka Sata and Tetsuji Takayama : Pulmonary Tumor Thrombotic Microangiopathy Due to Gastric Cancer Diagnosed Antemortem by a Cytological Examination of Aspirated Pulmonary Artery Blood., Internal Medicine, Vol.61, No.10, 1491-1495, 2022. (Tokushima University Institutional Repository) ● Metadata: 118012 (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.8313-21 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34670901 ● Search Scopus @ Elsevier (PMID): 34670901 ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.8313-21 (Tokushima University Institutional Repository: 118012, DOI: 10.2169/internalmedicine.8313-21, PubMed: 34670901)
6.	Fumika Nakamura, Yasushi Sato, Koichi Okamoto, Yasuteru Fujino, Yasuhiro Mitsui, kaizo kagemoto, Tomoyuki Kawaguchi, Hiroshi Miyamoto, Naoki Muguruma, Tomoko Sonoda, Koichi Tsuneyama and Tetsuji Takayama : Colorectal carcinoma occurring via the adenoma-carcinoma pathway in patients with serrated polyposis syndrome., Journal of Gastroenterology, Vol.57, No.4, 286-299, 2022. (Summary) Although serrated polyposis syndrome (SPS) is associated with an increased colorectal cancer (CRC) risk, the carcinogenic mechanisms remain unknown. We investigated clinicopathological characteristics and genetic abnormalities in colorectal polyps and CRC to elucidate carcinogenic mechanisms in SPS. We retrospectively analyzed clinicopathological features of colorectal polyps in 44 SPS patients, and examined mutations of genes including APC, RAS, BRAF, and TP53, and microsatellite instability (MSI) in CRC tissues. Of the 44 patients, 25 (56%) fulfilled WHO criterion 1, 11 (25%) fulfilled criterion 2, and 8 (18%) fulfilled both. A total of 956 polyps were observed; 642 (67%) hyperplastic polyps (HP), 204 (21%) sessile serrated lesions (SSL), 10 (1%) traditional serrated adenoma (TSA), and 100 (11%) adenomas. The median numbers of polyps (/patient) were 10.5 (IQR 2.75-23) HPs, 4.0 (2.0-6.0) SSLs, 0 (0-0) TSA, and 1 (0-3.3) adenoma. SSL and HP located preferentially in the proximal and distal colon, respectively. Twenty-two CRCs were found in 18 patients. Based on the histological coexistence of SSL/TSA, BRAF mutation and MSI, 5 CRCs (26%) were classified as serrated-neoplasia pathway. Conversely, based on the coexistence of adenoma, APC/RAS and TP53 mutations, 11 CRCs (58%) were classified as adenoma-carcinoma pathway. The remaining three were unclassifiable. Most CRCs through adenoma-carcinoma pathway were located in the left-side colorectum and patients bearing those met criterion 2, characterized by many HP and advanced adenomas. Adenoma was a significant risk factor for CRC. Our results suggest that more than half of the CRCs, particularly those in the left-side colorectum, developed through the adenoma-carcinoma pathway in SPS patients. Adenoma was a risk factor for CRCs, suggesting its importance in colorectal carcinogenesis. (Keyword) Adenoma / Carcinoma / Colonic Polyps / Colorectal Neoplasms / Humans / Intestinal Polyposis / Microsatellite Instability / Mutation / Proto-Oncogene Proteins B-raf / Retrospective Studies (Tokushima University Institutional Repository) ● Metadata: 117614 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00535-022-01858-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35194694 ● Search Scopus @ Elsevier (PMID): 35194694 ● Search Scopus @ Elsevier (DOI): 10.1007/s00535-022-01858-8 (Tokushima University Institutional Repository: 117614, DOI: 10.1007/s00535-022-01858-8, PubMed: 35194694)
7.	Noriaki Murayama, Koichi Okamoto, Tadahiko Nakagawa, Jinsei Miyoshi, Kensei Nishida, Tomoyuki Kawaguchi, kaizo kagemoto, Shinji Kitamura, Beibei Ma, Hiroshi Miyamoto, Naoki Muguruma, Mitsuyasu Yano, Koichi Tsuneyama, Takahiro Fujimori, Yasushi Sato and Tetsuji Takayama : miR-144-3p/miR-451a promotes lymphovascular invasion through repression of PTEN/p19 in rectal neuroendocrine tumors., Journal of Gastroenterology and Hepatology, Vol.37, No.5, 919-927, 2022. (Summary) Although rectal neuroendocrine tumor (NET-G1) have potential metastatic capability, even among small tumors, no predictive biomarker for invasion and metastasis has been reported. We analyzed microRNA (miRNA) expression profiles in rectal NET-G1 tissues with and without lymphovascular invasion (LVI). Moreover, we then investigated their target genes to clarify the mechanism of invasion/metastasis in NET-G1. miRNA array analysis was performed using seven rectal NET-G1 tissues with LVI and seven without LVI. miRNA expression was confirmed by quantitative real-time PCR. A NET cell line H727 was transfected with miRNA mimic or target gene small interfering RNA, and migration and invasion assays were performed. The expression levels of miR-144-3p and miR-451a were significantly higher in NET-G1 with LVI versus without LVI, as determined by miRNA array analysis and RT-qPCR. A significant correlation was observed between miR-144-3p and miR-451a expression levels, strongly suggesting miR144/451 cluster overexpression in NET-G1 with LVI. Bioinformatic analysis of target genes revealed that miR-144-3p and miR-451a directly interact with PTEN and p19 mRNA, respectively. Immunohistochemistry revealed significantly lower expression of PTEN and p19 in NET-G1 tissues with LVI than in those without LVI. The miR-144-3p and miR-451a mimic significantly increased cell migration/invasion capability, respectively. Knockdown of PTEN and p19 induced significant augmentation of cell invasion and migration capability, respectively. Our data suggest that overexpression of miR-144/miR-451 cluster promotes LVI via repression of PTEN and p19 in rectal NET-G1 cells. miR-144/451 cluster may be a novel biomarker for predicting invasion/metastasis in rectal NET-G1. (Keyword) Biomarkers / Cell Line, Tumor / Cell Movement / Cell Proliferation / Gene Expression Regulation, Neoplastic / Humans / MicroRNAs / Neuroendocrine Tumors / PTEN Phosphohydrolase / Rectal Neoplasms (Tokushima University Institutional Repository) ● Metadata: 117699 (Link to Publication Site) ● Publication site (DOI): 10.1111/jgh.15833 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35332577 ● Search Scopus @ Elsevier (PMID): 35332577 ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.15833 (Tokushima University Institutional Repository: 117699, DOI: 10.1111/jgh.15833, PubMed: 35332577)
8.	Satoshi Teramae, Naoki Muguruma, Koichi Okamoto, Kumiko Oseto, Ryutaro Nishikawa, Takayuki Tanoue, Keiji Hirata, Shunichi Yanai, Takayuki Matsumoto, Seiji Shimizu, Jun Miwa, Yu Sakaki, Kazuo Yashima, Hiroyuki Ohnuma, Yasushi Sato, Yoshitaka Kitayama, Yoshio Ohda, Atsushi Yamauchi, Yoji Sanomura, Kumiko Tanaka, Yoshiaki Kubo, Hideki Ishikawa, Yoshimi Bando, TOmoko Sonoda and Tetsuji Takayama : Cancer risk and genotype-phenotype correlation in Japanese patients with Cowden syndrome., International Journal of Clinical Oncology, Vol.27, No.4, 639-647, 2022. (Summary) Cowden syndrome (CS) is an autosomal-dominant hereditary disorder caused by a germline PTEN variant and characterized by multiple hamartomas and a high risk of cancers. However, no detailed data on CS in Asian patients nor genotype-phenotype correlation have been reported. We performed the first Japanese nationwide questionnaire survey on CS and obtained questionnaire response data on 49 CS patients. Patients included 26 females (median age 48 years). The incidence of breast, thyroid, endometrium, and colorectal cancer was 32.7%, 12.2%, 19.2% (among females), and 6.1%, respectively. The incidence of any cancers was relatively high among all patients (46.9%, 23/49), and particularly female patients (73.1%, 19/26), compared with previous reports from Western countries. Gastrointestinal (GI) polyps were more frequently found throughout the GI tract compared with previous studies. PTEN variants were detected in 95.6% (22/23) of patients; 12 in the N-terminal region (11 in phosphatase domain) and 10 in the C-terminal (C2 domain) region. The incidence of cancer in the C2 domain group was significantly higher than in the N-terminal region (phosphatase) group. All female patients with C2 domain variant had breast cancer. Our data suggest that Japanese patients with CS, particularly female patients and patients with C2 domain variant may have a high risk of cancers. (Keyword) Breast Neoplasms / Female / Genetic Association Studies / Hamartoma Syndrome, Multiple / Humans / Intestinal Polyps / Japan / Male / Middle Aged / PTEN Phosphohydrolase / Risk (Tokushima University Institutional Repository) ● Metadata: 117152 (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-022-02116-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35106660 ● Search Scopus @ Elsevier (PMID): 35106660 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-022-02116-w (Tokushima University Institutional Repository: 117152, DOI: 10.1007/s10147-022-02116-w, PubMed: 35106660)
9.	Kumiko Tanaka, Yasushi Sato, Hideki Ishikawa, Naoki Muguruma, Satoshi Teramae, Yoji Takeuchi, Yasuhiro Mitsui, Koichi Okamoto, Hiroshi Miyamoto, Yoshimi Bando, Tomoko Sonoda, Naoki Omiya, Michihiro Mutoh and Tetsuji Takayama : Small Intestinal Involvement and Genotype-Phenotype Correlation in Familial Adenomatous Polyposis., Techniques and Innovations in Gastrointestinal Endoscopy, Vol.24, No.1, 26-34, 2022. (Tokushima University Institutional Repository) ● Metadata: 116979 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.tige.2021.10.001 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1360861291391377024 ● Summary page in Scopus @ Elsevier: 2-s2.0-85119353922 (Tokushima University Institutional Repository: 116979, DOI: 10.1016/j.tige.2021.10.001, CiNii: 1360861291391377024, Elsevier: Scopus)
10.	Tetsu Tomonari, Yasushi Sato, Hironori Tanaka, Takeshi Mitsuhashi, Akihiro Hirao, Takahiro Tanaka, Tatsuya Taniguchi, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma., JGH Open, Vol.5, No.11, 1275-1283, 2021. (Tokushima University Institutional Repository) ● Metadata: 116741 (Link to Publication Site) ● Publication site (DOI): 10.1002/jgh3.12663 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1002/jgh3.12663 (Tokushima University Institutional Repository: 116741, DOI: 10.1002/jgh3.12663)
11.	Masanori Takehara, Hiroshi Miyamoto, Yasuteru Fujino, Tetsu Tomonari, Tatsuya Taniguchi, Shinji Kitamura, Koichi Okamoto, Masahiro Sogabe, Yasushi Sato, Naoki Muguruma, Yoshimi Bando and Tetsuji Takayama : Long-Term Survival due to Chemotherapy including Paclitaxel in a Patient with Metastatic Primary Splenic Angiosarcoma., Case Reports in Gastroenterology, Vol.15, No.3, 910-918, 2021. (Summary) A primary splenic angiosarcoma is a rare type of soft tissue sarcoma and is associated with an extremely poor prognosis. In this study, we describe the case of a patient who was diagnosed with metastatic primary splenic angiosarcoma and survived for about 2 years. A 62-year-old female was referred to us for the treatment of splenic angiosarcoma with disseminated intravascular coagulation (DIC) and multiple liver and bone metastases. Paclitaxel therapy resulted in recovery from DIC and enabled her to continue sequential treatment through to sixth-line chemotherapy. We reviewed all splenic angiosarcoma case reports which were described as stage IV to date and compared with our case. From these data, we found that the median overall survival was 105 days, and the prognosis of splenic angiosarcoma of stage IV was worse than conventional case series. Splenectomy was performed in more patients than chemotherapy as a treatment. Moreover, various chemotherapeutic regimens were used. These data suggest that administering chemotherapy including paclitaxel to patients with splenic angiosarcoma might improve their prognosis. (Tokushima University Institutional Repository) ● Metadata: 116721 (Link to Publication Site) ● Publication site (DOI): 10.1159/000519211 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34720843 ● Summary page in Scopus @ Elsevier: 2-s2.0-85117511057 (Tokushima University Institutional Repository: 116721, DOI: 10.1159/000519211, PubMed: 34720843, Elsevier: Scopus)
12.	Akihiro Hirao, Yasushi Sato, Hironori Tanaka, Kensei Nishida, Tetsu Tomonari, Misato Hirata, Masahiro Bando, Yoshifumi Kida, Takahiro Tanaka, Tomoyuki Kawaguchi, Hironori Wada, Tatsuya Taniguchi, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Toshihito Tanahashi and Tetsuji Takayama : MiR-125b-5p is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma., Cancers, Vol.13, No.19, 4917, 2021. (Summary) The mechanism of resistance to sorafenib in hepatocellular carcinoma (HCC) remains unclear. We analyzed miRNA expression profiles in sorafenib-resistant HCC cell lines (PLC/PRF5-R1/R2) and parental cell lines (PLC/PRF5) to identify the miRNAs responsible for resistance. Drug sensitivity, migration/invasion capabilities, and epithelial-mesenchymal transition (EMT) properties were analyzed by biochemical methods. The clinical relevance of the target genes to survival in HCC patients were assessed using a public database. Four miRNAs were significantly upregulated in PLC/PRF5-R1/-R2 compared with PLC/PRF5. Among them, miR-125b-5p mimic-transfected PLC/PRF5 cells (PLC/PRF5-miR125b) and showed a significantly higher IC50 for sorafenib compared with controls, while the other miRNA mimics did not. PLC/PRF5-miR125b showed lower E-cadherin and higher Snail and vimentin expression-findings similar to those for PLC/PRF5-R2-which suggests the induction of EMT in those cells. PLC/PRF5-miR125b exhibited significantly higher migration and invasion capabilities and induced sorafenib resistance in an in vivo mouse model. Bioinformatic analysis revealed ataxin-1 as a target gene of miR-125b-5p. PLC/PRF5 cells transfected with ataxin-1 siRNA showed a significantly higher IC50, higher migration/invasion capability, higher cancer stem cell population, and an EMT phenotype. Median overall survival in the low-ataxin-1 patient group was significantly shorter than in the high-ataxin-1 group. In conclusion, miR-125b-5p suppressed ataxin-1 and consequently induced Snail-mediated EMT and stemness, leading to a poor prognosis in HCC patients. (Tokushima University Institutional Repository) ● Metadata: 116647 (Link to Publication Site) ● Publication site (DOI): 10.3390/cancers13194917 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34638401 ● Search Scopus @ Elsevier (PMID): 34638401 ● Search Scopus @ Elsevier (DOI): 10.3390/cancers13194917 (Tokushima University Institutional Repository: 116647, DOI: 10.3390/cancers13194917, PubMed: 34638401)
13.	Shinji Kitamura, Naoki Muguruma, Koichi Okamoto, Kaizo Kagemoto, Yoshifumi Kida, Yasuhiro Mitsui, Hiroyuki Ueda, Tomoyuki Kawaguchi, Hiroshi Miyamoto, Yasushi Sato, Rika Aoki, Joji Shunto, Yoshimi Bando and Tetsuji Takayama : Clinicopathological characteristics of early gastric cancer associated with autoimmune gastritis., JGH Open, Vol.5, No.10, 1210-1215, 2021. (Tokushima University Institutional Repository) ● Metadata: 116931 (Link to Publication Site) ● Publication site (DOI): 10.1002/jgh3.12656 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34622010 ● Summary page in Scopus @ Elsevier: 2-s2.0-85114915216 (Tokushima University Institutional Repository: 116931, DOI: 10.1002/jgh3.12656, PubMed: 34622010, Elsevier: Scopus)
14.	Tetsu Tomonari, Yasushi Sato, Joji Tani, Akira Hirose, Chikara Ogawa, Akihiro Morishita, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Kazushige Uchida, Tsutomu Masaki and Tetsuji Takayama : Comparison of therapeutic outcomes of Sorafenib and Lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular-targeted agent sequential therapy: A propensity score-matched analysis., Hepatology Research, Vol.51, No.4, 472-481, 2021. (Summary) The optimal choice between sorafenib (SOR) or lenvatinib (LEN) as the first-line treatment for unresectable hepatocellular carcinoma (u-HCC) remains debatable. Using propensity score matching, this study compares the outcomes of SOR and LEN in the molecular-targeted agent (MTA) sequential treatment of u-HCC patients. This retrospective, multicenter, observational study recruited 137 u-HCC patients who underwent primary treatment with LEN (n = 52) or SOR (n = 85) between June 2017 and June 2020 after regorafenib was approved as the secondary treatment for u-HCC. Propensity score matching was used to reduce confounding, resulting in the selection of 104 patients (n = 52 for the SOR and LEN cohorts). The median overall survival was 21.8 months for LEN and 20.4 months for SOR. LEN exhibited significantly greater therapeutic efficacy as compared to SOR (objective response rate: 3.8% [SOR] vs. 42.3% [LEN], P <0.01; progression-free survival: 10 months [LEN] vs. 5.1 months [SOR], P <0.01). No significant intergroup differences were noted in the rate of transition to secondary MTA treatments (SOR: 58.7%; LEN: 48.4%), adverse events (SOR: 86%; LEN: 95%), and maintenance of the Child-Pugh (CP) score during treatment. Compared to non-MTA treatments, secondary MTA treatment achieved a greater improvement in survival ( 4.3 months vs. 2.8 months, P=0.0047). Multivariate analysis demonstrated that the CP score (P <0.01) and alpha-fetoprotein level (P <0.01) were independent prognostic factors. Both SOR and LEN treatments showed a clinically comparable therapeutic efficacy as the first-line treatments for u-HCC patients in an MTA sequential therapy. (Link to Publication Site) ● Publication site (DOI): 10.1111/hepr.13597 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33238074 ● Search Scopus @ Elsevier (PMID): 33238074 ● Search Scopus @ Elsevier (DOI): 10.1111/hepr.13597 (DOI: 10.1111/hepr.13597, PubMed: 33238074)
15.	Hironori Tanaka, Yoshihito Saijyo, Tetsu Tomonari, Takahiro Tanaka, Tatsuya Taniguchi, Shusuke Yagi, Koichi Okamoto, Hiroshi Miyamoto, Masahiro Sogabe, Yasushi Sato, Naoki Muguruma, Koichi Tsuneyama, Masataka Sata and Tetsuji Takayama : An Adult Case of Congenital Extrahepatic Portosystemic Shunt Successfully Treated with Balloon-occluded Retrograde Transvenous Obliteration, Internal Medicine, Vol.60, No.12, 1839-1845, 2021. (Summary) A 42-year-old woman visited our hospital due to syncope. Contrast-enhanced CT revealed portosystemic shunt, portal vein hypoplasia, and multiple liver nodules. The histological examination of a liver biopsy specimen exhibited portal vein hypoplasia and revealed that the liver tumor was positive for glutamine synthetase. The patient was therefore diagnosed with congenital extrahepatic portosystemic shunt type II, and with focal nodular hyperplasia (FNH)-like nodules. She had the complication of severe portopulmonary hypertension and underwent complete shunt closure by balloon-occluded retrograde transvenous obliteration (B-RTO). The intrahepatic portal vein was well developed at 1 year after B-RTO, and multiple liver nodules completely regressed. Her pulmonary hypertension also improved. (Tokushima University Institutional Repository) ● Metadata: 116336 (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.5914-20 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33456037 ● Search Scopus @ Elsevier (PMID): 33456037 ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.5914-20 (Tokushima University Institutional Repository: 116336, DOI: 10.2169/internalmedicine.5914-20, PubMed: 33456037)
16.	Sayo Takahashi, Koichi Okamoto, Toshihito Tanahashi, Shota Fujimoto, Tadahiko Nakagawa, Masahiro Bando, beibei ma, Tomoyuki Kawaguchi, Yasuteru Fujino, Yasuhiro Mitsui, Shinji Kitamura, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma, Yoshimi Bando, Toshiro Sato, Takahiro Fujimori and Tetsuji Takayama : S100P expression via DNA hypomethylation promotes cell growth in the sessile serrated adenoma/polyp-cancer sequence., Digestion, Vol.102, No.5, 789-802, 2021. (Summary) Sessile serrated adenomas/polyps (SSA/Ps) are a putative precursor lesion of colon cancer. Although the relevance of DNA hypermethylation in the SSA/P-cancer sequence is well documented, the role of DNA hypomethylation is unknown. We investigated the biological relevance of DNA hypomethylation in the SSA/P-cancer sequence by using 3-dimensional organoids of SSA/P. We first analyzed hypomethylated genes using datasets from our previous DNA methylation array analysis on 7 SSA/P and 2 cancer in SSA/P specimens. Expression levels of hypomethylated genes in SSA/P specimens were determined by RT-PCR and immunohistochemistry. We established 3-dimensional SSA/P organoids and performed knockdown experiments using a lentiviral shRNA vector. DNA hypomethylation at CpG sites of the gene was quantitated by MassARRAY analysis. The mean number of hypomethylated genes in SSA/P and cancer in SSA/P was 41.6 ± 27.5 and 214 ± 19.8, respectively, showing a stepwise increment in hypomethylation during the SSA/P-cancer sequence. S100P, S100α2, PKP3, and MUC2 were most commonly hypomethylated in SSA/P specimens. The mRNA and protein expression levels of S100P, S100α2, and MUC2 were significantly elevated in SSA/P compared with normal colon tissues, as revealed by RT-PCR and immunohistochemistry, respectively. Among these, mRNA and protein levels were highest for S100P. Knockdown of the S100P gene using a lentiviral shRNA vector in 3-dimensional SSA/P organoids inhibited cell growth by >50% (p < 0.01). The mean diameter of SSA/P organoids with S100P gene knockdown was significantly smaller compared with control organoids. MassARRAY analysis of DNA hypomethylation in the S100P gene revealed significant hypomethylation at specific CpG sites in intron 1, exon 1, and the 5'-flanking promoter region. These results suggest that DNA hypomethylation, including S100P hypomethylation, is supposedly associated with the SSA/P-cancer sequence. S100P overexpression via DNA hypomethylation plays an important role in promoting cell growth in the SSA/P-cancer sequence. (Tokushima University Institutional Repository) ● Metadata: 115966 (Link to Publication Site) ● Publication site (DOI): 10.1159/000512575 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33395688 ● Summary page in Scopus @ Elsevier: 2-s2.0-85099095900 (Tokushima University Institutional Repository: 115966, DOI: 10.1159/000512575, PubMed: 33395688, Elsevier: Scopus)
17.	Tomoyuki Kawaguchi, Koichi Okamoto, Shota Fujimoto, Masahiro Bando, Hironori Wada, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma, Katsuhisa Horiimoito and Tetsuji Takayama : Lansoprazole Inhibits the Development of Sessile Serrated Lesions by Inducing G1 Arrest via Skp2/p27 Signaling Pathway., Journal of Gastroenterology, Vol.59, No.1, 11-23, 2021. (Summary) Although the serrated-neoplasia pathway reportedly accounts for 15-30% of colorectal cancer (CRC), no studies on chemoprevention of sessile serrated lesions (SSLs) have been reported. We searched for effective compounds comprehensively from a large series of compounds by employing Connectivity Map (CMAP) analysis of SSL-specific gene expression profiles coupled with in vitro screening using SSL patient-derived organoids (PDOs), and validated their efficacy using a xenograft mouse model of SSL. We generated SSL-specific gene signatures based on DNA microarray data, and applied them to CMAP analysis with 1309 FDA-approved compounds to select candidate compounds. We evaluated their inhibitory effects on SSL-PDOs using a cell viability assay. SSL-PDOs were orthotopically transplanted into NOG mice for in vivo evaluation. The signal transduction pathway was evaluated by gene expression profile and protein expression analysis. We identified 221 compounds by employing CMAP analysis of SSL-specific signatures, which should cancel the gene signatures, and narrowed them down to 17 compounds. Cell viability assay using SSL-PDOs identified lansoprazole as having the lowest IC50 value (47 µM) among 17 compounds. When SSL-PDO was orthotopically transplanted into murine intestinal tract, the tumor grew gradually. Administration of lansoprazole to mice inhibited the growth of SSL xenograft whereas the tumor in control mice treated with vehicle alone grew gradually over time. The Ki67 index in xenograft lesions from the lansoprazole group was significantly lower compared with the control group. Cell cycle analysis of SSL-PDOs treated with lansoprazole exhibited a significant increase in G1 phase cell population. Microarray and protein analysis revealed that lansoprazole downregulated Skp2 expression and upregulated p27 expression in SSL-PDOs. Our data strongly suggest that lansoprazole is the most effective chemopreventive agent against SSL, and that lansoprazole induces G1 cell cycle arrest by downregulating Skp2 and upregulating p27 in SSL cells. (Tokushima University Institutional Repository) ● Metadata: 119258 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00535-023-02052-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37989907 ● Search Scopus @ Elsevier (PMID): 37989907 ● Search Scopus @ Elsevier (DOI): 10.1007/s00535-023-02052-0 (Tokushima University Institutional Repository: 119258, DOI: 10.1007/s00535-023-02052-0, PubMed: 37989907)
18.	Tamotsu Sagawa, Yasushi Sato, Masahiro Hirakawa, Kyoko Hamaguchi, Akira Fukuya, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Koshi Fujikawa, Yasuo Takahashi and Tetsuji Takayama : Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab., Scientific Reports, Vol.10, No.1, 19815, 2020. (Summary) The primary tumour location is an important prognostic factor for previously untreated metastatic colorectal cancer (mCRC). However, the predictive efficacies of primary tumour location, early tumour shrinkage (ETS), and depth of response (DpR) on mCRC treatment has not been fully evaluated. This study aimed to investigate the predictive efficacies of these traits in mCRC patients treated with first-line 5-fluorouracil-based chemotherapy plus biologic agents, namely, cetuximab and bevacizumab. This was a retrospective analysis of the medical records of 110 patients with pathology-documented unresectable mCRC. Patients with left-sided mCRC receiving any first-line regimen showed better overall survival (OS) than those with right-sided mCRC [33.3 vs 16.3 months; hazard ratio (HR) 0.44; 95% confidence interval (CI) 0.27-0.74; p < 0.001]. In patients with left-sided tumours, treatment with chemotherapy plus cetuximab yielded longer OS than chemotherapy plus bevacizumab (50.6 vs 27.8 months, HR 0.55; 95% CI 0.32-0.97; p = 0.0378). mCRC patients with ETS and high DpR showed better OS than those lacking ETS and with low DpR (33.5 vs 19.6 months, HR 0.50, 95% CI 0.32-0.79, p = 0.023 and 38.3 vs 19.0 months, HR 0.43, 95% CI 0.28-0.68, p < 0.001, respectively). Moreover, ETS and/or high DpR achieved in patients with right-sided mCRC receiving chemotherapy plus cetuximab were associated with significantly better OS than in those lacking ETS and with low DpR (34.3 vs 10.4 months, HR 0.19, 95% CI 0.04-0.94, p = 0.025 and 34.3 vs 10.4 months, HR 0.19, 95% CI 0.04-0.94, p = 0.0257, respectively). Taken together, our study demonstrates that primary tumour location is not only a well-known prognostic factor but also a relevant predictive factor in patients with mCRC receiving chemotherapy plus cetuximab. Additionally, both ETS and DpR could predict treatment outcomes and also potentially guide cetuximab treatment even in right-sided mCRCs. (Tokushima University Institutional Repository) ● Metadata: 115620 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-020-76756-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33188279 ● Summary page in Scopus @ Elsevier: 2-s2.0-85095953611 (Tokushima University Institutional Repository: 115620, DOI: 10.1038/s41598-020-76756-1, PubMed: 33188279, Elsevier: Scopus)
19.	Jun Okazaki, Toshihito Tanahashi, Yasushi Sato, Jinsei Miyoshi, Tadahiko Nakagawa, Tetsuo Kimura, Hiroshi Miyamoto, Yasuteru Fujino, Fumika Nakamura, Masanori Takehara, beibei ma, Masahiro Bando, Shinji Kitamura, Koichi Okamoto, Naoki Muguruma, Masahiro Sogabe and Tetsuji Takayama : MicroRNA-296-5p Promotes Cell Invasion and Drug Resistance by Targeting Bcl2-Related Ovarian Killer, Leading to a Poor Prognosis in Pancreatic Cancer., Digestion, Vol.101, No.6, 794-806, 2020. (Summary) Pancreatic ductal adenocarcinoma (PDAC) is characterized by aggressive invasion, early metastasis, and resistance to chemotherapy, leading to a poor prognosis. To clarify the molecular mechanism of these malignant characteristics, we performed a genome-wide microRNA (miRNA) array analysis utilizing micro-cancer tissues from patients with unresectable PDAC (stage IV), obtained by endoscopic ultrasound-fine needle aspiration (EUS-FNA). The expression profiles of 2,042 miRNAs were determined using micro-cancer tissues from 13 patients with unresectable PDAC obtained by EUS-FNA. The relationship between individual miRNA levels and overall survival (OS) was analyzed. Possible target genes for miRNAs were bioinformatically analyzed using the online database miRDB. Pancreatic cancer cell lines PANC-1, MIA PaCa-2, and PK-8 were transfected with miRNA mimic or small interfering RNA, and cell invasion, epithelial-mesenchymal transition (EMT), and apoptosis markers were examined. miRNA and mRNA expressions were examined by quantitative polymerase chain reaction. Of 2,042 miRNAs, the 10 that exhibited the lowest correlation coefficient (p 0.005) between miRNA expression level and OS among the patients were identified. The miRDB and expression analysis in cancer cell lines for the 10 miRNAs identified miR-296-5p and miR-1207-5p as biomarkers predictive of shorter survival (p < 0.0005). Bioinformative target gene analysis and transfection experiments with miRNA mimics showed that Bcl2-related ovarian killer (BOK), a pro-apoptotic gene, is a target for miR296-5p in pancreatic cancer cells; transfection of miR-296-5p mimic into PANC-1, MIA PaCa-2, and PK-8 cells resulted in significant suppression of BOK mRNA and protein expression. These transfectants showed significantly higher invasion capability compared with control cells, and knock down of BOK in pancreatic cancer cells similarly enhanced invasion capability. Transfectants of miR-296-5p mimic also exhibited aberrant expression of EMT markers, including vimentin and N-cadherin. Moreover, these transfectants showed a significantly lower apoptosis rate in response to 5-fluorouracil and gemcitabine with a decrease of BOK expression, suggesting a role of miR-296-5p in drug resistance. These results suggest that miR-296-5p is a useful biomarker for a poor prognosis in patients with PDAC, and that the miR-296-5p/BOK signaling axis plays an important role in cell invasion, drug resistance, and EMT in PDACs. (Tokushima University Institutional Repository) ● Metadata: 114153 (Link to Publication Site) ● Publication site (DOI): 10.1159/000503225 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31563901 ● Summary page in Scopus @ Elsevier: 2-s2.0-85072925180 (Tokushima University Institutional Repository: 114153, DOI: 10.1159/000503225, PubMed: 31563901, Elsevier: Scopus)
20.	Shota Fuimoto, Naoki Muguruma, Michiyasu Nakao, Hidenori ANDO, Takanori Kashihara, Yoshihiko Miyamoto, Koichi Okamoto, Shigeki Sano, Tatsuhiro Ishida, Yasushi Sato and Tetsuji Takayama : Indocyanine green-labeled dasatinib as a new fluorescent probe for molecular imaging of gastrointestinal stromal tumors., Journal of Gastroenterology and Hepatology, Vol.36, No.5, 1253-1262, 2020. (Summary) It is difficult to differentiate gastrointestinal stromal tumors (GISTs) from other subepithelial lesions under gastrointestinal endoscopy. Because most GISTs express tyrosine kinase receptor c-KIT, fluorescence-labeled c-KIT-specific tyrosine kinase inhibitors seem to be useful agents for molecular imaging of GIST. We aimed to develop a near-infrared fluorescent imaging technology for GIST targeting c-KIT using the novel fluorescent probe indocyanine green-labeled dasatinib (ICG-dasatinib) and to investigate the antitumor effect of ICG-dasatinib on GIST cells. Indocyanine green-labeled dasatinib was synthesized by labeling linker-induced dasatinib with ICG derivative 3-indocyanine-green-acyl-1,3-thiazolidine-2-thione. Human GIST cell lines GIST-T1 and GIST-882M were incubated with ICG-dasatinib and observed by fluorescent microscopy. GIST cells were incubated with ICG-dasatinib, unlabeled dasatinib, or imatinib, and cell viabilities were evaluated. Subcutaneous GIST model mice or orthotopic GIST model rats were intravenously injected with ICG-dasatinib and observed using an IVIS Spectrum. Strong fluorescent signals of ICG-dasatinib were observed in both GIST cell lines in vitro. IC50 values for ICG-dasatinib, unlabeled dasatinib, and imatinib were 13.9, 1.17, and 16.2 nM in GIST-T1 and 26.6, 3.63, and 47.6 nM in GIST-882M cells, respectively. ICG-dasatinib accumulated in subcutaneous xenografts in mice. Fluorescent signals were also observed in liver and gallbladder, indicating biliary excretion; however, fluorescence intensity of tumors was significantly higher than that of intestine after washing. Strong fluorescent signals were observed in orthotopic xenografts through the covering normal mucosa in rats. Indocyanine green-labeled dasatinib could visualize GIST cells and xenografted tumors. The antitumor effect of ICG-dasatinib was preserved to the same degree as imatinib. (Link to Publication Site) ● Publication site (DOI): 10.1111/jgh.15281 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32989784 ● Search Scopus @ Elsevier (PMID): 32989784 ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.15281 (DOI: 10.1111/jgh.15281, PubMed: 32989784)
21.	Tetsu Tomonari, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Masahiro Sogabe, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Yu Saitou, Satoru Imura, Yoshimi Bando, Mitsuo Shimada and Tetsuji Takayama : Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib Three case reports., Medicine, Vol.99, No.42, e22782, 2020. (Summary) Lenvatinib (LEN) is a novel potent multi-tyrosine kinase inhibitor, approved as first-line treatment for unresectable hepatocellular carcinoma (HCC). Considering its high objective response rate, LEN therapy could be expected to achieve downstaging of tumors and lead to conversion therapy with hepatectomy or ablation. However, the feasibility of conversion therapy after LEN treatment in unresectable HCC remains largely unknown. Here, we reported 3 cases of unresectable HCC: case 1, a 69-year-old man diagnosed with ruptured HCC; case 2, a 72-year-old woman with nonalcoholic steatohepatitis-based HCC; and case 3, a 73-year-old man with a history of alcoholic cirrhosis-based HCC. In all cases, cirrhosis was classified as Child-Pugh 5 and modified albumin-bilirubin grade 1 or 2a. HCC was diagnosed as Barcelona Clinic Liver Cancer (BCLC) stage B. In all cases, LEN was initiated after conventional-transcatheter arterial embolization enforcement, while maintaining liver function. In all cases, the main tumor size decreased after 6 months of LEN treatment and no satellite nodes were detected, indicating downstaging of HCC to BCLC stage A. Subsequently, conversion hepatectomy or ablation was performed. After successful conversion therapy, the general condition of the patients was good, without tumor recurrence during the observation period (median 10 months). This study demonstrated that LEN enables downstaging of HCC and thus represents a bridge to successful surgery or ablation therapy. In particular, LEN treatment may facilitate the possibility for conversion therapy of initially unresectable HCC, while maintaining the hepatic functional reserve. (Keyword) Ablation Techniques / Aged / Biomarkers / Carcinoma, Hepatocellular / Female / Hepatectomy / Humans / Liver Neoplasms / Male / Phenylurea Compounds / Protein Kinase Inhibitors / Quinolines / alpha-Fetoproteins (Tokushima University Institutional Repository) ● Metadata: 116240 (Link to Publication Site) ● Publication site (DOI): 10.1097/MD.0000000000022782 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33080748 ● Search Scopus @ Elsevier (PMID): 33080748 ● Search Scopus @ Elsevier (DOI): 10.1097/MD.0000000000022782 (Tokushima University Institutional Repository: 116240, DOI: 10.1097/MD.0000000000022782, PubMed: 33080748)
22.	藤井祥平, Fumika Nakamura, Yasushi Sato, 岸和弘, Sumiko Yoshida, Yasuhiro Mitsui, Yasuteru Fujino, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : 胃癌における免疫チェックポイント阻害薬の効果と免疫関連副作用(irAE) との関連性についての検討, Shikoku Acta Medica, Vol.76, No.3-4, 173-178, 2020. (Summary) Recently, immune checkpoint inhibitors(ICI)have been approved for use in advanced gastric cancer(AGC)based on the positive results of ATTRACTION‐2 trial in Japan. There has been accumulating evidence that the development of immune-related adverse events(irAE)may be associated with a response to ICI therapy, particularly in lung cancer, although little is known about these correlations in gastrointestinal cancer. To investigate the efficacy and irAE of ICI treatment and their correlation in AGC, we retrospectively examined 29 patients with AGC who received nivolumab therapy in our departments. Among them, 15 patients(52%)developed irAEs including 4 patients(14%)for grade 3 irAEs ; liver dysfunction(n＝2), type 1 diabetes mellitus(n＝2) and adrenal insufficiency(n＝1). The median overall survival was12．0months in the irAE group and 3．25 months in the non-irAE group(p＝0．164), which suggested the relationship between the effects and irAEs in ICI treatment of AGC. Further research is required to understand the implications of irAE characteristics on ICI response in GCA patients. (Keyword) Immune-checkpoint inhibitors / Gastric cancer / Immune-related adverse events / Nivolumab (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050865265018642176 (CiNii: 1050865265018642176)
23.	藤井有美子, 小林誠司, 大西芳明, Katsuya Tanaka, Naoki Muguruma and Tetsuji Takayama : Assessment of accidental events in images during capsule endoscopy, Shikoku Acta Medica, Vol.76, No.3,4, 159-164, 2020. (Summary) Recently, there have been some reports of electromagnetic interference during capsule endoscopy(CE)in regards to other medical devices and facility environment. These accidental events have not been analyzed sufficiently although academic societies and related ministries are proposing guidelines with cautious attention. Based on this, detailed analyses and development of solution are required. In this study, we review our experience with cases of accidental events during CE and assessed the causes and preventive solutions. A total of149CE cases(male :89, female :60, mean age :56±18 8)from January 2017 until December 2019 were analyzed retrospectively. Four cases(2%)with defective images were noted. Detailed events were as follows ;1 disorder of the sensor array, 2 recorder freezes, and 1 electromagnetic interference. These mechanical and electromagnetic troubles should be assessed and shared among medical staffs and manufacturers to propose possible solutions and perform CE safely. (Keyword) Capsule endoscopy / Image defect / Electromagnetic interference (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050302315065222016 (CiNii: 1050302315065222016)
24.	Tetsu Tomonari, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Tatsuya Taniguchi, Masahiro Sogabe, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma, JGH Open, Vol.4, No.6, 1135-1139, 2020. (Summary) Abstract Background and Aim Currently, there is no molecular-targeted agent that has demonstrated evidence of efficacy in patients with unresectable hepatocellular carcinoma (u-HCC) who have developed resistance to treatment with lenvatinib (LEN). In this real-world study, we aimed to investigate the therapeutic effect and safety of sorafenib (SOR) in patients with u-HCC after progression on treatment with LEN. Methods (Patients) and Results A total of 13 patients with u-HCC (12 males and 1 female), who were treated with SOR after progression on LEN, were enrolled in this retrospective study. Therapeutic efficacy was evaluated via contrast-enhanced computerized tomography at 8 weeks after the initiation of SOR therapy according to modified response evaluation criteria in solid tumors (mRECIST) and RECIST. According to mRECIST, the objective response rate (ORR) and disease control rate (DCR) were 15.3 (Tokushima University Institutional Repository) ● Metadata: 115923 (Link to Publication Site) ● Publication site (DOI): 10.1002/jgh3.12408 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33319048 ● Summary page in Scopus @ Elsevier: 2-s2.0-85089378719 (Tokushima University Institutional Repository: 115923, DOI: 10.1002/jgh3.12408, PubMed: 33319048, Elsevier: Scopus)
25.	Masanori Takehara, Yasushi Sato, Tetsuo Kimura, Kazuyoshi Noda, Hiroshi Miyamoto, Yasuteru Fujino, Jinsei Miyoshi, Fumika Nakamura, Hironori Wada, Yoshimi Bando, Tetsuya Ikemoto, Mitsuo Shimada, Naoki Muguruma and Tetsuji Takayama : Cancer-associated Adipocytes Promote Pancreatic Cancer Progression Through SAA1 Expression, Cancer Science, Vol.111, No.8, 2883-2894, 2020. (Summary) Although pancreatic cancer often invades into peripancreatic adipose tissue, little is known about the cancer-adipocyte interaction. We first investigated the ability of adipocytes to de-differentiate to cancer-associated adipocytes (CAAs) by co-culturing with pancreatic cancer cells. We then examined the effects of CAA-conditioned media (CAA-CM) on the malignant characteristics of cancer cells, the mechanism underlying those effects, and their clinical relevance in pancreatic cancer. When 3T3-L1 adipocytes were co-cultured with pancreatic cancer cells (PANC-1) using Transwell system, adipocytes lost their lipid droplets and morphologically changed to fibroblast-like cells (CAA). Adipocyte-specific marker mRNA levels significantly decreased but those of fibroblast-specific markers appeared, characteristic findings of CAA, as revealed by real-time PCR. When PANC-1 cells were cultured with CAA-CM, significantly higher migration/invasion capability, chemoresistance, and epithelial-mesenchymal transition (EMT) properties were observed compared with control cells. To investigate the mechanism underlying these effects, we performed microarray analysis of PANC-1 cells cultured with CAA-CM, and found 78.5-fold higher expression of SAA1 compared with control cells. When SAA1 gene in PANC-1 cells was knocked down with SAA1 siRNA, migration/invasion capability, chemoresistance, and EMT properties were significantly attenuated compared with control cells. Immunohistochemical analysis on human pancreatic cancer tissues revealed positive SAA1 expression in 46/61 (75.4%). Overall survival in the SAA1-positive group was significantly shorter than in the SAA1-negative group (p=0.013). In conclusion, we demonstrated that pancreatic cancer cells induced de-differentiation in adipocytes toward CAA, and CAA promoted malignant characteristics of pancreatic cancer via SAA1 expression, suggesting that SAA1 is a novel therapeutic target in pancreatic cancer. (Tokushima University Institutional Repository) ● Metadata: 115328 (Link to Publication Site) ● Publication site (DOI): 10.1111/cas.14527 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32535957 ● Summary page in Scopus @ Elsevier: 2-s2.0-85087562532 (Tokushima University Institutional Repository: 115328, DOI: 10.1111/cas.14527, PubMed: 32535957, Elsevier: Scopus)
26.	Hironori Tanaka, Koichi Okamoto, Yasushi Sato, Takahiro Tanaka, Tetsu Tomonari, Fumika Nakamura, Yasuteru Fujino, Yasuhiro Mitsui, Hiroshi Miyamoto, Naoki Muguruma, Akinori Morita, Hitoshi Ikushima and Tetsuji Takayama : Synergistic anti-tumor activity of miriplatin and radiation through PUMA-mediated apoptosis in hepatocellular carcinoma., Journal of Gastroenterology, Vol.55, No.11, 1072-1086, 2020. (Summary) The prognosis for patients with unresectable advanced hepatocellular carcinoma (HCC) is poor. Miriplatin is a hydrophobic platinum compound that has a long retention time in lesions after transarterial chemoembolization (TACE). We investigated anti-tumor activity of miriplatin combined with irradiation on HCC cells, and its underlying mechanism of apoptosis. We also analyzed the effectiveness of miriplatin-TACE and radiotherapy for locally advanced HCC. Human HCC cell lines HepG2 and HuH-7 were treated with DPC (active form of miriplatin) and radiation, and synergy was evaluated using a combination index (CI). Apoptosis-related proteins and cell cycles were analyzed by western blotting and flowcytometry. We retrospectively analyzed treatment outcomes in 10 unresectable HCC patients with vascular/bile duct invasion treated with miriplatin-TACE and radiotherapy. DPC or X-ray irradiation decreased cell viability dose-dependently. DPC plus irradiation decreased cell viability synergistically in both cell lines (CI < 1, respectively). Cleaved PARP expression was induced much more strongly by DPC plus irradiation than by each treatment alone. Expression of p53 up-regulated modulator of apoptosis (PUMA) was significantly induced by the combination, and knockdown of PUMA with siRNA significantly decreased apoptosis in both cell lines. DPC plus irradiation caused sub-G1, G2/M, and S phase cell arrest in those cells. The combination of miriplatin-TACE and radiotherapy showed a high response rate for patients with locally advanced HCC despite small number of patients. Miriplatin plus irradiation had synergistic anti-tumor activity on HCC cells through PUMA-mediated apoptosis and cell cycle arrest. This combination may possibly be effective in treating locally advanced HCC. (Tokushima University Institutional Repository) ● Metadata: 115325 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00535-020-01705-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32666201 ● Summary page in Scopus @ Elsevier: 2-s2.0-85087895196 (Tokushima University Institutional Repository: 115325, DOI: 10.1007/s00535-020-01705-8, PubMed: 32666201, Elsevier: Scopus)
27.	Tetsu Tomonari, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Yasuteru Fujino, Yasuhiro Mitsui, Akihiro Hirao, Tatsuya Taniguchi, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Harumi Kagiwada, Masashi Kitazawa, Kazuhiro Fukui, Ktsuhisa Horimoto and Tetsuji Takayama : Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and in vitro assessment via protein phosphorylation array., Oncotarget, Vol.11, No.26, 2531-2542, 2020. (Summary) The efficacy and safety of lenvatinib (LEN) as a second/third-line treatment for unresectable hepatocellular carcinoma (HCC) after sorafenib (SOR) therapy remains unknown. We evaluated the outcomes of second/third-line LEN treatment, investigated the sensitivity of a SOR-resistant HCC cell line (PLC/PRF5-R2) to LEN, and assessed their signal transduction pathways by protein array analysis. We retrospectively enrolled 57 patients with unresectable HCC. Fifty-three radiologically evaluated patients comprised 34 molecular-targeted agent (MTA)-naive (first-line), nine intolerant to SOR (second-line), and 10 resistant to regorafenib (third-line). The objective response rates (ORRs) were 61.8% in first-line, 33.3% in second-line, and 20.0% in third-line groups. The overall survival (OS) in the first-line was significantly longer than that in the third-line group ( < 0.05). Patients with better liver functional reserves (child score, ALBI grade) exhibited higher ORR and longer OS. The IC of LEN against PLC/PRF5-R2 was significantly higher than that against PLC/PRF5. LEN significantly inhibited more LEN-related signal transduction pathways in PLC/PRF5 than in PLC/PRF5-R2 cells. This suggests that LEN is active and safe as a second/third-line treatment for unresectable HCC. LEN seems more effective for patients with HCC with better hepatic reserve functions or before MTA-resistance is acquired because of the partial cross-resistance to SOR. (Tokushima University Institutional Repository) ● Metadata: 116246 (Link to Publication Site) ● Publication site (DOI): 10.18632/oncotarget.27640 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32655838 ● Search Scopus @ Elsevier (PMID): 32655838 ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.27640 (Tokushima University Institutional Repository: 116246, DOI: 10.18632/oncotarget.27640, PubMed: 32655838)
28.	Tadahiko Nakagawa, Yasushi Sato, Toshihito Tanahashi, Yasuhiro Mitsui, Yoshifumi Kida, Yasuteru Fujino, Misato Hirata, Shinji Kitamura, Hiroshi Miyamoto, Koichi Okamoto, Naoki Muguruma, Yoshimi Bando and Tetsuji Takayama : JMJD2A sensitizes gastric cancer to chemotherapy by cooperating with CCDC8., Gastric Cancer, Vol.23, No.3, 426-436, 2020. (Summary) Jumonji domain-containing protein 2A (JMJD2A) of the JMJD2 family of histone lysine demethylases has been implicated in tumorigenesis. However, its expression and role in gastric cancer (GC) drug resistance remain unknown. Here, we investigated the role of JMJD2A in GC chemotherapeutic susceptibility and its clinical relevance in GC. We selected 12 relevant genes from previously identified gene signatures that can predict GC susceptibility to docetaxel, cisplatin, and S-1 (DCS) therapy. Each gene was knocked down using siRNA in GC cell lines, and cell viability assays were performed. JMJD2A expression in GC cell lines and tissues was assessed using qRT-PCR and immunohistochemistry, respectively. A JMJD2A downstream target related to drug susceptibility was examined using whole-gene expression array and immunoprecipitation. Among the 12 candidate genes, down-regulation of JMJD2A showed the maximum effect on GC susceptibility to anti-cancer drugs and increased the IC values for 5-FU, cisplatin, and docetaxel 15.3-, 2.7-, and 4.0-fold, respectively. JMJD2A was universally expressed in 12 GC cell lines, and its overexpression in GC tissue was positively correlated with tumor regression in 34 DCS-treated patients. A whole-gene expression array of JMJD2A-knockdown GC cells demonstrated a significant decrease in the expression of pro-apoptotic coiled-coil domain containing 8 (CCDC8), a downstream target of JMJD2A. Direct interaction between CCDC8 and JMJD2A was verified using immunoprecipitation. CCDC8 inhibition restored drug resistance to docetaxel, cisplatin, and S-1. Our results indicate that JMJD2A is a novel epigenetic factor affecting GC chemotherapeutic susceptibility, and JMJD2A/CCDC8 is a potential GC therapeutic target. (Link to Publication Site) ● Publication site (DOI): 10.1007/s10120-019-01024-9 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31677131 ● Summary page in Scopus @ Elsevier: 2-s2.0-85074813194 (DOI: 10.1007/s10120-019-01024-9, PubMed: 31677131, Elsevier: Scopus)
29.	Yoshihiko Miyamoto, Naoki Muguruma, Shota Fujimoto, Yasuyuki Okada, Yoshifumi Kida, Fumika Nakamura, Kumiko Tanaka, Tadahiko Nakagawa, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato and Tetsuji Takayama : Epidermal growth factor receptortargeted molecular imaging of colorectal tumors: Detection and treatment evaluation of tumors in animal models., Cancer Science, Vol.110, No.6, 1921-1930, 2019. (Summary) To overcome the problem of overlooking colorectal tumors, a new and highly sensitive modality of colonoscopy is needed. Moreover, it is also important to establish a new modality to evaluate viable tumor volume in primary lesions of colorectal cancer (CRC) during chemotherapy. Therefore, we carried out molecular imaging of colorectal tumors targeting epidermal growth factor receptor (EGFR), which is highly expressed on tumor cells, for evaluating chemotherapeutic efficacy and for endoscopic detection of colorectal adenomas. We first attempted to image five CRC cell lines with various levels of EGFR expression using an Alexa Fluor-labeled anti-EGFR monoclonal antibody (AF-EGFR-Ab). A strong fluorescence signal was observed in the cells depending on the level of EGFR expression. When nude mice xenografted with LIM1215 CRC cells, which highly express EGFR, were i.v. injected with AF-EGFR-Ab, a strong fluorescence signal appeared in the tumor with a high signal to noise ratio, peaking at 48 hours after injection and then gradually decreasing, as shown using an IVIS Spectrum system. When the xenografted mice were treated with 5-fluorouracil, fluorescence intensity in the tumor decreased in proportion to the viable tumor cell volume. Moreover, when the colorectum of azoxymethane-treated rats was observed using a thin fluorescent endoscope with AF-EGFR-Ab, all 10 small colorectal adenomas (3 mm) were detected with a clear fluorescence signal. These preliminary results of animal experiments suggest that EGFR-targeted fluorescent molecular imaging may be useful for quantitatively evaluating cell viability in CRC during chemotherapy, and also for detecting small adenomas using a fluorescent endoscope. (Keyword) Animals / Antineoplastic Agents / Azoxymethane / Cell Line, Tumor / Cell Survival / Colorectal Neoplasms / ErbB Receptors / female / Fluorouracil / HT29 Cells / Humans / male / Mice, Inbred BALB C / Mice, Nude / Molecular Targeted Therapy / Rats, Inbred F344 / Xenograft Model Antitumor Assays (Tokushima University Institutional Repository) ● Metadata: 113790 (Link to Publication Site) ● Publication site (DOI): 10.1111/cas.14020 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30973663 ● Summary page in Scopus @ Elsevier: 2-s2.0-85066789077 (Tokushima University Institutional Repository: 113790, DOI: 10.1111/cas.14020, PubMed: 30973663, Elsevier: Scopus)
30.	Hiroshi Miyamoto, Kumiko Tanaka, Fumika Nakamura, Takahiro Ikeda, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Masahiro Sogabe, Naoki Muguruma, Yoshimi Bando and Tetsuji Takayama : Massive hemobilia following plastic stent removal in common bile duct cancer associated with primary sclerosing cholangitis (with video)., Clinical Journal of Gastroenterology, Vol.12, No.1, 2019. (Summary) Hemobilia is defined as bleeding into the biliary tract. Herein, we report a very rare case of massive hemobilia following plastic stent (PS) removal in common bile duct (CBD) cancer. A 72-year-old man with primary sclerosing cholangitis had undergone repeated insertion of a PS into the CBD. Biliary tract biopsy was performed based on suspicion of combined CBD cancer. Biopsy revealed poorly differentiated adenocarcinoma of the CBD. One month after the biliary tract biopsy, he was admitted for acute cholangitis, and endoscopic retrograde cholangiography was performed for the exchange of the PS. When one of the two biliary PSs was removed, spurting bleeding from the major papilla began abruptly. The massive bleeding caused the patient to be in a pre-shock state. A retrieval balloon catheter was compressed against the papilla for hemostasis. Although he was treated conservatively, the patient developed a bloody discharge. Upper gastrointestinal endoscopy revealed that the pulsatile bleeding beside the PSs started immediately after the removal of the coagula. Emergent contrast-enhanced computed tomography showed right hepatic artery aneurysm across the CBD. Therefore, transarterial embolization was performed. The patient's post-therapeutic course was uneventful. He received chemotherapy, but died about a half year after hemobilia occurred. (Link to Publication Site) ● Publication site (DOI): 10.1007/s12328-018-0888-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30056613 ● Summary page in Scopus @ Elsevier: 2-s2.0-85050721343 (DOI: 10.1007/s12328-018-0888-7, PubMed: 30056613, Elsevier: Scopus)
31.	Yasushi Sato, Tamotsu Sagawa, Hiroyuki Ohnuma, Masahiro Hiarakawa, Yasuo Takahashi, Kyoko Hamaguchi, Koshi Fujikawa, Takayuki Nobuoka, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Ichiro Takemasa and Tetsuji Takayama : A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer., Cancer Chemotherapy and Pharmacology, Vol.83, No.1, 161-167, 2019. (Summary) The aim of this study was to determine the recommended dose (RD) for a docetaxel/oxaliplatin/S-1 (DOS) regimen in patients with unresectable gastric cancer and to preliminarily evaluate its efficacy. Previously untreated patients with histologically proven unresectable metastatic gastric cancer were enrolled (n = 16). Docetaxel and oxaliplatin were administered intravenously on day 8 and S-1 was administered orally twice a day on days 1-14. Each cycle was repeated every 3 weeks. Dose-limiting toxicities (DLTs) were evaluated during the first treatment cycle. Three dose escalations of DOS were employed in this study: level 1 (50/100/80 mg/m), level 2 (50/130/80 mg/m), and level 3 (60/130/80 mg/m). According to the 3 + 3 dose-escalating schedule, we determined that the RD and maximum tolerated dose for this regimen were level 1 and level 2, respectively. The DLTs were grade 3 diarrhea and febrile neutropenia. The overall response rate was 78% (7/9) for patients with measurable lesions and consisted of two complete responses and five partial responses. Five patients underwent conversion surgery. The median follow-up time was 19 months with median survival time and progression-free survival being 19.6 months and 7.6 months, respectively. The results from this study demonstrated the safety and tolerability of DOS in unresectable metastatic gastric cancer patients and revealed promising preliminary efficacy with a high conversion rate. A phase II trial of DOS regimen using the identified RD is ongoing. (Link to Publication Site) ● Publication site (DOI): 10.1007/s00280-018-3719-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30406285 ● Search Scopus @ Elsevier (PMID): 30406285 ● Search Scopus @ Elsevier (DOI): 10.1007/s00280-018-3719-0 (DOI: 10.1007/s00280-018-3719-0, PubMed: 30406285)
32.	Kaizo Kagemoto, Koichi Okamoto, Tohshi Takaoka, Yasushi Sato, Shinji Kitamura, Tetsuo Kimura, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Koichi Tsuneyama and Tetsuji Takayama : Detection of aberrant crypt foci with image-enhanced endoscopy., Endoscopy International Open, Vol.6, No.8, E924-E933, 2018. (Summary) Conventional detection of aberrant crypt foci (ACF) with dye-spraying and magnifying observation is labor- and skill-intensive. We performed a prospective non-inferiority study to investigate the utility of image-enhanced endoscopy (IEE) for detection of ACF. Patients with a history of colorectal neoplasm were eligible. The number of ACF in the lower rectum was counted first using IEE magnification with narrow-band imaging (NBI) or blue-laser imaging (BLI), and subsequently using the methylene blue method. The primary endpoint was the ACF detection rate with IEE, i. e., the number of ACF detected with IEE relative to the number of ACF detected with methylene blue. The secondary endpoints were bowel preparation time, ACF detection time, and the detection rate with NBI or BLI. A total of 40 patients were enrolled (NBI 20 and BLI 20). The overall detection rate for ACF with IEE was 81.7 % (503/616; 95 %CI 78.8 - 84.6 %), meeting the primary endpoint. The detection rate for ACF with BLI (84.9 %, 258/304) was significantly higher than with NBI (78.5 %, 245/312; < 0.05). Both bowel preparation time and ACF detection time were significantly shorter with IEE versus the methylene blue method ( < 0.01, respectively). The detection rates for dysplastic and non-dysplastic ACF with IEE were 84.4 % (27/32) and 80.3 % (469/584), respectively. IEE is able to detect ACF during colonoscopy with sensitivity non-inferior to that of the conventional methylene blue method. IEE is simpler than the methylene blue method and is therefore a potentially useful new tool for ACF detection. (Tokushima University Institutional Repository) ● Metadata: 112032 (Link to Publication Site) ● Publication site (DOI): 10.1055/a-0621-8794 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30123821 ● Search Scopus @ Elsevier (PMID): 30123821 ● Search Scopus @ Elsevier (DOI): 10.1055/a-0621-8794 (Tokushima University Institutional Repository: 112032, DOI: 10.1055/a-0621-8794, PubMed: 30123821)
33.	Yasuhiro Mitsui, Reiko Yokoyama, Shota Fujimoto, Kaizoh Kagemoto, Shinji Kitamura, Koichi Okamoto, Naoki Muguruma, Yoshimi Bando, Hidetaka Eguchi, Yasushi Okazaki, Hideyuki Ishida and Tetsuji Takayama : First report of an Asian family with gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) revealed with the germline mutation of the APC exon 1B promoter region., Gastric Cancer, Vol.21, No.6, 1058-1063, 2018. (Summary) A 48-year-old Japanese female with left hypochondralgia presented at our hospital. Esophagogastroduodenoscopy (EGD) revealed gastric cancers and carpeting fundic gland polyposis (FGPs) without Helicobacter pylori infection. Computed tomography showed multiple liver metastases. Total colonoscopy revealed a colonic tubular adenoma but not polyposis. She was diagnosed as having advanced gastric cancer with liver metastasis and received chemotherapy. Her mother had died from gastric cancer, and her elderly brother and niece had FGPs as revealed by EGD. Thus, the pedigree was diagnosed as gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS). Germline mutation analysis exhibited a point mutation in exon1B of the APC gene (c.-191T > C). Adenocarcinoma showed a gastric mucinous phenotype and was positive for a somatic mutation of p53, suggesting that p53 mutation may play a role in FGPs carcinogenesis. This is the first family with GAPPS in Asia in whom germline mutation of APC exon 1B has been detected. (Link to Publication Site) ● Publication site (DOI): 10.1007/s10120-018-0855-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29968043 ● Summary page in Scopus @ Elsevier: 2-s2.0-85049558259 (DOI: 10.1007/s10120-018-0855-5, PubMed: 29968043, Elsevier: Scopus)
34.	Shota Fujimoto, Naoki Muguruma, Koichi Okamoto, Takeshi Kurihara, Yasushi Sato, Yoshihiko Miyamoto, Shinji Kitamura, Hiroshi Miyamoto, Takahiro Taguchi, Koichi Tsuneyama and Tetsuji Takayama : A Novel Theranostic Combination of Near-infrared Fluorescence Imaging and Laser Irradiation Targeting c-KIT for Gastrointestinal Stromal Tumors., Theranostics, Vol.8, No.9, 2313-2328, 2018. (Summary) It is difficult to distinguish gastrointestinal stromal tumors (GISTs) from other types of submucosal tumors under conventional gastrointestinal endoscopy. We aimed to detect GISTs by molecular fluorescence imaging using a near-infrared (NIR) photosensitizer (IR700)-conjugated anti-c-KIT antibody and to treat GISTs by photoimmunotherapy with NIR irradiation as a non-invasive theranostic procedure. We also investigated the therapeutic mechanisms. Human GIST cell lines GIST-T1 and GIST-882M were incubated with IR700-conjugated anti-c-KIT antibody, IR700-12A8, and observed by confocal laser microscopy. Mice with GIST-T1 xenografts or rats with orthotopic xenografts were injected with IR700-12A8 or AF488-conjugated antibody, and observed under IVIS or autofluorescence imaging (AFI) endoscopy. GIST cells were treated with IR700-12A8 and NIR light and vivo, and cell viability, histology and apoptosis were evaluated. Strong red fluorescence of IR700-12A8 was observed on the cell membrane of GIST cells and was gradually internalized into the cytoplasm. Tumor-specific accumulation of IR700-12A8 was observed in GIST-T1 xenografts in mice. Under AFI endoscopy, a strong fluorescence signal was observed in orthotopic GIST xenografts in rats through the normal mucosa covering the tumor. The percentage of dead cells significantly increased in a light-dose-dependent manner and both acute necrotic and late apoptotic cell death was observed with annexin/PI staining. Cleaved PARP expression was significantly increased after IR700-12A8-mediated NIR irradiation, which was almost completely reversed by NaN. All xenograft tumors (7/7) immediately regressed and 4/7 tumors completely disappeared after IR700-12A8-mediated NIR irradiation. Histologic assessment and TUNEL staining revealed apoptosis in the tumors. NIR fluorescence imaging using IR700-12A8 and subsequent NIR irradiation could be a very effective theranostic technology for GIST, the underlying mechanism of which appears to involve acute necrosis and supposedly late apoptosis induced by singlet oxygen. (Tokushima University Institutional Repository) ● Metadata: 111436 (Link to Publication Site) ● Publication site (DOI): 10.7150/thno.22027 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29721082 ● Summary page in Scopus @ Elsevier: 2-s2.0-85044356978 (Tokushima University Institutional Repository: 111436, DOI: 10.7150/thno.22027, PubMed: 29721082, Elsevier: Scopus)
35.	Rie Harada, Masako Kimura, Yasushi Sato, Tatsuya Taniguchi, Tetsu Tomonari, Takahiro Tanaka, Hironori Tanaka, Naoki Muguruma, Hirohiko Shinomiya, Hirohito Honda, Issei Imoto, Masahiro Sogabe, Toshiya Okahisa and Tetsuji Takayama : APOB codon 4311 polymorphism is associated with hepatitis C virus infection through altered lipid metabolism., BMC Gastroenterology, Vol.18, No.1, 24, 2018. (Summary) It has been reported that some single-nucleotide polymorphisms (SNPs) in lipid regulators such as apolipoproteins and cell surface molecules for hepatitis C virus (HCV) entry into hepatocytes are associated with HCV infection. However, it is unknown how HCV infection is affected by altered lipid metabolism resulting from the SNPs. We investigated the relationship between these SNPs and HCV infection status, and also analyzed the mechanism by which these SNPs mediate HCV infection via lipid metabolism alterations. Serum lipid and apolipoprotein profiles were tested in 158 HCV-positive and 220 HCV-negative subjects. We selected 22 SNPs in five lipid regulator genes which were related to HCV entry into hepatocytes and to lipid metabolism (APOA1, APOB, SR-B1, LDLR, and APOE), and their polymorphisms were analyzed using the PCR-sequence-specific oligonucleotide probe-Luminex method. An APOB N4311S (g.41553a > g) SNP, rs1042034, was significantly associated with HCV positivity; the HCV positivity rate for the minor allele AA genotype was significantly higher than for genotype AG + GG (P = 0.016). Other SNPs except for APOB P2712L SNP rs676210, which is in linkage disequilibrium with rs1042034, showed no significant difference in genotype distribution. The serum level of low density lipoprotein-cholesterol (LDL-C) in the genotype AA group was significantly lower than in the genotype non-AA group (P = 0.032), whereas the triglyceride (TG) level was significantly higher (P = 0.007). An APOB SNP, rs1042034, is closely associated with HCV infection through lipid metabolism alteration. The minor allele AA genotype might contribute to facilitating serum LDL uptake into hepatocytes via LDLR by modifying their affinity and interaction and may have an influence on HCV infection by their entry to the liver through the LDLR. (Tokushima University Institutional Repository) ● Metadata: 111808 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12876-018-0747-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29382324 ● Summary page in Scopus @ Elsevier: 2-s2.0-85041353404 (Tokushima University Institutional Repository: 111808, DOI: 10.1186/s12876-018-0747-5, PubMed: 29382324, Elsevier: Scopus)
36.	Daisaku Fujimoto, Naoki Muguruma, Koichi Okamoto, Yasuteru Fujino, Kaizoh Kagemoto, Yasuyuki Okada, Yoshifumi Takaoka, Yasuhiro Mitsui, Shinji Kitamura, Tetsuo Kimura, Hiroshi Miyamoto, Yoshimi Bando, Tomoko Sonoda and Tetsuji Takayama : Linked color imaging enhances endoscopic detection of sessile serrated adenoma/polyps., Endoscopy International Open, Vol.6, No.3, E322-E334, 2017. (Summary) Although new image-enhanced endoscopy (IEE) technologies such as blue laser imaging (BLI), BLI-bright, and linked color imaging (LCI) have been developed, their utility for the detection of sessile serrated adenoma/polyps (SSA/Ps) is still unclear. This study aimed to evaluate the utility of BLI, BLI-bright, and LCI for SSA/P detection in still image examinations and in a prospective randomized controlled trial (RCT). A group of 6 expert and non-expert endoscopists read 200 endoscopic still images containing SSA/P lesions using white light image (WLI), BLI, BLI-bright, and LCI. Color differences were calculated using the color space method. A prospective RCT of tandem colonoscopy with WLI and LCI was performed. Patients with SSA/P and those with a history of SSA/P that had been endoscopically removed were enrolled and randomly allocated to WLI-LCI or LCI-WLI groups. Additional endoscopic detection rates for SSA/P were compared between the 2 groups. LCI showed the highest SSA/P detection rate among the 4 modes for both expert and non-expert endoscopists. The detection rate with LCI for the 6 expert endoscopists (mean 98.3 ± standard deviation 2.0 %) was significantly higher than that with WLI (86.7 ± 6.0 %, < 0.01). Likewise, the detection rate with LCI for the 6 non-expert endoscopists (92.3 ± 2.9 %) was significantly higher than that with WLI (72.7 ± 11.5 %, < 0.01). The color difference of SSA/P with LCI was the highest among the 4 modes, and was significantly higher than with WLI (median 15.9, (interquartile range 13.7 - 20.6) vs. 10.2, (7.6 - 14.2); < 0.0001). In the RCT, a total of 44 patients (WLI-LCI 22 vs. LCI-WLI 22) underwent colonoscopy. The additional detection rate for SSA/P in the second inspection in the WLI-LCI group (21.6 %, 8/37) was significantly higher than in the LCI-WLI group (3.2 %, 1/31; = 0.02). The small, flat, non-mucus and isochromatic SSA/Ps in the transverse colon were detected more frequently in the second inspection with LCI. LCI was the most sensitive mode for SSA/P detection among WLI, BLI, BLI-bright, and LCI in the still image examinations. Our RCT strongly suggests that LCI is superior to conventional WLI for SSA/P detection during colonoscopy. UMIN000017599. (Tokushima University Institutional Repository) ● Metadata: 111442 (Link to Publication Site) ● Publication site (DOI): 10.1055/s-0043-124469 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29527554 ● Search Scopus @ Elsevier (PMID): 29527554 ● Search Scopus @ Elsevier (DOI): 10.1055/s-0043-124469 (Tokushima University Institutional Repository: 111442, DOI: 10.1055/s-0043-124469, PubMed: 29527554)
37.	Yasushi Sato, Masahiro Hirakawa, Hiroyuki Ohnuma, Minoru Takahashi, Tetsuro Okamoto, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Tomohisa Furuhata, Ichiro Takemasa, Junji Kato and Tetsuji Takayama : A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study., Cancer Chemotherapy and Pharmacology, Vol.80, No.6, 1133-1139, 2017. (Summary) The addition of cetuximab to triplet chemotherapy can increase treatment efficacy for patients with metastatic colorectal cancer (mCRC). We explored the dose-limiting toxicity and feasibility of a triweekly capecitabine, oxaliplatin, irinotecan, plus cetuximab (XELOXIRI plus cetuximab) regimen in patients with wild-type KRAS mCRC. Patients received oxaliplatin (100 mg/m, day 1), capecitabine (1700 mg/m per day from day 2 to 15), irinotecan (100, 120, and 150 mg/m for dose levels 1, 2, 3, respectively, on day 1), and cetuximab (400 mg/m, day 1 and, thereafter, 250 mg/m every week), repeated every 3 weeks. Dose-limiting toxicities (DLTs) were assessed in the first 2 treatment cycles to determine the maximum tolerated dose (MTD) and the recommended dose (RD). Twelve patients received a median of 7 cycles of therapy (range 2-10). The DLT was grade 4 neutropenia, observed in 1 of 6 patients at dose level 2. The MTD was not reached at dose level 3. Therefore, the RD of irinotecan was defined as 150 mg/m. Most common grade ≥ 3 toxicities were neutropenia (50%), diarrhea (17%), and febrile neutropenia (8%). The response rate was 83% (complete and partial response: 1 and 9 patient(s), respectively), including 4 conversion cases. The combination of XELOXIRI and cetuximab is feasible and has an acceptable toxicity profile; neutropenia was the DLT. The RD of irinotecan is 150 mg/m. The observed response rate was promising and warrants further investigation. (Keyword) Adult / Aged / Antimetabolites, Antineoplastic / Antineoplastic Combined Chemotherapy Protocols / Camptothecin / Capecitabine / Cetuximab / Colorectal Neoplasms / Female / Humans / Male / Middle Aged / Neoplasm Metastasis / Organoplatinum Compounds (Link to Publication Site) ● Publication site (DOI): 10.1007/s00280-017-3458-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29038850 ● Summary page in Scopus @ Elsevier: 2-s2.0-85031928685 (DOI: 10.1007/s00280-017-3458-7, PubMed: 29038850, Elsevier: Scopus)
38.	Yasuyuki Okada, Tetsuo Kimura, Tadahiko Nakagawa, Koichi Okamoto, Akira Fukuya, Takahiro Goji, Shota Fujimoto, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Yasushi Tsuji, Toshiya Okahisa and Tetsuji Takayama : EGFR Down-regulation After anti-EGFR Therapy Predicts the Anti-tumor Effect in Colorectal Cancer., Molecular Cancer Research : MCR, Vol.15, No.10, 1445-1454, 2017. (Summary) Anti-EGFR mAb is reported to induce EGFR internalization in colorectal cancer cells. However, the biological relevance of EGFR internalization with anti-EGFR mAb is unknown. Therefore, the relevance of EGFR downregulation with anti-EGFR mAb to antitumor activity in colorectal cancer cells was investigated. Quantification of EGFR on the cell surface before cetuximab treatment was assessed by flow cytometry, and its growth-inhibitory effects were measured by Trypan blue exclusion, in 10 wild-type colorectal cancer cell lines, but there was no significant correlation between EGFR number and its growth-inhibitory effect. However, a significant correlation existed between the percentage decrease in the number of EGFRs after cetuximab treatment and its growth-inhibitory effect in those cell lines. Treatment with TGFα, a ligand for EGFR, induced EGFR internalization in colorectal cancer cells, but most EGFRs subsequently recycled to the cell surface, consistent with previous studies. While cetuximab treatment induced EGFR internalization, most receptors subsequently translocated into the late endosome, leading to lysosomal degradation, as revealed by immunoblotting and double immunofluorescence. Cetuximab-sensitive colorectal cancer cells showed greater EGFR internalization, stronger cell growth inhibition, and more augmented apoptotic signals than nonsensitive cells. IHC for EGFR, performed using an EGFR pharmDx Kit (mouse anti-human EGFR mAb clone 2-18C9), in clinical specimens before and after anti-EGFR mAb therapy in 13 colorectal cancer patients showed a significant correlation between the response to anti-EGFR mAb and decreased staining after therapy. This report clearly demonstrates that anti-EGFR mAb facilitates internalization and subsequent degradation of EGFRs in lysosomes, which is an important determinant of the efficacy of anti-EGFR mAb treatment for colorectal cancer. . (Keyword) Adult / Aged / Antineoplastic Agents, Immunological / Caco-2 Cells / Cell Line, Tumor / Cell Survival / Cetuximab / Colorectal Neoplasms / Down-Regulation / Endosomes / Female / HCT116 Cells / HT29 Cells / Humans / Male / Middle Aged / Proto-Oncogene Proteins B-raf / Receptor, Epidermal Growth Factor / Transforming Growth Factor alpha / ras Proteins (Tokushima University Institutional Repository) ● Metadata: 110960 (Link to Publication Site) ● Publication site (DOI): 10.1158/1541-7786.MCR-16-0383 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28698359 ● Search Scopus @ Elsevier (PMID): 28698359 ● Search Scopus @ Elsevier (DOI): 10.1158/1541-7786.MCR-16-0383 (Tokushima University Institutional Repository: 110960, DOI: 10.1158/1541-7786.MCR-16-0383, PubMed: 28698359)
39.	Shinji Kitamura, Naoki Muguruma, Koichi Okamoto, Toshihito Tanahashi, Akira Fukuya, Kumiko Tanaka, Daisaku Fujimoto, Tetsuo Kimura, Hiroshi Miyamoto, Yoshimi Bando, Hisashi Takeuchi, Masako Shiba and Tetsuji Takayama : Clinicopathological Assessment of Gastric Xanthomas as Potential Predictive Markers of Gastric Cancer., Digestion, Vol.96, No.4, 199-206, 2017. (Summary) Gastric xanthomas are frequently observed in the stomach as small yellowish plaques or nodules. A close relationship among Helicobacter pylori infection, atrophic gastritis, and xanthomas has been reported. We assessed the clinicopathological features of gastric cancer with or without xanthomas. A total of 91 patients who were diagnosed as having early gastric cancer were enrolled. We evaluated the gastritis status using scores for gastritis and atrophy, positivity of H. pylori infection, the prevalence rate of xanthomas, and the clinicopathological features of gastric cancer. Gastric xanthomas were observed in 72.5% of early gastric cancer cases. Scores for gastritis and atrophy were significantly higher in the xanthoma-positive group than those in the xanthoma-negative group. A higher prevalence of differentiated-type adenocarcinoma was found in the xanthoma-positive group. Among the cases with multiple gastric xanthomas, the prevalence of males was significantly higher than that of females. A high prevalence rate of gastric xanthomas in gastric cancer cases was shown. Xanthomas were highly associated with age, the severities of gastritis and atrophy, and differentiated-type adenocarcinoma. Regardless of the eradication of H. pylori, xanthomas may be useful predictive markers for the development of differentiated-type adenocarcinoma. (Link to Publication Site) ● Publication site (DOI): 10.1159/000481346 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28965110 ● Summary page in Scopus @ Elsevier: 2-s2.0-85030724288 (DOI: 10.1159/000481346, PubMed: 28965110, Elsevier: Scopus)
40.	Masanori Takehara, Naoki Muguruma, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Yoshimi Bando and Tetsuji Takayama : Twin Rectal Tonsils Mimicking Carcinoid or Mucosa-Associated Lymphoid Tissue Lymphoma., Clinical Endoscopy, Vol.50, No.5, 500-503, 2017. (Summary) The rectal tonsil is a rare polypoid lesion exclusively found in the rectum and is considered a reactive proliferation of the lymphoid tissue. Although this lesion is benign, we recommend that it should be differentiated from carcinoid or polypoid type of mucosaassociated lymphoid tissue (MALT) lymphomas, based on gross findings. In this case report, we describe a case of rectal lesions with a unique appearance in a 41-year-old man. Colonoscopy revealed two 5-mm-sized nodules located opposite from each other on the left and right sides of the lower rectum. Endoscopic mucosal resection was conducted. Histopathologically, both lesions were mainly located in the submucosa and consisted of prominent lymphoid follicles with germinal centers of various sizes. No immunoreactivity of Bcl-2 was seen in the germinal centers. Immunohistochemical staining for kappa and lambda light chains revealed a polyclonal pattern. Therefore, these lesions were diagnosed as rectal tonsils. (Tokushima University Institutional Repository) ● Metadata: 115063 (Link to Publication Site) ● Publication site (DOI): 10.5946/ce.2016.157 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28241409 ● Summary page in Scopus @ Elsevier: 2-s2.0-85030241581 (Tokushima University Institutional Repository: 115063, DOI: 10.5946/ce.2016.157, PubMed: 28241409, Elsevier: Scopus)
41.	Naoki Muguruma, Koichi Okamoto, Tadahiko Nakagawa, Katsutaka Sannomiya, Shota Fujimoto, Yasuhiro Mitsui, Tetsuo Kimura, Hiroshi Miyamoto, Jun Higashijima, Mitsuo Shimada, Yoko Horino, Shinya Matsumoto, Kenjiro Hanaoka, Tetsuo Nagano, Makoto Shibutani and Tetsuji Takayama : Molecular imaging of aberrant crypt foci in the human colon targeting glutathione S-transferase P1-1., Scientific Reports, Vol.7, No.1, 6536, 2017. (Summary) Aberrant crypt foci (ACF), the earliest precursor lesion of colorectal cancers (CRCs), are a good surrogate marker for CRC risk stratification and chemoprevention. However, the conventional ACF detection method with dye-spraying by magnifying colonoscopy is labor- and skill-intensive. We sought to identify rat and human ACF using a fluorescent imaging technique that targets a molecule specific for ACF. We found that glutathione S-transferase (GST) P1-1 was overexpressed in ACF tissues in a screening experiment. We then synthesized the fluorogenic probe, DNAT-Me, which is fluorescently quenched but is activated by GSTP1-1. A CRC cell line incubated with DNAT-Me showed strong fluorescence in the cytosol. Fluorescence intensities correlated significantly with GST activities in cancer cell lines. When we sprayed DNAT-Me onto colorectal mucosa excised from azoxymethane-treated rats and surgically resected from CRC patients, ACF with strong fluorescent signals were clearly observed. The ACF number determined by postoperative DNAT-Me imaging was almost identical to that determined by preoperative methylene blue staining. The signal-to-noise ratio for ACF in DNAT-Me images was significantly higher than that in methylene blue staining. Thus, we sensitively visualized ACF on rat and human colorectal mucosa by using a GST-activated fluorogenic probe without dye-spraying and magnifying colonoscopy. (Tokushima University Institutional Repository) ● Metadata: 112373 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-017-06857-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28747791 ● Search Scopus @ Elsevier (PMID): 28747791 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-017-06857-x (Tokushima University Institutional Repository: 112373, DOI: 10.1038/s41598-017-06857-x, PubMed: 28747791)
42.	Masahiro Sogabe, Toshiya Okahisa, Masahiko Nakasono, Hiroshi Fukuno, Yoshihiko Miyamoto, Yasuyuki Okada, Jun Okazaki, Jinsei Miyoshi, Tetsu Tomonari, Tatsuya Taniguchi, Takahiro Goji, Shinji Kitamura, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : The differing influence of several factors on the development of fatty liver with elevation of liver enzymes between genders with metabolic syndrome: A cross-sectional study., PLoS ONE, Vol.12, No.6, e0177925, 2017. (Summary) Nonalcoholic fatty liver disease (NAFLD) is known to be strongly associated with obesity, visceral fat, metabolic syndrome (MS), lifestyle, and lifestyle-related diseases in both males and females. However, the prevalence of NAFLD, MS, and clinical backgrounds is different between males and females. We conducted a cross-sectional study to examine the differing influence of lifestyle-related factors and visceral fat on fatty liver (FL) with elevation of liver enzymes between males and females with MS. We enrolled 42,134 persons who underwent a regular health check-up, and after excluding subjects who fulfilled excluding criteria, the remaining subjects were 2,110 persons with MS. We examined the differing influence of lifestyle-related factors and visceral fat on FL with elevation of alanine aminotransferase (ALT) (ALT elevation was defined as ALT level of ≥31 IU/l in the present study). The odds rations for FL with ALT elevation were as follows: WC, 1.83 (95% confidence interval (CI) 1.36-2.46); dyslipidemia, 1.89 (95% CI 1.34-2.68); hemoglobin A1c, 1.36 (95% CI 1.00-1.85); visceral fat type MS (V-type MS), 5.78 (95% CI 4.29-7.80); and light drinker, 0.56 (95% CI 0.41-0.78) in males with MS and BMI, 2.18 (95% CI 1.43-3.33); WC, 1.85 (95% CI 1.27-2.70); diastolic blood pressure, 1.69 (95% CI 1.16-2.45); triglyceride, 2.22 (95% CI 1.56-3.17); impaired glucose tolerance, 1.66 (95% CI 1.11-2.47); and V-type MS, 3.83 (95% CI 2.57-5.70) in females with MS. The prevalence of FL with ALT elevation and ALT was significantly higher in V-type MS than in the subcutaneous fat type MS in both males and females with MS (P < 0.001). Although V-type MS and WC is a common significant predictor of an increased prevalence of FL with ALT elevation in both males and females with MS, gender, lifestyle-related factors, and MS type in individuals with MS should be considered for the development of FL with ALT elevation. (Tokushima University Institutional Repository) ● Metadata: 112319 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0177925 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28574988 ● Summary page in Scopus @ Elsevier: 2-s2.0-85020298128 (Tokushima University Institutional Repository: 112319, DOI: 10.1371/journal.pone.0177925, PubMed: 28574988, Elsevier: Scopus)
43.	S Bando, Takeshi Soeki, Tomomi Matsuura, Takeshi Tobiume, Takayuki Ise, Kenya Kusunose, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Michio Shimabukuro, Naoki Muguruma, Tetsuji Takayama, I Kishimoto, Kenji Kangawa and Masataka Sata : Plasma brain natriuretic peptide levels are elevated in patients with cancer, PLoS ONE, Vol.12, No.6, e0178607, 2017. (Summary) Natriuretic peptides have been proposed as biomarkers of cardiovascular disease, especially heart failure. Brain natriuretic peptide (BNP) has also been shown to be upregulated at the transcriptional and translational levels by pro-inflammatory cytokines in cardiac myocytes. Although we often measure plasma BNP levels in cancer patients, it remains unknown whether cancer-related inflammation affects the plasma BNP levels. We investigated the relationship between the BNP and human cancers. We retrospectively studied 2,923 patients in whom the plasma BNP levels and serum C-reactive protein (CRP) were measured and echocardiography was performed. Patients with clinically evident heart failure (NYHA II or higher), heart disease requiring medical treatment or surgery, renal dysfunction, and inflammatory disease were excluded. There were 234 patients in the final analysis. Blood sampling was performed before surgery and chemotherapy. In addition, we evaluated the relationship between the inflammation and plasma BNP levels in mouse models of colon cancer. Of the 234 patients, 80 were diagnosed with cancer. Both the plasma BNP and serum CRP levels were significantly higher in cancer patients than those without. There were no significant differences in the echocardiographic parameters. There was a significant positive correlation between the plasma BNP and serum CRP levels in cancer patients (r = 0.360, P<0.01) but not in those without. In cancer patients, only the CRP correlated with the BNP independent of the age, creatinine level, hypertension, and body mass index. In addition, in nude mice with subcutaneous colon cancer, the plasma BNP level was elevated compared with that in non-cancer mice, and there was a significant relationship between the plasma BNP and serum levels of the inflammatory markers. In cancer patients, as well as colon cancer model mice, the plasma BNP levels were elevated, possibly due to cancer-related inflammation. The effect of cancer on the BNP levels should be considered when using BNP as an indicator of heart failure in cancer patients. (Tokushima University Institutional Repository) ● Metadata: 112318 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0178607 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28570595 ● Search Scopus @ Elsevier (PMID): 28570595 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0178607 (Tokushima University Institutional Repository: 112318, DOI: 10.1371/journal.pone.0178607, PubMed: 28570595)
44.	Jun Okazaki, Naoki Muguruma, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Kazuhiro Kishi, Yoshimi Bando, Takeshi Kondo, Itsuro Endo, Masahiro Abe and Tetsuji Takayama : Paraneoplastic hypocalcemia developed in gastric cancer accompanied by osteoblastic metastasis, Internal Medicine, Vol.56, No.11, 1345-1349, 2017. (Summary) Paraneoplastic syndromes are generally defined as clinical disorders associated with malignant diseases, and hypocalcemia associated with cancer is a rare condition. A woman in her 60s was referred to our hospital for the further examination of massive ascites due to carcinoma of unknown primary origin. She complained of numbness around her lips, and marked hypocalcemia of 5.0 mg/dL was noted. After two courses of chemotherapy, computed tomography showed a decrease in the ascites, and her serum calcium level increased. Although hypocalcemia is a very rare condition in patients with gastric cancer, serum calcium values should be evaluated when neurological symptoms are observed. (Keyword) Adult / Aged / Female / Humans / Hypocalcemia / Middle Aged / Neoplasm Metastasis / Osteoblasts / Paraneoplastic Syndromes / Stomach Neoplasms / Tomography, X-Ray Computed / Treatment Outcome / Young Adult (Tokushima University Institutional Repository) ● Metadata: 114393 (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.56.8545 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28566596 ● Summary page in Scopus @ Elsevier: 2-s2.0-85020067897 (Tokushima University Institutional Repository: 114393, DOI: 10.2169/internalmedicine.56.8545, PubMed: 28566596, Elsevier: Scopus)
45.	Shinji Kitamura, Toshihito Tanahashi, Eriko Aoyagi, Tadahiko Nakagawa, Koichi Okamoto, Tetsuo Kimura, Hiroshi Miyamoto, Yasuhiro Mitsui, Kazuhito Rokutan, Naoki Muguruma and Tetsuji Takayama : Response Predictors of S-1, Cisplatin, and Docetaxel Combination Chemotherapy for Metastatic Gastric Cancer: Microarray Analysis of Whole Human Genes., Oncology, Vol.93, No.2, 127-135, 2017. (Summary) The aim of this study was to identify biomarkers for predicting the efficacy of docetaxel, cisplatin, and S-1 (DCS) therapy for advanced gastric cancer using microarrays of biopsy specimens before chemotherapy. Nineteen samples were taken from 19 patients with unresectable metastatic gastric cancer who received DCS as a first-line therapy. Laser capture microdissection was performed, and total cellular RNA was extracted from each microdissected sample. Whole-gene expression was analyzed by microarray, and the difference in mRNA expression observed with the microarrays was confirmed by quantitative real-time PCR. Immunohistochemical staining was performed using clinical tissue sections obtained by endoscopic biopsy. Eleven patients were identified as early responders and 8 patients as nonresponders to DCS therapy. Twenty-nine genes showed significant differences in relative expression ratios between tumor and normal tissues. A classifier set of 29 genes had high accuracy (94.7%) for distinguishing gene expression between 11 early responders and 8 nonresponders. Decreasing the size of the classifier set to 4 genes (PDGFB, PCGF3, CISH, and ANXA5) increased the accuracy to 100%. Expression levels by real-time PCR for validation were well correlated with those 4 genes in microarrays. The genes identified may serve as efficient biomarkers for personalized cancer-targeted therapy. (Tokushima University Institutional Repository) ● Metadata: 111015 (Link to Publication Site) ● Publication site (DOI): 10.1159/000464329 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28511180 ● Summary page in Scopus @ Elsevier: 2-s2.0-85019884830 (Tokushima University Institutional Repository: 111015, DOI: 10.1159/000464329, PubMed: 28511180, Elsevier: Scopus)
46.	Koichi Okamoto, Naoki Muguruma, Kaizo Kagemoto, Yasuhiro Mitsui, Daisaku Fujimoto, Shinji Kitamura, Tetsuo Kimura, Masahiro Sogabe, Hiroshi Miyamoto and Tetsuji Takayama : Efficacy of hybrid endoscopic submucosal dissection (ESD) as a rescue treatment in difficult colorectal ESD cases., Digestive Endoscopy, Vol.29, No.suppl.2, 45-52, 2017. (Summary) Endoscopic submucosal dissection (ESD), which provides a higher en bloc resection rate than conventional endoscopic mucosal resection (EMR), is considered to be a useful treatment option for large colorectal tumors. However, colorectal ESD is not widely used because of its technical difficulty, risk of complications and time required. To overcome these drawbacks, a simpler modified technique, ESD with snaring (hybrid ESD), has been developed. The aim of the present study was to retrospectively compare the safety and efficacy of hybrid ESD and conventional ESD for colorectal tumors. Between September 2008 and June 2016, ESD was carried out on 137 lesions and hybrid ESD on 27 lesions. All hybrid ESD cases were carried out as a rescue treatment in difficult ESD cases. We retrospectively investigated procedure time, and the rates of en bloc resection, perforation, bleeding, and local recurrence. In the hybrid ESD group, procedure time was shorter compared with the ESD group (108 ± 59.5 min vs 122 ± 72.2 min), but the en bloc resection rate was lower (66.7% vs 94.2%). However, there were no significant differences in procedure time, or in rates of en bloc resection, perforation and bleeding between the two groups. Local recurrence did not develop in any of our cases. Hybrid ESD as a rescue treatment in difficult ESD cases may be less effective for en bloc resection of large colorectal tumors. Indication for hybrid ESD may be limited to scheduled treatment from the outset and emergency cases with patients who present unstable vital signs during ESD. (Link to Publication Site) ● Publication site (DOI): 10.1111/den.12863 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28425649 ● Search Scopus @ Elsevier (PMID): 28425649 ● Search Scopus @ Elsevier (DOI): 10.1111/den.12863 (DOI: 10.1111/den.12863, PubMed: 28425649)
47.	Tatsuya Taniguchi, Kazuhiro Kishi, Tadahiko Nakagawa, Hironori Tanaka, Takahiro Tanaka, Tetsu Tomonari, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Toshiya Okahisa, Naoki Muguruma, Mayumi Kajimoto, Ikuko Sagawa and Tetsuji Takayama : Poly-(ADP-Ribose) Polymerase-1 Promotes Prothrombin Gene Transcription and Produces Des-Gamma-Carboxy Prothrombin in Hepatocellular Carcinoma., Digestion, Vol.95, No.3, 242-251, 2017. (Summary) Although des-gamma-carboxy prothrombin (DCP) is a well-known tumor marker for hepatocellular carcinoma (HCC), the mechanism of DCP production is unclear. This study aimed to investigate the mechanism how DCP is produced in HCC cells. Levels of mRNA and DCP were analyzed by real-time polymerase chain reaction and electro-chemiluminescence immunoassay respectively. Secreted alkaline phosphatase (SEAP) expression vectors including deletion mutants of the prothrombin gene promoter were constructed for reporter gene assay. The transcription factors bound to DNA fragments were analyzed by mass spectrometry. An electrophoretic mobility shift assay (EMSA) was performed using a biotin end-labeled DNA. The prothrombin mRNA levels in all 5 DCP producing cell lines were appreciably high. However, those in 2 DCP non-producing cell lines were below detectable levels. A SEAP vector with -2985 to +27 showed a very high transcription activity in DCP-producing Huh-1 cells. However, transcription abruptly decreased when the vector with -2955 to +27 was transfected, and then remained at the similar levels with larger deletion mutants, indicating the existence of a cis-element at -2985 to -2955 (31-bp). Mass spectrometry analysis identified the protein that bound to the 31-bp DNA as poly-(ADP-ribose) polymerase-1 (PARP-1). Knockdown of the PARP-1 gene by small interfering RNA in Huh-1 cells induced marked inhibition of prothrombin gene transcription. The EMSA clearly showed that PARP-1 specifically binds to the 31-bp DNA fragment in the prothrombin gene promoter. Our data suggest that PARP-1 activates prothrombin gene transcription and that the excessive prothrombin gene transcription induces DCP production in DCP-producing HCC cells. (Tokushima University Institutional Repository) ● Metadata: 110173 (Link to Publication Site) ● Publication site (DOI): 10.1159/000470837 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28384634 ● Search Scopus @ Elsevier (PMID): 28384634 ● Search Scopus @ Elsevier (DOI): 10.1159/000470837 (Tokushima University Institutional Repository: 110173, DOI: 10.1159/000470837, PubMed: 28384634)
48.	Naoki Muguruma, Kumiko Tanaka, satoshi teramae and Tetsuji Takayama : Colon capsule endoscopy: toward the future., Clinical Journal of Gastroenterology, Vol.10, No.1, 1-6, 2017. (Summary) Colon capsule endoscopy is a wireless and minimally invasive technique for visualization of the whole colon. With recent improvements of technical features in second-generation systems, a more important role for colon capsule endoscopy is rapidly emerging. Although several limitations and drawbacks are yet to be resolved, its usefulness as a tool for colorectal cancer screening and monitoring disease activity in inflammatory bowel diseases has become more apparent with increased use. Further investigations, including multicenter trials, are required to evaluate the substantial role of the colon capsule in managing colorectal diseases. (Keyword) Capsule Endoscopes / Capsule Endoscopy / Colonic Diseases / Colonic Polyps / Colonoscopy / Colorectal Neoplasms / Early Detection of Cancer / Equipment Design / Humans / Inflammatory Bowel Diseases (Link to Publication Site) ● Publication site (DOI): 10.1007/s12328-016-0710-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28084581 ● Search Scopus @ Elsevier (PMID): 28084581 ● Search Scopus @ Elsevier (DOI): 10.1007/s12328-016-0710-3 (DOI: 10.1007/s12328-016-0710-3, PubMed: 28084581)
49.	Yuri Matsumoto, Hiroshi Miyamoto, Akira Fukuya, Fumika Nakamura, Takahiro Goji, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Masahiro Sogabe, Naoki Muguruma, Mitsuo Shimada, Yoshimi Bando and Tetsuji Takayama : Hemosuccus pancreaticus caused by a mucinous cystic neoplasm of the pancreas., Clinical Journal of Gastroenterology, Vol.10, No.2, 185-190, 2017. (Summary) Hemosuccus pancreaticus is a gastrointestinal hemorrhage through the main pancreatic duct. Here, we report a rare case of hemosuccus pancreaticus due to a mucinous cystic neoplasm of the pancreas. A 62-year-old woman who had been followed for a branch duct intraductal papillary mucinous neoplasm visited our emergency room due to severe abdominal pain and bloody discharge. Computed tomography revealed that the pancreatic cyst increased the tension of the wall and a high-density area indicative of bleeding into the cyst was observed. Endoscopy showed opening of and hemorrhaging from the papilla of Vater. The patient was diagnosed with hemosuccus pancreaticus caused by hemorrhaging into the cyst from the branch duct intraductal papillary mucinous neoplasm. Based on this diagnosis, elective distal pancreatectomy was performed. The histopathological diagnosis was a mucinous cystic neoplasm with intermediate-grade dysplasia based upon the pathological findings that fibrous ovarian-type stroma existed abundantly and the stroma cells were positive for progesterone receptor and inhibin. Hemosuccus pancreaticus caused by a mucinous cystic neoplasm is extremely rare and there has been only one case reported to date. In conclusion, it should be recognized that pancreatic cystic neoplasms including mucinous cystic neoplasms may cause hemosuccus pancreaticus. (Keyword) Ampulla of Vater / female / Gastrointestinal Hemorrhage / Humans / magnetic resonance imaging / Middle Aged / Neoplasms, Cystic, Mucinous, and Serous / Pancreatic Cyst / Pancreatic Ducts / Pancreatic Neoplasms / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1007/s12328-016-0711-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28054178 ● Summary page in Scopus @ Elsevier: 2-s2.0-85008158342 (DOI: 10.1007/s12328-016-0711-2, PubMed: 28054178, Elsevier: Scopus)
50.	Satoshi Teramae, Koichi Okamoto, Kumiko Tanaka, Reika Matsumoto, Shinji Kitamura, Tetsuo Kimura, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Yoshimi Bando, Mitsuo Shimada and Tetsuji Takayama : Duodenal cancer in a young patient with Peuts-Jeghers syndrome harboring an entire deletion of the STK11 gene., Clinical Journal of Gastroenterology, Vol.10, No.3, 232-239, 2017. (Link to Publication Site) ● Publication site (DOI): 10.1007/s12328-017-0731-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28303455 ● Summary page in Scopus @ Elsevier: 2-s2.0-85015616972 (DOI: 10.1007/s12328-017-0731-6, PubMed: 28303455, Elsevier: Scopus)
51.	Yasuteru Fujino, Shunsaku Takeishi, Kensei Nishida, Koichi Okamoto, Naoki Muguruma, Tetsuo Kimura, Shinji Kitamura, Hiroshi Miyamoto, Akiko Fujimoto, Jun Higashijima, Mitsuo Shimada, Kazuhito Rokutan and Tetsuji Takayama : Downregulation of miR-100/miR-125b is associated with lymph node metastasis in early colorectal cancer with submucosal invasion., Cancer Science, Vol.108, No.3, 390-397, 2017. (Summary) A majority of early colorectal cancers (CRCs) with submucosal invasion undergo surgical operation, despite a very low incidence of lymph node metastasis. Our study aimed to identify microRNAs (miRNAs) specifically responsible for lymph node metastasis in submucosal CRCs. MicroRNA microarray analysis revealed that miR-100 and miR-125b expression levels were significantly lower in CRC tissues with lymph node metastases than in those without metastases. These results were validated by quantitative real-time PCR in a larger set of clinical samples. The transfection of a miR-100 or miR-125b inhibitor into colon cancer HCT116 cells significantly increased cell invasion, migration, and MMP activity. Conversely, overexpression of miR-100 or miR-125b mimics significantly attenuated all these activities but did not affect cell growth. To identify target mRNAs, we undertook a gene expression array analysis of miR-100-silenced HCT116 cells as well as negative control cells. The Ingenuity Pathway Analysis, TargetScan software analyses, and subsequent verification of mRNA expression by real-time PCR identified mammalian target of rapamycin (mTOR) and insulin-like growth factor 1 receptor (IGF1R) as direct, and Fas and X-linked inhibitor-of-apoptosis protein (XIAP) as indirect candidate targets for miR-100 involved in lymph node metastasis. Knockdown of each gene by siRNA significantly reduced the invasiveness of HCT116 cells. These data clearly show that downregulation of miR-100 and miR-125b is closely associated with lymph node metastasis in submucosal CRC through enhancement of invasion, motility, and MMP activity. In particular, miR-100 may promote metastasis by upregulating mTOR, IGF1R, Fas, and XIAP as targets. Thus, miR-100 and miR-125b may be novel biomarkers for lymph node metastasis of early CRCs with submucosal invasion. (Keyword) Antigens, CD95 / Cell Line, Tumor / Cell Movement / Cell Proliferation / Colorectal Neoplasms / HCT116 Cells / HT29 Cells / Humans / Lymphatic Metastasis / Matrix Metalloproteinases / MicroRNAs / RNA Interference / RNA, Small Interfering / Receptors, Somatomedin / TOR Serine-Threonine Kinases / X-Linked Inhibitor of Apoptosis Protein (Tokushima University Institutional Repository) ● Metadata: 112375 (Link to Publication Site) ● Publication site (DOI): 10.1111/cas.13152 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28032929 ● Search Scopus @ Elsevier (PMID): 28032929 ● Search Scopus @ Elsevier (DOI): 10.1111/cas.13152 (Tokushima University Institutional Repository: 112375, DOI: 10.1111/cas.13152, PubMed: 28032929)
52.	Koichi Okamoto, Shinji Kitamura, Tetsuo Kimura, Tadahiko Nakagawa, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : Clinicopathological Characteristics of Serrated Polyps as Precursors to Colorectal Cancer: Current Status and Management., Journal of Gastroenterology and Hepatology, Vol.32, No.2, 358-367, 2017. (Summary) Serrated polyps have long been thought to lack malignant potential in the human colorectum. However, identification of the serrated pathway to colorectal cancer based on molecular biology has improved our understanding of the pathogenesis of colorectal cancers. Accordingly, serrated polyps such as traditional serrated adenoma and sessile serrated adenoma/polyps (SSA/P) are now considered to be precursor lesions of the serrated pathway. Recently, serrated polyps were classified into three subtypes, consisting of hyperplastic polyp, SSA/P, and traditional serrated adenoma, according to the World Health Organization classification. It has been suggested that SSA/P in the proximal colon are a precursor lesion of pathogenesis of colorectal cancer and are characterized by BRAF mutation and a CpG island methylator phenotype with or without microsatellite instability. However, SSA/P is more challenging to detect by colonoscopy and is likely to account for some interval cancers, particularly in the proximal colon because it presents flat or sessile, isochroous appearance, and occasionally has a mucous cap. Furthermore, the possibility has been raised that pathologists misclassify SSA/P as hyperplastic polyp. It is important for gastroenterologists to recognize the endoscopic features of serrated polyps to facilitate their detection and removal and also to establish postpolypectomy surveillance guidelines. In this review, we discuss the recent classification of serrated polyps; the molecular characteristics of the serrated pathway; appropriate diagnostic methods using endoscopy, including a new image-enhanced endoscopic technique; and management of these lesions. (Link to Publication Site) ● Publication site (DOI): 10.1111/jgh.13482 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27376251 ● Summary page in Scopus @ Elsevier: 2-s2.0-85013296238 (DOI: 10.1111/jgh.13482, PubMed: 27376251, Elsevier: Scopus)
53.	Shinji Kitamura, Naoki Muguruma and Tetsuji Takayama : 隆起を呈する病変上皮性・非腫瘍性胃黄色腫, 消化器内視鏡, Vol.28, No.8, 1178-1179, 2016.
54.	Tetsuo Kimura, Hiroshi Miyamoto, Akira Fukuya, Shinji Kitamura, Koichi Okamoto, Masako Kimura, Naoki Muguruma, Tetsuya Ikemoto, Mitsuo Shimada, Akiko Yoneda, Yoshimi Bando, Makoto Takishita and Tetsuji Takayama : Neuroendocrine carcinoma of the pancreas with similar genetic alterations to invasive ductal adenocarcinoma., Clinical Journal of Gastroenterology, Vol.9, No.4, 261-265, 2016. (Summary) Neuroendocrine carcinoma (NEC) of the pancreas is very rare, and its origin is not fully elucidated. Here, we present a case of a small-size NEC of the pancreas that is genetically similar to invasive ductal adenocarcinoma (IDA). A 65-year-old man was referred to our hospital due to obstructive jaundice and found to have a 12-mm solid tumor in the pancreas head. The tumor exhibited low vascularity on enhanced computed tomography, and endoscopic retrograde pancreatographic imaging revealed an irregular obstruction in a branch duct of the pancreas. The patient was thereby diagnosed with a pancreatic ductal cancer, and stomach-preserving pancreaticoduodenectomy with regional lymph node resection was performed. Histochemical analysis of the resected tumor showed that the neoplastic cells with scanty cytoplasm and hyperchromatic nuclei strongly expressed chromogranin A and synaptophysin. The Ki-67 index was 40 % in the most proliferative tumor regions, and the tumor was diagnosed as a NEC of the pancreas. However, in the analysis of genetic alterations of the tumor tissue, the neoplastic cells showed altered KRAS, TP53, and SMAD4/DPC4, suggesting that the NEC in our case is genetically related to IDA. Our data suggest that poorly differentiated IDAs may transform into NECs. (Keyword) Aged / Carcinoma, Neuroendocrine / Carcinoma, Pancreatic Ductal / Cholangiopancreatography, Endoscopic Retrograde / Disease Progression / Genes, p53 / Humans / Male / Mutation / Pancreatic Neoplasms / Proto-Oncogene Proteins p21(ras) / Smad4 Protein / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1007/s12328-016-0655-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27262570 ● Search Scopus @ Elsevier (PMID): 27262570 ● Search Scopus @ Elsevier (DOI): 10.1007/s12328-016-0655-6 (DOI: 10.1007/s12328-016-0655-6, PubMed: 27262570)
55.	Toshi Takaoka, Tetsuo Kimura, Rai Shimoyama, Shunji Kawamoto, Kazuki Sakamoto, Fuminori Goda, Hiroshi Miyamoto, Yuji Negoro, Akihito Tsuji, Koji Yoshizaki, Takahiro Goji, Shinji Kitamura, Hiromi Yano, Koichi Okamoto, Masako Kimura, Toshiya Okahisa, Naoki Muguruma, Yoshiro Niitsu and Tetsuji Takayama : Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer., Cancer Chemotherapy and Pharmacology, Vol.78, No.2, 397-403, 2016. (Tokushima University Institutional Repository) ● Metadata: 109985 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00280-016-3096-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27342247 ● Summary page in Scopus @ Elsevier: 2-s2.0-84976254460 (Tokushima University Institutional Repository: 109985, DOI: 10.1007/s00280-016-3096-5, PubMed: 27342247, Elsevier: Scopus)
56.	Masahiro Sogabe, Toshiya Okahisa, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : Influence of metabolic syndrome on upper gastrointestinal disease., Clinical Journal of Gastroenterology, Vol.9, No.4, 191-202, 2016. (Summary) A recent increase in the rate of obesity as a result of insufficient physical exercise and excess food consumption has been seen in both developed and developing countries throughout the world. Additionally, the recent increased number of obese individuals with lifestyle-related diseases associated with abnormalities in glucose metabolism, dyslipidemia, and hypertension, defined as metabolic syndrome (MS), has been problematic. Although MS has been highlighted as a risk factor for ischemic heart disease and arteriosclerotic diseases, it was also recently shown to be associated with digestive system disorders, including upper gastrointestinal diseases. Unlike high body weight and high body mass index, abdominal obesity with visceral fat accumulation is implicated in the onset of various digestive system diseases because excessive visceral fat accumulation may cause an increase in intra-abdominal pressure, inducing the release of various bioactive substances, known as adipocytokines, including tumor necrosis factor-α, interleukin-6, resistin, leptin, and adiponectin. This review article focuses on upper gastrointestinal disorders and their association with MS, including obesity, visceral fat accumulation, and the major upper gastrointestinal diseases. (Keyword) Adenocarcinoma / Barrett Esophagus / Esophageal Neoplasms / Gastritis / Gastroesophageal Reflux / Gastrointestinal Diseases / Hernia, Hiatal / Humans / Metabolic Syndrome X / Peptic Ulcer / Stomach Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1007/s12328-016-0668-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27372302 ● Summary page in Scopus @ Elsevier: 2-s2.0-84976486171 (DOI: 10.1007/s12328-016-0668-1, PubMed: 27372302, Elsevier: Scopus)
57.	Tetsuji Takayama, Hiroshi Miyamoto and Naoki Muguruma : Prevention of colorectal cancer, The Japanese Journal of Gastro-enterology, Vol.113, No.7, 1168-1175, 2016. (Summary) 食生活を改善して大腸癌を予防する1次予防では，赤身肉，加工肉，アルコール，喫煙などの危険因子を回避(または減量)すること，野菜，線維，果物，牛乳，カルシウムなどを十分に摂取するとともに，適度な運動を行うように心がけるべきである．また，大腸癌を早期に発見する2次予防では，便潜血検査や大腸内視鏡検査を受けることが重要である．大腸内視鏡検査では，前癌病変である腺腫を摘除することも癌の予防に重要である．一方，現在種々の薬剤の発癌予防効果を調べる臨床試験が行われており，近い将来，有効な予防薬が開発されることが期待される．大腸癌の3次予防としては，異時性の大腸癌予防の観点から定期検査の受診が必要である． (Keyword) 大腸癌 / 予防 / スクリーニング / chemoprevention (Link to Publication Site) ● Publication site (DOI): 10.11405/nisshoshi.113.1168 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001206403529600 ● Search Scopus @ Elsevier (DOI): 10.11405/nisshoshi.113.1168 (DOI: 10.11405/nisshoshi.113.1168, CiNii: 1390001206403529600)
58.	Yoshihiko Miyamoto, Naoki Muguruma, Tetsuo Kimura, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Seiya Kohno, Masahiko Nakasono, Hiroshige Hayashi, Yoshimi Bando and Tetsuji Takayama : Protein-losing enteropathy in a patient with familial adenomatous polyposis and advanced colon cancer., Clinical Journal of Gastroenterology, Vol.9, No.3, 134-139, 2016. (Summary) A 29-year-old female visited a hospital because of increasingly severe lower leg edema. She was diagnosed as having multiple polyps in the stomach and colon by gastroscopy and sigmoidoscopy as well as multiple liver tumors by abdominal CT. She was referred to our hospital for further examination. Total colonoscopy revealed a type 2 tumor in the transverse colon and more than 200 polyps distributed throughout the colorectum. Biopsies of the tumor and polyps showed histological characteristics of adenocarcinoma and tubulovillous adenoma, respectively. Thus, she was diagnosed as having metastatic colon cancer derived from familial adenomatous polyposis (FAP). Laboratory tests showed a marked hypoalbuminemia of 1.1 g/dl. The fecal alpha-1 anti-trypsin test showed abnormal clearance (62.1 ml/day), and scintigraphy using 99mTc-human serum albumin revealed protein loss in the whole colon. Multiple ligation probe amplification analysis of the APC gene identified a germline duplication of exons 11-13. Direct sequencing of the reverse transcription PCR products of APC mRNA revealed a deletion of 25 base pairs and a tandem duplication of exons 11-13. This case was considered to be protein-losing enteropathy resulting from numerous colonic tubulovillous adenomas and advanced colon cancer in a FAP patient with unusual mutational events in APC. (Keyword) Adenomatous Polyposis Coli / Adult / Colonic Neoplasms / Colonoscopy / DNA Mutational Analysis / Edema / Female / Gastroscopy / Genes, APC / Humans / Leg / Liver Neoplasms / Mutation / Pedigree / Protein-Losing Enteropathies / Radionuclide Imaging / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1007/s12328-016-0650-y (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27170298 ● Summary page in Scopus @ Elsevier: 2-s2.0-84966709449 (DOI: 10.1007/s12328-016-0650-y, PubMed: 27170298, Elsevier: Scopus)
59.	Miwako Kagawa, Yasuteru Fujino, Naoki Muguruma, Noriaki Murayama, Koichi Okamoto, Shinji Kitamura, Tetsuo Kimura, Kazuhiro Kishi, Hiroshi Miyamoto, Hisanori Uehara and Tetsuji Takayama : Localized amyloidosis of the stomach mimicking a superficial gastric cancer., Clinical Journal of Gastroenterology, Vol.9, No.3, 109-113, 2016. (Summary) A 73-year-old man was referred to our hospital for further examination of a depressed lesion in the stomach found by cancer screening gastroscopy. A barium upper gastrointestinal series showed an area of irregular mucosa measuring 15 mm on the anterior wall of the gastric body. Esophagogastroduodenoscopy revealed a 15 mm depressed lesion on the anterior wall of the lower gastric body. We suspected an undifferentiated adenocarcinoma from the appearance and took some biopsies. However, histology of the specimens revealed amyloidal deposits in the submucosal layer without malignant findings. Congo red staining was positive for amyloidal protein and green birefringence was observed under polarized light microscopy. Congo red staining with prior potassium permanganate incubation confirmed the light chain (AL) amyloid type. There were no amyloid deposits in the colon or duodenum. Computed tomography of the chest, abdomen, and pelvis showed no remarkable findings. Thus, this case was diagnosed as a localized gastric amyloidosis characterized by AL type amyloid deposition in the mucosal or submucosal layer. As the clinical outcome of gastric AL amyloidosis seems favorable, this case is scheduled for periodic examination to recognize potential disease progression and has been stable for 2 years. (Keyword) Aged / Amyloidosis / Biopsy / Diagnosis, Differential / Gastroscopy / Humans / Male / Stomach / Stomach Diseases / Stomach Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1007/s12328-016-0651-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27170299 ● Summary page in Scopus @ Elsevier: 2-s2.0-84966708422 (DOI: 10.1007/s12328-016-0651-x, PubMed: 27170299, Elsevier: Scopus)
60.	Masahiro Sogabe, Toshiya Okahisa, Tadahiko Nakagawa, Hiroshi Fukuno, Masahiko Nakasono, Tetsu Tomonari, Takahiro Tanaka, Hironori Tanaka, Tatsuya Taniguchi, Naoki Muguruma and Tetsuji Takayama : Influence of light alcohol consumption on lifestyle-related diseases: a predictor of fatty liver with liver enzyme elevation in Japanese females with metabolic syndrome., BMC Gastroenterology, Vol.16, No.1, 17, 2016. (Summary) Although heavy drinking is known to lead to liver injury, some recent studies have reported that light alcohol consumption (LAC) may play a protective role against fatty liver in the general population, and may even play a protective role against non-alcoholic fatty liver disease (NAFLD) in males with metabolic syndrome (MS). However, the association between LAC and fatty liver with liver enzyme elevation in females with MS is unclear. Participants of this study were 20,853 females who underwent a regular health check-up between April 2008 and March 2012 at our hospital. Enrolled subjects were 1141 females with MS, who underwent all necessary tests and drank less than 20 g/day of alcohol. We investigated the presence of fatty liver with liver enzyme elevation, defined in this study as alanine aminotransferase (ALT) levels ≧31 IU/I, and the association between LAC and fatty liver with ALT elevation. There was no significant difference in the prevalence of fatty liver and ALT between light drinkers and non-drinkers. The prevalence of individuals receiving a treatment for dyslipidemia and impaired glucose tolerance (IGT) was significantly lower in light drinkers than in non-drinkers. Body mass index (BMI), waist circumference (WC), diastolic blood pressure (DBP), triglyceride (TG), uric acid (UA), IGT, and visceral fat type MS (V-type MS) were significant predictors of the prevalence of fatty liver with ALT elevation in logistic regression analysis. The odds ratio [OR] (95 % confidence interval [CI], p value) for fatty liver with ALT elevation were as follows: BMI, 2.181 (1.445-3.293, p <0.001); WC, 1.853 (1.280-2.684, p <0.01); DBP, 1.604 (1.120-2.298, p <0.05); TG, 2.202 (1.562-3.105, p <0.001); UA, 2.959 (1.537-5.698, p <0.01); IGT, 1.692 (1.143-2.506, p <0.01); and V-type MS, 3.708 (2.529-5.437, p <0.001). There was no significant difference in the prevalence of fatty liver with ALT elevation in females with MS between light drinkers and non-drinkers, suggesting that other factors such as BMI, WC, V-type MS, and lifestyle-related disease may be more important than LAC for the prevalence of fatty liver with ALT elevation. (Tokushima University Institutional Repository) ● Metadata: 114348 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12876-016-0431-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26892109 ● Search Scopus @ Elsevier (PMID): 26892109 ● Search Scopus @ Elsevier (DOI): 10.1186/s12876-016-0431-6 (Tokushima University Institutional Repository: 114348, DOI: 10.1186/s12876-016-0431-6, PubMed: 26892109)
61.	Tetsu Tomonari, Shunsaku Takeishi, Tatsuya Taniguchi, Takahiro Tanaka, Hironori Tanaka, Shota Fujimoto, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma, Oncotarget, Vol.7, No.6, 7207-7215, 2016. (Summary) The mechanism of resistance of hepatocellular carcinoma (HCC) to sorafenib is unknown and no useful predictive biomarker for sorafenib treatment has been reported. Accordingly, we established sorafenib-resistant HCC cells and investigated the underlying mechanism of resistance to sorafenib. Sorafenib-resistant cell lines were established from the HCC cell line PLC/PRF5 by cultivation under continuous exposure to increasing concentration of sorafenib. The IC50 values of the 2 resistant clones PLC/PRF5-R1 and PLC-PRF5-R2 were 9.2±0.47 M (1.8-fold) and 25±5.1 M (4.6-fold) respectively, which were significantly higher than that of parental PLC/PRF5 cells (5.4±0.17 M) (p < 0.01 respectively), as determined by MTT assay. Western blot analysis of signal transduction-related proteins showed no significant differences in expression of AKT/pAKT, mTOR/pmTOR, or ERK/pERK between the 2 resistant clones versus parent cells, suggesting no activation of an alternative signal transduction pathway. Likewise, when expression of membrane transporter proteins was determined, there were no significant differences in expression levels of BSEP, MDR1, MRP2, BCRP, MRP4 and OCT1 between resistant clones and parent cells. However, the expression levels of MRP3 in the 2 resistant clones were significantly higher than that of parent cells. When MRP3 gene was knocked down by siRNA in PLC-PRF5-R2 cells, the sensitivity of the cells to sorafenib was restored. In the analysis of gene mutation, there was no mutation in the activation segment of Raf1 kinase in the resistant clones. Our data clearly demonstrate that the efflux transporter MRP3 plays an important role in resistance to sorafenib in HCC cells. (Tokushima University Institutional Repository) ● Metadata: 109929 (Link to Publication Site) ● Publication site (DOI): 10.18632/oncotarget.6889 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26769852 ● Summary page in Scopus @ Elsevier: 2-s2.0-84981164782 (Tokushima University Institutional Repository: 109929, DOI: 10.18632/oncotarget.6889, PubMed: 26769852, Elsevier: Scopus)
62.	Jinsei Miyoshi, Hiroshi Miyamoto, Takahiro Goji, Tatsuya Taniguchi, Tetsu Tomonari, Masahiro Sogabe, Tetsuo Kimura, Shinji Kitamura, Koichi Okamoto, Yasuteru Fujino, Naoki Muguruma, Toshiya Okahisa and Tetsuji Takayama : Serum diamine oxidase activity as a predictor of gastrointestinal toxicity and malnutrition due to anticancer drugs., Journal of Gastroenterology and Hepatology, Vol.30, No.11, 1582-1590, 2015. (Summary) Objective evaluation of intestinal mucosal damage due to anticancer drugs is generally difficult. Serum diamine oxidase (DAO) activity is reported to reflect the integrity and maturity of the small intestinal mucosa. Therefore, we investigated whether serum DAO activity is an indicator of gastrointestinal toxicity or nutritional status in patients receiving chemotherapy. We prospectively enrolled 20 patients with unresectable metastatic gastric cancer who received oral S-1 (80 mg/m(2) ) on days 1-14, and intravenous cisplatin (60 mg/m(2) ) and docetaxel (50 mg/m(2) ) on day 8 every 3 weeks. Serum DAO activity was measured by colorimetry. Gastrointestinal toxicity was evaluated by CTCAE v4.0. Endoscopic examination and biopsy of duodenal mucosa assessed mucosal damage. Malnutrition was evaluated by measuring serum total protein and albumin levels. Serum DAO activity decreased step-by-step significantly during anticancer drug treatment and recovered after drug holidays. In all 14 patients who experienced diarrhea, serum DAO activity significantly decreased prior to diarrhea onset. Percent decrease in DAO activity was significantly correlated with severity of diarrhea. Significant correlation was observed between percent decrease in DAO activity and percent decrease in duodenal villus height or surface area from baseline. There were also significant correlations between percent decrease in serum DAO activity at day 14 and percent decrease in serum total protein or albumin levels at day 21 from baseline. Serum DAO activity sensitively indicates gastrointestinal damage prior to symptom onset and can be a useful predictor of intestinal mucosal damage and nutritional status in patients receiving chemotherapy. (Tokushima University Institutional Repository) ● Metadata: 109519 (Link to Publication Site) ● Publication site (DOI): 10.1111/jgh.13004 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25968084 ● Summary page in Scopus @ Elsevier: 2-s2.0-84943595915 (Tokushima University Institutional Repository: 109519, DOI: 10.1111/jgh.13004, PubMed: 25968084, Elsevier: Scopus)
63.	Takahiro Goji, Tetsuo Kimura, Hiroshi Miyamoto, Masanori Takehara, kaizo Kagamoto, Yasuyuki Okada, Jun Okazaki, Yoshifumi Takaoka, Yoshihiko Miyamoto, Yasuhiro Mitsui, Tatsunao Sueuchi, Kumiko Tanaka, Yasuteru Fujino, Sayo Matsumoto, Toshi Takaoka, Shinji Kitamura, Koichi Okamoto, Masako Kimura, Masahiro Sogabe, Naoki Muguruma, Toshiya Okahisa, Yasuhiro Sato, Tamotsu Sagawa, Koji Fujikawa, Yasushi Sato, Hitoshi Ikushima and Tetsuji Takayama : A Phase I/II Study of Fixed-dose-rate Gemcitabine and S-1 with Concurrent Radiotherapy for Locally Advanced Pancreatic Cancer, Cancer Chemotherapy and Pharmacology, Vol.76, No.3, 615-620, 2015. (Summary) This study was conducted to identify the maximum-tolerated dose (MTD) of fixed-dose-rate gemcitabine (FDR-gem) administered concurrently with S-1 and radical radiation for locally advanced pancreatic cancer (LAPC) and to provide efficacy and safety data. Patients with unrespectable pancreatic cancer confined to the pancreatic region were treated with FDR-gem (300-400 mg/m(2), 5 mg/m(2)/min) on days 1, 8, 22, and 29 and 60 mg/m(2) of S-1 orally on days 1-14, 22-35. A total radiation dose of 50.4 Gy (1.8 Gy/day, 28 fractions) was delivered concurrently. Twenty-five patients were enrolled; all were evaluable for toxicity assessment. In phase I, eight patients were treated in sequential cohorts of three to five patients per dose level. The MTD was reached at level 2, and dose-limiting toxicities were neutropenia and thrombocytopenia. The recommended doses were 300 mg/m(2) of gemcitabine and 60 mg/m(2) of S-1 daily. The overall response rate was 25% and disease control rate (partial response plus stable disease) was 92%. The progression-free survival was 11.0 months. The median overall survival and 1-year survival rates were 16.0 months and 73%, respectively. The combination of FDR-gem and S-1 with radiation is a feasible regimen that shows favorable antitumor activity with an acceptable safety profile in patients with LAPC. (Tokushima University Institutional Repository) ● Metadata: 110046 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00280-015-2835-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26220846 ● Summary page in Scopus @ Elsevier: 2-s2.0-84939568942 (Tokushima University Institutional Repository: 110046, DOI: 10.1007/s00280-015-2835-3, PubMed: 26220846, Elsevier: Scopus)
64.	Masahiro Sogabe, Toshiya Okahisa, Masahiko Nakasono, Yasuteru Fujino, Yasuhiro Mitsui, Yoshihumi Takaoka, Tetsuo Kimura, Koichi Okamoto, Naoki Muguruma and Tetsuji Takayama : Investigation of Gastroduodenal Mucosal Injury in Japanese Asymptomatic Antiplatelet Drug Users, Medicine, Vol.94, No.26, e1047, 2015. (Summary) Antiplatelet drugs are widely used for the prevention of cardiovascular disease and cerebral vascular disorders. Although there have been several studies on gastroduodenal mucosal injury with gastrointestinal (GI) symptoms such as GI bleeding, in antiplatelet drug users (including low-dose aspirin (LDA)), there have been few reports on the association between antiplatelet drug use and gastroduodenal mucosal injury in asymptomatic antiplatelet drug users. This study was a cross-sectional study elucidating the association between antiplatelet drug use and gastroduodenal mucosal injury in asymptomatic antiplatelet drug users.Subjects were 186 asymptomatic Japanese antiplatelet drug users who underwent a regular health checkup. Subjects were divided into those with and without gastroduodenal mucosal injury endoscopically, and the association between gastroduodenal mucosal injury and other data in asymptomatic antiplatelet drug users was investigated.The prevalence of males and drinkers were significantly higher in subjects with gastroduodenal mucosal injury than in those without. In addition, the prevalence of proton pump inhibitor (PPI) users was significantly lower in subjects with gastroduodenal mucosal injury than in subjects without gastroduodenal mucosal injury. Logistic regression analysis showed PPI (odds ratios: 0.116; 95% confidence intervals: 0.021-0.638; P < 0.05) was a significant predictor of a decreased prevalence of gastroduodenal mucosal injury and closed-type (C-type) atrophy (3.172; 1.322-7.609; P < 0.01) was a significant predictor of an increased prevalence of severe gastroduodenal mucosal injury in asymptomatic antiplatelet drug users.Gender and lifestyle, such as drinking, may have an impact on risk of gastroduodenal mucosal injury in asymptomatic subjects taking antiplatelet drugs. Although PPI is a significant predictor of a decreased prevalence of gastroduodenal mucosal injury, including in asymptomatic antiplatelet drug users, status of gastric atrophy should also be considered against severe gastroduodenal mucosal injury. (Keyword) Adult / Aged / Aged, 80 and over / Endoscopy, Gastrointestinal / Female / Gastric Mucosa / Humans / Male / Middle Aged / Platelet Aggregation Inhibitors / Retrospective Studies / Stomach Diseases / Young Adult (Tokushima University Institutional Repository) ● Metadata: 115594 (Link to Publication Site) ● Publication site (DOI): 10.1097/MD.0000000000001047 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26131815 ● Summary page in Scopus @ Elsevier: 2-s2.0-84942531762 (Tokushima University Institutional Repository: 115594, DOI: 10.1097/MD.0000000000001047, PubMed: 26131815, Elsevier: Scopus)
65.	Naoki Muguruma, Shinji Kitamura, Tetsuo Kimura, Hiroshi Miyamoto and Tetsuji Takayama : Endoscopic Management of Nonvariceal Upper Gastrointestinal Bleeding: State of the Art., Clinical Endoscopy, Vol.48, No.2, 96-101, 2015. (Summary) Nonvariceal upper gastrointestinal (GI) bleeding is one of the most common reasons for hospitalization and a major cause of morbidity and mortality worldwide. Recently developed endoscopic devices and supporting apparatuses can achieve endoscopic hemostasis with greater safety and efficiency. With these advancements in technology and technique, gastroenterologists should have no concerns regarding the management of acute upper GI bleeding, provided that they are well prepared and trained. However, when endoscopic hemostasis fails, endoscopy should not be continued. Rather, endoscopists should refer patients to radiologists and surgeons without any delay for evaluation regarding the appropriateness of emergency interventional radiology or surgery. (Tokushima University Institutional Repository) ● Metadata: 115064 (Link to Publication Site) ● Publication site (DOI): 10.5946/ce.2015.48.2.96 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25844335 ● Summary page in Scopus @ Elsevier: 2-s2.0-84961291895 (Tokushima University Institutional Repository: 115064, DOI: 10.5946/ce.2015.48.2.96, PubMed: 25844335, Elsevier: Scopus)
66.	Shinji Kitamura, Yasuyuki Okada, Naoki Muguruma, Hiroshi Miyamoto, Yoshimi Bando, Rika Aoki and Tetsuji Takayama : Epidermoid metaplasia of the esophagus with an unusual appearance on magnification., Endoscopy, Vol.47, No.S1, E100, 2015. (Link to Publication Site) ● Publication site (DOI): 10.1055/s-0034-1391299 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25734803 ● Summary page in Scopus @ Elsevier: 2-s2.0-84930007610 (DOI: 10.1055/s-0034-1391299, PubMed: 25734803, Elsevier: Scopus)
67.	Yasuhiro Mitsui, Kaizo Kagemoto, Tatsuzo Itagaki, Shuji Inoue, Keishi Naruse, Naoki Muguruma and Tetsuji Takayama : Gastric inflammatory fibroid polyp morphologically changed by Helicobacter pylori eradication., Clinical Journal of Gastroenterology, Vol.8, No.2, 71-88, 2015. (Summary) A 60-year-old male presented to our hospital for further investigation of abnormal findings on an upper gastrointestinal series. Esophagogastroduodenoscopy demonstrated atrophic gastritis and a submucosal tumor (SMT) at the anterior wall of the antrum. The patient was positive for serum anti-Helicobacter pylori (H. pylori) antibody and H. pylori eradication therapy was performed. Five months later, the SMT showed a remarkable morphological change in that an ulcer had developed on its apex, and partial gastrectomy was performed. Pathological examination suggested an inflammatory fibroid polyp (IFP), and genetic analysis revealed no mutation in the platelet-derived growth factor receptor alpha gene. This case suggests that H. pylori infection plays an important role in the etiology of IFPs. (Link to Publication Site) ● Publication site (DOI): 10.1007/s12328-015-0557-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25733031 ● Summary page in Scopus @ Elsevier: 2-s2.0-84939983772 (DOI: 10.1007/s12328-015-0557-z, PubMed: 25733031, Elsevier: Scopus)
68.	Satoshi Teramae, Hiroshi Miyamoto, Naoki Muguruma, Yasuyuki Okada, Takahiro Goji, Shinji Kitamura, Tetsuo Kimura, Masako Kimura, Yoshimi Bando and Tetsuji Takayama : Insulin-like growth factor II-producing metastatic colon cancer with recurrent hypoglycemia., Clinical Journal of Gastroenterology, Vol.8, No.1, 35-40, 2015. (Summary) A 45-year-old man was referred to our hospital and found to have a tubular adenocarcinoma of the descending colon with multiple liver metastases. During hospitalization, the patient suffered recurrent hypoglycemic attacks that required intravenous 50% glucose infusion. He was diagnosed with non-islet cell tumor hypoglycemia (NICTH) because the colon cancer tissue obtained by biopsy was strongly stained for insulin-like growth factor-II (IGF-II) by immunohistochemistry. He received chemotherapy with oxaliplatin, 5-FU and leucovorin (FOLFOX) plus bevacizumab (Bmab), and showed a partial response. As the metastatic lesions decreased in size, the hypoglycemic attacks gradually disappeared. Subsequently, he received outpatient chemotherapy and maintained a high quality of life for about 10 months. Western blot analysis of IGF-II in serum at the time of admission showed a high-molecular-weight form of IGF-II, which was considered to have caused hypoglycemia. This patient presents a very rare case of colorectal cancer associated with NICTH syndrome due to production of high-molecular-weight IGF-II by cancer cells. It is important to investigate IGF-II expression in cancer tissues for establishing the diagnosis of NICTH in cases with intractable hypoglycemia complicated by advanced cancer. (Keyword) Adenocarcinoma / Blotting, Western / Colonic Neoplasms / Humans / Hypoglycemia / Immunohistochemistry / Insulin-Like Growth Factor II / Liver Neoplasms / Male / Middle Aged / Recurrence (Link to Publication Site) ● Publication site (DOI): 10.1007/s12328-015-0552-4 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25605315 ● Summary page in Scopus @ Elsevier: 2-s2.0-84925493491 (DOI: 10.1007/s12328-015-0552-4, PubMed: 25605315, Elsevier: Scopus)
69.	Atsushi Inoue, Koichi Okamoto, Yasuteru Fujino, Tadahiko Nakagawa, Naoki Muguruma, Katsutaka Sannomiya, Yasuhiro Mitsui, Toshi Takaoka, Shinji Kitamura, Hiroshi Miyamoto, Toshiya Okahisa, Takahiro Fujimori, Issei Imoto and Tetsuji Takayama : B-RAF mutation and accumulated gene methylation in aberrant crypt foci (ACF),sessile serrated adenoma/polyp (SSA/P) and cancer in SSA/P., British Journal of Cancer, Vol.112, No.2, 403-412, 2015. (Summary) Sessile serrated adenomas/polyps (SSA/Ps) are a putative precursor of colon cancer with microsatellite instability (MSI). However, the developmental mechanism of SSA/P remains unknown. We performed genetic analysis and genome-wide DNA methylation analysis in aberrant crypt foci (ACF), SSA/P, and cancer in SSA/P specimens to show a close association between ACF and the SSA/P-cancer sequence. We also evaluated the prevalence and number of ACF in SSA/P patients. ACF in the right-side colon were observed in 36 patients with SSA/Ps alone, 2 with cancers in SSA/P, and 20 normal subjects and biopsied under magnifying endoscopy. B-RAF mutation and MSI were analysed by PCR-restriction fragment length polymorphism (RFLP) and PCR-SSCP, respectively, in 15 ACF, 20 SSA/P, and 2 cancer specimens. DNA methylation array analysis of seven ACF, seven SSA/P, and two cancer in SSA/P specimens was performed using the microarray-based integrated analysis of methylation by isochizomers (MIAMI) method. B-RAF mutations were frequently detected in ACF, SSA/P, and cancer in SSA/P tissues. The number of methylated genes increased significantly in the order of ACF<SSA/P<cancer. The most commonly methylated genes in SSA/P were PQLC1, HDHD3, RASL10B, FLI1, GJA3, and SLC26A2. Some of these genes were methylated in ACF, whereas all genes were methylated in cancers. Immunohistochemistry revealed their silenced expression. Microsatellite instability and MLH1 methylation were observed only in cancer. The prevalence and number of ACF were significantly higher in SSA/P patients than in normal subjects. A significant correlation was seen between the numbers of SSA/P and ACF in SSA/P patients. Our results suggest that ACF are precursor lesions of the SSA/P-cancer sequence in patients with SSA/P, where ACF arise by B-RAF mutation and methylation of some of the six identified genes and develop into SSA/Ps through accumulated methylation of these genes. (Keyword) Aberrant Crypt Foci / Adenoma / Aged / Case-Control Studies / Colonic Neoplasms / DNA Methylation / Female / Genetic Association Studies / Genetic Predisposition to Disease / Humans / Male / Middle Aged / Mutation, Missense / Proto-Oncogene Proteins B-raf (Tokushima University Institutional Repository) ● Metadata: 106441 (Link to Publication Site) ● Publication site (DOI): 10.1038/bjc.2014.545 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25314065 ● Summary page in Scopus @ Elsevier: 2-s2.0-84922337339 (Tokushima University Institutional Repository: 106441, DOI: 10.1038/bjc.2014.545, PubMed: 25314065, Elsevier: Scopus)
70.	Yoshitaka Imoto, Toshi Takaoka, Naoki Muguruma, Satoshi Teramae, Hirohiko Shinomiya, Satoshi Wada and Tetsuji Takayama : Impacted gastroscope in the esophagus, Endoscopy, Vol.46, No.S1, E523, 2014. (Keyword) Aged, 80 and over / Device Removal / Endoscopy, Gastrointestinal / Equipment Failure / Esophagus / Female / Gastroscopes / Hernia, Hiatal / Humans (Link to Publication Site) ● Publication site (DOI): 10.1055/s-0034-1377595 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25409050 ● Summary page in Scopus @ Elsevier: 2-s2.0-84911454657 (DOI: 10.1055/s-0034-1377595, PubMed: 25409050, Elsevier: Scopus)
71.	Yasuteru Fujino, Naoki Muguruma, Shinji Kitamura, Yasuhiro Mitsui, Tetsuo Kimura, Hiroshi Miyamoto, Hisanori Uehara, Koichi Kataoka and Tetsuji Takayama : Perineurioma in the sigmoid colon diagnosed and treated by endoscopic resection, Clinical Journal of Gastroenterology, Vol.7, No.5, 392-396, 2014. (Summary) Perineuriomas are rare benign peripheral nerve sheath tumors in the gastrointestinal tract. We recently encountered a submucosal lesion in the sigmoid colon that was resected by endoscopic mucosal resection and was then diagnosed as perineurioma by immunohistochemistry. A 51-year-old female with a positive test for fecal occult blood was referred to our hospital for screening colonoscopy. Colonoscopy identified a submucosal lesion, approximately 15 mm in diameter, in the sigmoid colon. Endoscopic ultrasound showed a 15-mm tumor with a strong acoustic shadow. Endoscopic mucosal resection was performed in order to make a precise diagnosis as well as removal. The specimen revealed spindle cell proliferation without atypia, and immunostaining revealed that the spindle cells were positive for collagen type IV and glut-1, and the lesion was diagnosed as a colonic perineurioma with no malignancy. Gastroenterologists as well as pathologists should be aware of this type of submucosal lesion, and immunohistochemical evaluation is highly recommended when an unusual mesenchymal tumor is found. (Keyword) perineurioma / colon / endoscopic mucosal resection (Link to Publication Site) ● Publication site (DOI): 10.1007/s12328-014-0519-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26184017 ● Summary page in Scopus @ Elsevier: 2-s2.0-84919872298 (DOI: 10.1007/s12328-014-0519-x, PubMed: 26184017, Elsevier: Scopus)
72.	Miyamoto Yoshihiko, Naoki Muguruma, Seisuke Okamura, Okada Yasuyuki, Shinji Kitamura, Koichi Okamoto, Takahiro Goji, Yoneda Akiko, Noriko Kagawa and Tetsuji Takayama : A pedunculated submucosal lesion in the stomach with inverted downgrowth, Internal Medicine, Vol.53, No.15, 1625-1628, 2014. (Summary) A 70-year-old man with a gastric lesion was referred to our hospital because of an unusual pedunculated lesion in the gastric body. Endoscopic ultrasound showed scattered cystic lesions within a heterogeneous area confined to the submucosal layer. Endoscopic mucosal resection was performed to obtain a precise diagnosis, as well as for removal. The lesion was histopathologically diagnosed as a heterotopic submucosal gland. We herein describe this rare type of gastric polyp and provide a literature review. (Keyword) Adenomatous Polyps / Aged / Endoscopy, Gastrointestinal / Endosonography / Gastric Mucosa / Humans / Male / Stomach Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.53.2719 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25088874 ● CiNii @ National Institute of Informatics (CRID): 1390282679846781312 ● Summary page in Scopus @ Elsevier: 2-s2.0-84905280970 (DOI: 10.2169/internalmedicine.53.2719, PubMed: 25088874, CiNii: 1390282679846781312, Elsevier: Scopus)
73.	Hirao Akihiro, Tetsu Tomonari, Tanaka Hironori, Kumiko Tanaka, Kagawa Miwako, Tanaka Takahiro, Tatsuya Taniguchi, Harada Rie, Momoko Sato, Naoki Muguruma and Tetsuji Takayama : Development of a renal subcapsular hematoma during angiography for diagnosis and subsequent treatment of hepatocellular carcinoma, Clinical Journal of Gastroenterology, Vol.7, No.2, 185-188, 2014. (Summary) A renal subcapsular hematoma rarely occurs without a history of trauma. It has been reported as a complication of urological interventions and also reported to occur spontaneously in patients with renal malignancies. However, there are no previous reports of renal subcapsular hematomas occurring in connection with abdominal angiography. We report here a case of a renal subcapsular hematoma that developed and was recognized during abdominal angiography for treatment of hepatocellular carcinoma (HCC). An 80-year-old male was referred to our hospital for transarterial embolization for multiple HCCs. His past medical history included hypertension. His laboratory data showed slightly decreased number of platelets and hepaplastin test due to liver cirrhosis. When computed tomography angiography was performed, a 7-cm subcapsular hematoma developed and was recognized over the right kidney during the procedure. He was successfully managed supportively with blood transfusion, tranexamic acid and antibiotics. Since thrombocytopenia and hypertension are reportedly risk factors for hematoma formation, careful manipulation is required during angiography in HCC patients with liver cirrhosis and hypertension. It must be kept in mind that rare complications, such as a renal subcapsular hematoma, can happen during abdominal angiography for diagnostic and interventional treatment of HCC. (Link to Publication Site) ● Publication site (DOI): 10.1007/s12328-014-0468-4 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26183639 ● Summary page in Scopus @ Elsevier: 2-s2.0-84900315664 (DOI: 10.1007/s12328-014-0468-4, PubMed: 26183639, Elsevier: Scopus)
74.	Shinji Kitamura, Naoki Muguruma, Koichi Okamoto, Fumika Nakamura, Yasuyuki Okada, Tetsuo Kimura, Hiroshi Miyamoto and Tetsuji Takayama : Endoscopic submucosal dissection through a gastrostomy for early gastric cancer in patients with pharyngeal stenosis., Gastrointestinal Endoscopy, Vol.79, No.2, 206-207, 2014. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.gie.2013.09.018 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24129250 ● Summary page in Scopus @ Elsevier: 2-s2.0-84892564534 (DOI: 10.1016/j.gie.2013.09.018, PubMed: 24129250, Elsevier: Scopus)
75.	Momoko Sato, Naoki Muguruma, Nakagawa Tadahiko, Koichi Okamoto, Tetsuo Kimura, Shinji Kitamura, Hiromi Yano, Sannomiya Katsutaka, Takahiro Goji, Hiroshi Miyamoto, Toshiya Okahisa, Hiroaki Mikasa, Wada Satoshi, Iwata Masao and Tetsuji Takayama : High antitumor activity of pladienolide B and its derivative in gastric cancer, Cancer Science, Vol.105, No.1, 110-116, 2014. (Summary) The antitumor activity of pladienolide B, a novel splicing inhibitor, against gastric cancer is totally unknown and no predictive biomarker of pladienolide B efficacy has been reported. We investigated the antitumor activity of pladienolide B and its derivative on gastric cancer cell lines and primary cultured cancer cells from carcinomatous ascites of gastric cancer patients. The effect of pladienolide B and its derivative on six gastric cancer cell lines was investigated using a MTT assay and the mean IC50 values determined to be 1.6 ± 1.2 (range, 0.6-4.0) and 1.2 ± 1.1 (range, 0.4-3.4) nM, respectively, suggesting strong antitumor activity against gastric cancer. The mean IC50 value of pladienolide B derivative against primary cultured cells from 12 gastric cancer patients was 4.9 ± 4.7 nM, indicative of high antitumor activity. When 18 SCID mice xenografted with primary cultured cells from three patients were administered the pladienolide B derivative intraperitoneally, all tumors completely disappeared within 2 weeks after treatment. Histological examination revealed a pathological complete response for all tumors. In the xenograft tumors after treatment with pladienolide B derivative, immature mRNA were detected and apoptotic cells were observed. When the expressions of cell-cycle proteins p16 and cyclin E in biopsied gastric cancer specimens were examined using immunohisctochemistry, positivities for p16 and cyclin E were significantly and marginally higher, respectively, in the low-IC50 group compared with the high-IC50 group, suggesting the possibility that they might be useful as predictive biomarkers for pladienolide B. In conclusion, pladienolide B was very active against gastric cancer via a mechanism involving splicing impairment and apoptosis induction. (Keyword) Aged / Aged, 80 and over / Animals / Antineoplastic Agents / Apoptosis / Cell Line, Tumor / Cyclin E / Cyclin-Dependent Kinase Inhibitor p16 / Epoxy Compounds / Female / Humans / Macrolides / Male / Mice / Mice, SCID / Middle Aged / RNA Splicing / Random Allocation / Stomach Neoplasms / Xenograft Model Antitumor Assays (Tokushima University Institutional Repository) ● Metadata: 106055 (Link to Publication Site) ● Publication site (DOI): 10.1111/cas.12317 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24635824 ● Summary page in Scopus @ Elsevier: 2-s2.0-84892849884 (Tokushima University Institutional Repository: 106055, DOI: 10.1111/cas.12317, PubMed: 24635824, Elsevier: Scopus)
76.	Toshihiro Omoya, Masako Shiba, Shingo Hibino, Rika Aoki, Shinji Kitamura, Naoki Muguruma and Tetsuji Takayama : Twig tea impaction in the colon causing abdominal pain, Clinical Journal of Gastroenterology, Vol.6, No.6, 438-441, 2013. (Summary) We describe a case of lower abdominal pain caused by a twig tea impaction at the rectosigmoid junction after inadvertent ingestion. The foreign body was detected and successfully dislodged from the colonic wall with grasping forceps during colonoscopy. The post-procedural course was uneventful, and the patient was discharged 10 days after the removal. Colonic injury, including perforation due to foreign body ingestion, must be considered in patients presenting with unexplained symptoms and findings, even when they do not recall any foreign body ingestion. (Keyword) abdominal pain / foreign body / endoscopic removal (Link to Publication Site) ● Publication site (DOI): 10.1007/s12328-013-0429-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26182134 ● Search Scopus @ Elsevier (PMID): 26182134 ● Search Scopus @ Elsevier (DOI): 10.1007/s12328-013-0429-3 (DOI: 10.1007/s12328-013-0429-3, PubMed: 26182134)
77.	Naoki Muguruma, Hiroshi Miyamoto, Toshiya Okahisa and Tetsuji Takayama : Endoscopic Molecular Imaging: Status and Future Perspective., Clinical Endoscopy, Vol.46, No.6, 603-610, 2013. (Summary) During the last decade, researchers have made great progress in the development of new image processing technologies for gastrointestinal endoscopy. However, diagnosis using conventional endoscopy with white light optical imaging is essentially limited, and ultimately, we still rely on the histopathological diagnosis from biopsy specimens. Molecular imaging represents the most novel imaging methods in medicine, and the future of endoscopic diagnosis is likely to be impacted by a combination of biomarkers and technology. Endoscopic molecular imaging can be defined as the visualization of molecular characteristics with endoscopy. These innovations will allow us not only to locate a tumor or dysplastic lesion but also to visualize its molecular characteristics and the activity of specific molecules and biological processes that affect tumor behavior and/or its response to therapy. In the near future, these promising technologies will play a central role in endoluminal oncology. (Tokushima University Institutional Repository) ● Metadata: 115065 (Link to Publication Site) ● Publication site (DOI): 10.5946/ce.2013.46.6.603 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24340252 ● Search Scopus @ Elsevier (PMID): 24340252 ● Search Scopus @ Elsevier (DOI): 10.5946/ce.2013.46.6.603 (Tokushima University Institutional Repository: 115065, DOI: 10.5946/ce.2013.46.6.603, PubMed: 24340252)
78.	Koichi Okamoto, Takaoka Toshi, Naoki Muguruma, Tetsuji Takayama and Niitsu Yoshiro : Endoscopy of aberrant crypt foci: the expert approach, Video Journal and Encyclopedia of GI Endoscopy, Vol.1, 357-358, 2013. (Link to Publication Site) ● Publication site (DOI): 10.1016/S2212-0971(13)70156-0 (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-84888331543 (DOI: 10.1016/S2212-0971(13)70156-0, Elsevier: Scopus)
79.	Miho Tsuda, Koichi Okamoto, Naoki Muguruma, Katsutaka Sannomiya, Tadahiko Nakagawa, Hiroshi Miyamoto, Shinji Kitamura, Takahiro Goji, Tetsuo Kimura, Toshiya Okahisa, Keisuke Izumi and Tetsuji Takayama : Suppressive effect of RAS inhibitor manumycin A on aberrant crypt foci formation in the azoxymethane-induced rat colorectal carcinogenesis model., Journal of Gastroenterology and Hepatology, Vol.28, No.10, 1616-1623, 2013. (Summary) Manumycin A suppressed ACF formation in the AOM-induced colorectal carcinogenesis model, demonstrating that RAS inhibitors may be very effective for chemoprevention of colorectal cancers. (Tokushima University Institutional Repository) ● Metadata: 105897 (Link to Publication Site) ● Publication site (DOI): 10.1111/jgh.12287 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23730936 ● Search Scopus @ Elsevier (PMID): 23730936 ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.12287 (Tokushima University Institutional Repository: 105897, DOI: 10.1111/jgh.12287, PubMed: 23730936)
80.	Koichi Okamoto, Shinji Kitamura, Naoki Muguruma, Toshi Takaoka, Yasuteru Fujino, Yoshiro Kawahara, Toshiya Okahisa and Tetsuji Takayama : Mucosectom2-short blade for safe and efficient endoscopic submucosal dissection of colorectal tumors., Endoscopy, Vol.45, No.11, 928-930, 2013. (Summary) The M2-SB seems to be a safe and efficient tool for colorectal ESD. (Link to Publication Site) ● Publication site (DOI): 10.1055/s-0033-1344644 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24019129 ● Search Scopus @ Elsevier (PMID): 24019129 ● Search Scopus @ Elsevier (DOI): 10.1055/s-0033-1344644 (DOI: 10.1055/s-0033-1344644, PubMed: 24019129)
81.	Shinji Kitamura, Mitsugi Yasuda, Naoki Muguruma, Koichi Okamoto, Hisashi Takeuchi, Yoshimi Bando, Hiroshi Miyamoto, Toshiya Okahisa, Mitsuyasu Yano, Ryusuke Torisu and Tetsuji Takayama : Prevalence and characteristics of nodular gastritis in Japanese elderly., Journal of Gastroenterology and Hepatology, Vol.28, No.7, 1154-1160, 2013. (Summary) NG in the elderly was also suggested to be a risk factor for gastric cancer as well as in the young. (Keyword) Age Factors / Aged / Aged, 80 and over / Asian Continental Ancestry Group / Gastritis / Gastroscopy / Humans / Japan / Prevalence / Risk Factors / Stomach Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1111/jgh.12180 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23432631 ● Search Scopus @ Elsevier (PMID): 23432631 ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.12180 (DOI: 10.1111/jgh.12180, PubMed: 23432631)
82.	Tetsuo Kimura, Naoki Muguruma, Takahiro Goji, Koichi Okamoto, Shinji Kitamura, Hiromi Yano, Hiroshi Miyamoto, Toshiya Okahisa, Naomi Sakashita and Tetsuji Takayama : Pedunculated duodenal carcinoid successfully removed by endoscopic resection with endoloop., Journal of Digestive Diseases, Vol.14, No.7, 402-404, 2013. (Link to Publication Site) ● Publication site (DOI): 10.1111/1751-2980.12033 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23302224 ● Summary page in Scopus @ Elsevier: 2-s2.0-84878388921 (DOI: 10.1111/1751-2980.12033, PubMed: 23302224, Elsevier: Scopus)
83.	Koichi Okamoto, Naoki Muguruma, Shinji Kitamura, Masako Shiba and Tetsuji Takayama : Lessons from imperfect endoscopic submucosal dissection of rectal tumor., Digestive Endoscopy, Vol.25, No.Suppl 2, 31-36, 2013. (Summary) Endoscopic mucosal resection (EMR) is a standard endoscopic treatment for gastrointestinal tumors, but resections done in a piecemeal fashion are difficult to diagnose pathologically as curative resections, and the local recurrence rate is relatively high. Recently, endoscopic submucosal dissection (ESD) for colorectal tumors, which provides a higher complete resection rate than conventional EMR, has rapidly come into widespread use in Japan. However, colorectal ESD is still technically difficult and has complications such as perforation, and the procedure time is longer than that of conventional EMR. We report herein a case in which a rectal tumor was resected with an inappropriate specimen due to imperfect ESD. This lesion had severe fibrosis in the submucosal layer because the lesion had been injected with a solution for EMR in another hospital, which resulted in non-lifting signs, and had been subjected to many biopsies. During the ESD in our hospital, the submucosal layer was not clearly identified, and a small injury was caused in the specimen. A precise diagnosis based on histopathological findings could not be made because of the inappropriate specimen. Thus, expertise in both the diagnostic and the therapeutic aspects is required before treating large colorectal tumors. (Link to Publication Site) ● Publication site (DOI): 10.1111/den.12074 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23617646 ● Search Scopus @ Elsevier (PMID): 23617646 ● Search Scopus @ Elsevier (DOI): 10.1111/den.12074 (DOI: 10.1111/den.12074, PubMed: 23617646)
84.	Koichi Okamoto, Naoki Muguruma, Shinji Kitamura, Y Fujino, Takahiro Goji, Hiromi Yano, Tetsuo Kimura, Hiroshi Miyamoto, Toshiya Okahisa and Tetsuji Takayama : A new large-diameter overtube for endoscopic submucosal dissection in the colon., Endoscopy, Vol.44, No.Suppl 2 UCTN, E395-6, 2012. (Keyword) Aged / Aged, 80 and over / Colonic Diseases / Colonoscopy / Equipment Design / Female / Humans / Intestinal Mucosa / Male / Middle Aged (Link to Publication Site) ● Publication site (DOI): 10.1055/s-0032-1310249 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23139039 ● Search Scopus @ Elsevier (PMID): 23139039 ● Search Scopus @ Elsevier (DOI): 10.1055/s-0032-1310249 (DOI: 10.1055/s-0032-1310249, PubMed: 23139039)
85.	Koichi Okamoto, Seisuke Okamura, Naoki Muguruma, Shinji Kitamura, Tetsuo Kimura, Yoshitaka Imoto, Hiroshi Miyamoto, Toshiya Okahisa and Tetsuji Takayama : Endoscopic submucosal dissection for early gastric cancer using a cross-counter technique., Surgical Endoscopy, Vol.26, No.12, 3676-3681, 2012. (Summary) Endoscopic submucosal dissection (ESD) in early gastric cancer has rapidly come into widespread use. However, since complications such as bleeding and perforation often occur, and the procedure time is longer for ESD than endoscopic mucosal resection (EMR), development of safer and more reliable technique is required. The subjects comprised 45 patients with lesions diagnosed histologically as early gastric cancer. They were divided into three groups: cross-counter technique group (CC, n = 15), peroral traction-assisted ESD with suture material group (PT, n = 15), and no-traction group (NT, n = 15). ESD was carried out by two endoscopists who had experienced fewer than 30 cases of ESD. To compare safety and efficacy of a new traction method (CC group) for ESD in early gastric cancer with other methods (PT group and NT group), procedure time, dissected area per unit time, complete resection rate, perforation rate, and bleeding rate were evaluated. There was no significant difference among these three groups in terms of complications, complete resection rate or procedure time. The dissection area per unit time was 22.4, 15.7, and 13.5 mm(2)/min in the CC, PT, and NT groups, respectively, and there was a significant difference between the CC and NT groups (p = 0.007). The cross-counter technique shortened the treatment time for endoscopists without abundant experience in gastric ESD, and it is considered a useful method to institute in order to introduce ESD. (Keyword) Aged / Aged, 80 and over / Early Medical Intervention / Equipment Design / Female / Gastric Mucosa / Gastroscopes / Gastroscopy / Humans / Male / Middle Aged / Stomach Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1007/s00464-012-2364-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22692462 ● Search Scopus @ Elsevier (PMID): 22692462 ● Search Scopus @ Elsevier (DOI): 10.1007/s00464-012-2364-7 (DOI: 10.1007/s00464-012-2364-7, PubMed: 22692462)
86.	Naoki Muguruma, Seisuke Okamura, Y Imoto, Koichi Okamoto, T Sueuchi, Shinji Kitamura, Tetsuo Kimura and Tetsuji Takayama : Hypopharyngeal injury caused by overtube insertion during endoscopic submucosal dissection., Endoscopy, Vol.44, No.Suppl 2 UCTN, E225, 2012. (Keyword) Fractures, Cartilage / Gastroscopy / Humans / Hypopharynx / Male / Middle Aged / Thyroid Cartilage (Link to Publication Site) ● Publication site (DOI): 10.1055/s-0032-1309351 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22622758 ● Search Scopus @ Elsevier (PMID): 22622758 ● Search Scopus @ Elsevier (DOI): 10.1055/s-0032-1309351 (DOI: 10.1055/s-0032-1309351, PubMed: 22622758)
87.	Naoki Muguruma, Seisuke Okamura, Y Imoto, T Sueuchi, Koichi Okamoto, H Fujimoto, K Arita, Takanori Hirose and Tetsuji Takayama : Perineurioma: an uncommon lesion in the gastrointestinal tract., Endoscopy, Vol.44, No.Suppl 2 UCTN, E182-3, 2012. (Keyword) Biopsy / Endosonography / Humans / Male / Middle Aged / Nerve Sheath Neoplasms / Stomach Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1055/s-0031-1291748 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22622734 ● Search Scopus @ Elsevier (PMID): 22622734 ● Search Scopus @ Elsevier (DOI): 10.1055/s-0031-1291748 (DOI: 10.1055/s-0031-1291748, PubMed: 22622734)
88.	Koichi Okamoto, Naoki Muguruma, Shinji Kitamura, Tetsuo Kimura and Tetsuji Takayama : Endoscopic submucosal dissection for large colorectal tumors using a cross-counter technique and a novel large-diameter balloon overtube., Digestive Endoscopy, Vol.24, No.Suppl.1, 96-99, 2012. (Summary) Endoscopic submucosal dissection (ESD) in early gastric cancer (EGC), which provides a higher complete resection rate than conventional endoscopic mucosal resection (EMR), has rapidly come into widespread use. However, colorectal ESD is not widely used because of its technical difficulty and complications such as perforation, and the procedure time is longer than that of conventional EMR. Development of safer and more reliable devices as well as technique modifications are therefore required. The aim of our study is to compare safety and efficacy of a new traction method, the cross-counter technique, for large colorectal tumors combined with a balloon overtube. A total of 30 patients with large colorectal tumors were analyzed retrospectively; 15 patients for the cross-counter technique group (CC group) and 15 patients for the no-traction group (NT group). Procedure time, complete resection rate, perforation rate and bleeding rate were assessed. The procedure time was 126 ± 42.2 min and 165 ± 61.3 min in the CC and NT groups, respectively, and there was a significant difference between the two groups (P < 0.05). There were no significant differences in complete resection rate, perforation rate and bleeding rate between the two groups. The cross-counter technique shortened the treatment time in colorectal ESD without any complication. (Keyword) Aged / Colorectal Neoplasms / Dissection / Endoscopy, Gastrointestinal / Female / Humans / Intestinal Mucosa / Male / Middle Aged / Retrospective Studies (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1443-1661.2012.01264.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22533761 ● Search Scopus @ Elsevier (PMID): 22533761 ● Search Scopus @ Elsevier (DOI): 10.1111/j.1443-1661.2012.01264.x (DOI: 10.1111/j.1443-1661.2012.01264.x, PubMed: 22533761)
89.	Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Masako Kimura, Shinji Kitamura, Hidetaka Takenaka, Naoki Muguruma, Toshiya Okahisa, Eriko Aoyagi, Mayumi Kajimoto, Yasushi Tsuji, Takahiro Kogawa, Akihito Tsuji and Tetsuji Takayama : Clinical benefit of high-sensitivity KRAS mutation testing in metastatic colorectal cancer treated with anti-EGFR antibody therapy., Oncology, Vol.82, No.5, 298-304, 2012. (Summary) We compared high-sensitivity KRAS mutation testing with direct sequencing for predicting the efficacy of antiepidermal growth factor receptor antibodies in patients with metastatic colorectal cancer (mCRC). We analyzed the KRAS status in 61 tumors from cetuximab-treated mCRC patients by both direct sequencing and a high-sensitivity method: 2-step PCR restriction fragmentation length polymorphism (RFLP). Therapeutic effects in each mutational status were evaluated. The incidences of KRAS mutations determined by direct sequencing and 2-step PCR RFLP were 34.4 and 52.5%, respectively (p = 0.02). Patients were categorized into 3 groups [W/W, wild-type by both methods (n = 29); W/M, wild-type by direct sequencing, detected mutation by 2-step PCR RFLP (n = 11); M/M, mutant-type by both methods (n = 21)]. The response rate for cetuximab in the W/M group (0%) was the same as that in the M/M group, and was significantly lower than in the W/W group (41.4%) (p < 0.001). Progression-free survival in the W/M group (11.0 weeks) was similar to that in the M/M group (8.0 weeks), and was significantly shorter than in the W/W group (18.0 weeks) (p < 0.002). High-sensitivity KRAS mutation testing is useful for selecting true responders to cetuximab. (Keyword) Adult / Aged / Aged, 80 and over / Antibodies, Monoclonal / Antineoplastic Agents / Colorectal Neoplasms / Female / Humans / Male / Middle Aged / Mutation / Proto-Oncogene Proteins / Receptor, Epidermal Growth Factor / Retrospective Studies / ras Proteins (Link to Publication Site) ● Publication site (DOI): 10.1159/000336792 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22555244 ● Search Scopus @ Elsevier (PMID): 22555244 ● Search Scopus @ Elsevier (DOI): 10.1159/000336792 (DOI: 10.1159/000336792, PubMed: 22555244)
90.	Naoki Muguruma, Koichi Okamoto, Tetsuo Kimura, Kazuhiro Kishi, Toshiya Okahisa, Seisuke Okamura and Tetsuji Takayama : Endoscopic ablation therapy for gastrointestinal superficial neoplasia., Digestive Endoscopy, Vol.24, No.3, 139-149, 2011. (Summary) In Japan, endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) have been widely accepted and standardized for the treatment of gastrointestinal superficial neoplasia. In contrast, mucosal ablation techniques are more common in Western countries and a variety of endoscopic ablation modalities, including argon plasma coagulation (APC), photodynamic therapy (PDT) and lasers, are used. Recently developed modalities such as radiofrequency ablation (RFA) and cryotherapy are also available for the treatment of superficial lesions such as dysplasia of Barrett's esophagus. Although we should understand that the completeness of destruction of neoplastic tissue can only be judged at follow up, endoscopic ablation is a viable alternative to endoscopic resection for dysplasia and early-stage malignancies, especially for poor candidates of surgery or endoscopic resection. (Keyword) Adenoma / Argon Plasma Coagulation / Carcinoma, Squamous Cell / Catheter Ablation / Cryotherapy / Endoscopy, Gastrointestinal / Forecasting / Gastrointestinal Neoplasms / Humans / Japan / Laser Therapy / Photochemotherapy / Precancerous Conditions (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1443-1661.2011.01227.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22507086 ● Search Scopus @ Elsevier (PMID): 22507086 ● Search Scopus @ Elsevier (DOI): 10.1111/j.1443-1661.2011.01227.x (DOI: 10.1111/j.1443-1661.2011.01227.x, PubMed: 22507086)
91.	Naoki Muguruma and Susumu Ito : Labeled anti-mucin antibody detectable by infrared-fluorescence endoscopy., Cancer Biomarkers, Vol.4, No.6, 321-328, 2008. (Summary) The goal of our study was to develop a method for molecular imaging of the gastrointestinal tract using an infrared fluorescence endoscope (IRFE) and antibodies labeled with an indocyanine green (ICG) derivative to detect cancerous tissue. The IRFE comprised an infrared endoscope equipped with excitation (710-790 nm) and barrier (810-920 nm) filters. We developed ICG-N-hydroxysulfosuccinimide ester (ICG-sulfo-OSu) and 3-ICG-acyl-1,3-thiazolidine-2-thione (ICG-ATT) as infrared fluorescent-labeling reagents, and anti-human carcinoembryonic antigen (CEA) antibody and MUC1 antibody were labeled with the ICG-derivatives. Freshly resected specimens of gastric cancer were observed by IRFE after reaction with ICG-derivative-labeled antibodies. Positive fluorescence was observed at the tumor location by IRFE, and the immunofluorescent images correlated well with the tumor sites. The immunofluorescence studies suggested that the intensity of the infrared fluorescence of the ICG-ATT-labeled MUC1 antibody is stronger than the ICG-sulfo-OSu-labeled MUC1 antibody. We concluded that specific antibodies for gastrointestinal cancer labeled with an ICG-derivative accompanied by a reinforcing agent and an optimal electronic device can generate a strong enough fluorescent signal to visualize cancer proteins. (Keyword) Animals / Antibodies / Coloring Agents / Endoscopy, Gastrointestinal / Fluorescence / Gastrointestinal Neoplasms / Humans / Indocyanine Green / Mucin-1 / Spectroscopy, Near-Infrared (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19126960 ● Search Scopus @ Elsevier (PMID): 19126960 (PubMed: 19126960)
92.	Sogabe Masahiro, Kimura Yoshitaka, Iwaki Hiroshi, Okita Yoshio, Hibino Shingo, Sawda Seizo, Toshiya Okahisa, Okamoto Koichi, Tsujigami Koji, Hayashi Hiroshige, Hukui Yasuo, Nakamura Toshio, Taniki Toshikatsu, Nakasono Masahiko, Naoki Muguruma, Seisuke Okamura and Susumu Ito : Ultrasonographic comparison of gastric motility between diabetic gastroparesis patients with and without metabolic syndrome., Journal of Gastroenterology and Hepatology, Vol.23, No.7 Pt 2, e17-22, 2007. (Summary) Diabetic patients with poor glycemic control or long standing disease often have impaired gastric motility. Recently, metabolic factors such as blood glucose have been reported as influencing gastric motility independently of autonomic neuropathy. Many diabetic patients have metabolic syndrome, which is strongly associated with coronary and other diseases. We investigated whether metabolic syndrome influences diabetic gastroparesis patients. We observed gastric motility ultrasonographically in diabetic gastroparesis patients including nine with and nine without metabolic syndrome. Both groups complained of upper abdominal symptoms when hospitalized to improve blood sugar control. All patients underwent upper gastrointestinal endoscopy to rule out gastric and duodenal lesions. All had autonomic neuropathy. Gastric motility was evaluated within 3 days after admission by transabdominal ultrasonography after a test meal. Gastric emptying was 45.0 +/- 13.7% in patients with and 39.1 +/- 11.9% in patients without metabolic syndrome, which was not statistically significant. Frequency of gastric contractions was 8.33 +/- 2.78 per 3 min in patients with metabolic syndrome and 7.44 +/- 2.13 per 3 min in the others, which was not statistically significant. The motility index, which involves antral contractility, was 3.21 +/- 2.18 in patients with metabolic syndrome and 2.80 +/- 1.87 in the others, which was not statistically significant. Metabolic syndrome did not appear to contribute to delayed gastric motility in diabetic gastroparesis. (Keyword) Adult / Aged / Diabetes Complications / Female / Gastric Emptying / Gastroparesis / Humans / Male / Metabolic Syndrome X / Middle Aged (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1440-1746.2007.05055.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 17645473 ● Summary page in Scopus @ Elsevier: 2-s2.0-47649107714 (DOI: 10.1111/j.1440-1746.2007.05055.x, PubMed: 17645473, Elsevier: Scopus)
93.	井本佳孝, Naoki Muguruma, 木村哲夫, 梶雅子, 宮本弘志, Seisuke Okamura, Susumu Ito, 中園雅彦, Mitsuyoshi Hirokawa and Toshiaki Sano : A case of parathyroid hormone-related peptide producing gallbladder carcinoma presenting humoral hypercalcemia of malignancy, The Japanese Journal of Gastro-enterology, Vol.104, No.3, 401-406, 2007. (Summary) Humoral hypercalcemia of malignancy (HHM) in neoplastic syndrome has been most commonly reported in squamous cell carcinoma. Gallbladder carcinoma with HHM is uncommon. In this report, we describe a male case of gallbladder carcinoma with marked hypercalcemia and a high level of serum parathyroid hormone-related peptide (PTHrP). An immunohistochemical examination using PTHrP was also positive. (Keyword) HHM (humoral hypercalcemia of malignancy) / PTHrP (parathyroid hormone-related peptide) / 胆嚢癌 (Link to Publication Site) ● Publication site (DOI): 10.11405/nisshoshi.104.401 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 17337878 ● CiNii @ National Institute of Informatics (CRID): 1390001206399296000 ● Search Scopus @ Elsevier (PMID): 17337878 ● Search Scopus @ Elsevier (DOI): 10.11405/nisshoshi.104.401 (DOI: 10.11405/nisshoshi.104.401, PubMed: 17337878, CiNii: 1390001206399296000)
94.	Yoshitaka Imoto, Naoki Muguruma, Tetsuo Kimura, Eriko Aoyagi, Koichi Okamoto, Seisuke Okamura, Susumu Ito, Nobuya Sano and Mitsuo Shimada : Relationship between mucin expression and preoperatie bile juice cytology in biliary tract carcinoma, The Journal of Medical Investigation : JMI, Vol.54, No.1-2, 41-47, 2007. (Summary) The present study evaluated correlations between preoperative bile juice cytology and mucin expression of surgical specimens in biliary tract carcinoma. Twenty-five patients with biliary tract carcinoma surgically treated at our hospital, whose bile juice cytology had been evaluated before operation, were allocated to this study. Biliary cytology was classified into three categories based on the Papanicolaou classification. Immunohistochemical staining of tissues was performed using MUC1 and MUC2 monoclonal antibodies. Lesions showing MUC1 expression of ++ or higher and MUC2 expression of - were classified as Group A, and the remaining lesions as Group B. According to the epithelial site, preoperative cytology was highly correlated in Group A, while it was negative in Group B (p<0.05). In the advanced site of carcinomas, preoperative cytology tended to highly be positive in Group A, while it tended to be negative in Group B (p<0.05). These results suggest that the bile juice cytology results are affected by characteristics of mucin expression in the tissue. Based on the possibility that mucin expression correlates with the prognosis of each carcinoma, a positive cytological result suggests a poor prognosis for the carcinoma, which may be informative for predicting the post-operative courses and choosing treatments. (Keyword) Adult / Aged / Antigens, Neoplasm / Bile / Biliary Tract Neoplasms / Female / Humans / immunohistochemistry / Male / Middle Aged / Mucin-1 / Mucin-2 / Mucins (Tokushima University Institutional Repository) ● Metadata: 111493 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.54.41 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 17380013 ● Search Scopus @ Elsevier (PMID): 17380013 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.54.41 (Tokushima University Institutional Repository: 111493, DOI: 10.2152/jmi.54.41, PubMed: 17380013)
95.	Mihiro Yano, Naoki Muguruma, Susumu Ito, Eriko Aoyagi, Tetsuo Kimura, Yoshitaka Imoto, Jianxin Cao, Shohei Inoue, Shigeki Sano, Yoshimitsu Nagao and Hiroshi Kido : Fab fragment labeled with ICG-derivative for detecting digestive tract cancer, Photodiagnosis and Photodynamic Therapy, Vol.3, No.3, 177-183, 2006. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.pdpdt.2006.03.012 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.pdpdt.2006.03.012 (DOI: 10.1016/j.pdpdt.2006.03.012)
96.	Yoko Tadatsu, Naoki Muguruma, Susumu Ito, Masaya Tadatsu, Yoshihiro Kusaka, Koichi Okamoto, Yoshitaka Imoto, Hiromi Taue, Shigeki Sano and Yoshimitsu Nagao : Optimal Labeling Condition of Antibodies Available for Immunofluorescence Endoscopy, The Journal of Medical Investigation : JMI, Vol.53, No.1/2, 52-60, 2006. (Summary) In recent years, labeled antibodies have been used for diagnostic imaging in many studies. In this study, we investigated the mode of binding in antibodies labeled with ICG derivatives newly developed for the diagnosis of microcarcinomas, and evaluated the optimal binding molar ratio between the labeling compounds and antibody. MUC 1 antibody and ICG derivatives (ICG-ATT and ICG-sulfo-OSu) were used. ICG derivatives non-covalently bound to the antibody were removed with ethyl acetate, and the ratio of ICG derivatives covalently bound to the labeled antibody was confirmed. During purification of the labeled antibody, the amount of each labeling compound reacting with 1 molecule of the antibody varied as follows: 4, 8, 16, and 32 molar equivalents. Subsequently, the intensity of fluorescence was evaluated by spectroscopy and infrared fluoroscopy. The ratio of residual ICG derivative labeling the antibody was 67.4% for ICG-ATT and 65.0% for ICG-sulfo-OSu. When fluorescent antibody labeled with ICG-ATT at an F/P ratio of 2.94 or 4.18 was used, specific and clear fluorescent images of the antigen were obtained. When ICG-ATT-labeled antibody at an F/P ratio of 6.50 or 6.75 was used, the fluorescence intensity decreased and the fluorescent images of antigen became unclear. It was found that the ICG-ATT-labeled antibody was a more specific and sensitive marker than ICG-sulfo-OSu-labeled antibody, and that lower binding molar ratios of ICG-ATT were more useful for labeling the antibody. (Keyword) Antibodies, Neoplasm / Antigens, Neoplasm / Endoscopy / Fluorescent Antibody Technique / Fluorescent Dyes / Gastroscopy / Humans / Indocyanine Green / Infrared Rays / Mucin-1 / Mucins / Stomach Neoplasms (Tokushima University Institutional Repository) ● Metadata: 110788 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.53.52 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16537996 ● Search Scopus @ Elsevier (PMID): 16537996 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.53.52 (Tokushima University Institutional Repository: 110788, DOI: 10.2152/jmi.53.52, PubMed: 16537996)
97.	Naoki Muguruma, 木村哲夫, 板垣達三 *井本佳孝, 梶雅子, 宮本弘志, Seisuke Okamura and Susumu Ito : 尋常性天庖瘡に伴う食道病変, 消化器の臨床, Vol.19, No.3, 338-340, 2006.
98.	Seisuke Okamura, Toshiaki Sano, 木村哲夫, 矢野弘美, 井本佳孝, 梶雅子, 青木利佳, 佐藤康紀, 宮本弘志, Naoki Muguruma, Susumu Ito, 梅本淳, 下田忠和 and 春藤譲治 : 嚢胞変性により特異な形態を呈した胃GISTの一例, 胃と腸, Vol.41, No.5, 844-850, 2006.
99.	Masahiko Nakasono, Naoki Muguruma, Seisuke Okamura, Susumu Ito, Akiko Iga, Satoshi Wada, Michiyo Okazaki, Takahiro Horie, Tamotsu Fukuda and Toshiaki Sano : Colonic pseudolipomatosis, microscopically classified into two groups, Journal of Gastroenterology and Hepatology, Vol.21, No.1 Pt 1, 65-70, 2006. (Summary) Colonic pseudolipomatosis is rare and the pathogenesis is controversial. The purpose of the present paper was to clarify endoscopic and histological characteristics of colonic pseudolipomatosis and to discuss the etiology. A total of 15 lesions from 14 patients was reviewed. They were able to be histologically classified into two groups on the basis of variety in size of the vacuoles: Group A, the ratio of largest vacuole to smallest vacuole in size is less than three, Group B, the ratio is more than four. Four of 15 lesions were group A, and were endoscopically polypoid or flat lesions covered with normal-looking mucosa. They were microscopically characterized by (i) predominant location in the upper portion of the lamina propria; (ii) no submucosal involvement; (iii) less variation in vacuolar size; and (iv) no association with lymph follicles. The vacuoles of group A contained proteinaceous materials in two of four lesions. Group B (11 lesions) had small elevated mucosa with normal-looking surface or non-elevated reddish mucosa. Microscopically, the lesions were mainly located in the lower portion of the lamina propria, occasionally also in the submucosa, had variable-sized vacuoles, and were related to lymph follicles. It is suggested that the vacuoles in group A contain fluid, and may indicate an abnormal stagnation of interstitial fluid. Microscopic appearance of group B is essentially similar to that of pneumatosis coli. It is thought that group B probably results from penetration of gas from the crypts into the mucosa during colonoscopy. It is unclear why group B had a preference for ileocecal valve and an association with lymph follicles. (Keyword) Adult / Aged / Aged, 80 and over / Colon / Colonic Diseases / Colonoscopy / Female / Humans / Lipomatosis / Male / Microscopy / Middle Aged / Mucous Membrane / Pneumatosis Cystoides Intestinalis / Retrospective Studies / Vacuoles (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1440-1746.2005.03973.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16706814 ● Summary page in Scopus @ Elsevier: 2-s2.0-33645226290 (DOI: 10.1111/j.1440-1746.2005.03973.x, PubMed: 16706814, Elsevier: Scopus)
100.	Naoki Muguruma, Yoshitaka Imoto, Tetsuo Kimura, Seisuke Okamura and Susumu Ito : Adenomyomatosis of the Gallbladder as a Potential Risk Factor for Gallbladder Carcinoma, International Medical Journal, Vol.13, No.2, 91-94, 2006. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1572261550975660416 ● Summary page in Scopus @ Elsevier: 2-s2.0-33745659205 (CiNii: 1572261550975660416, Elsevier: Scopus)
101.	Masahiko Nakasono, Mitsuyoshi Hirokawa, Naoki Muguruma, Seisuke Okamura, Susumu Ito, Michiyo Okazaki, Takahiro Horie, Masuo Kimura, Mayuko Takeuchi, Toshi Inoshita and Toshiaki Sano : Duodenal lymphangitis carcinomatosa: endoscopic characteristics and clinical significance., Journal of Gastroenterology and Hepatology, Vol.21, No.(1 Pt 1), 79-83, 2006. (Summary) Duodenal lymphangitis carcinomatosa has been sporadically described, but so far little attention has been paid to duodenal lymphangitis carcinomatosa. Four cases with duodenal lymphangitis carcinomatosa were endoscopically and histologically examined. The four cases exhibited multiple polypoid lesions along the Kerckring's folds and/or were covered by characteristically granular, non-ulcerated mucosa upon thickening. The granularity seems to been caused by dilated lymph vessels containing the carcinoma cells. The lesions were microscopically characterized by: (i) involvement of lymph vessels located in the upper portion of the lamina propria; (ii) no inflammatory changes; and (iii) no desmoplastic changes. Primary sites were thought to be the stomach in case 1, the pancreas in cases 2 and 4, and unknown in case 3. All patients died within 6 months after admission or endoscopic examination. As duodenal lymphangitis carcinomatosis shows characteristic endoscopic appearance, endoscopic diagnosis is not difficult. We should realize that the lesion represents extremely poor prognosis, and it should be distinguished from ordinary metastatic duodenal carcinoma. (Keyword) Aged / Carcinoma / Diagnosis, Differential / Duodenal Neoplasms / Duodenoscopy / Fatal Outcome / Female / Humans / Intestinal Mucosa / Lymphangitis / Lymphatic Vessels / Male / Middle Aged / Pancreatic Neoplasms / Stomach Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1440-1746.2005.04203.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16706816 ● Summary page in Scopus @ Elsevier: 2-s2.0-33645214568 (DOI: 10.1111/j.1440-1746.2005.04203.x, PubMed: 16706816, Elsevier: Scopus)
102.	Mayuko Takagawa, Naoki Muguruma, Kaori Oguri, Yoshitaka Imoto, Koichi Okamoto, Kunio II and Susumu Ito : Prediction of Prognosis in Gallbladder Carcinoma by Mucin and p53 Immunohistochemistry, Digestive Diseases and Sciences, Vol.50, No.8, 1410-1413, 2005. (Summary) Mucin core proteins are known to be present in various organs and are specifically expressed with carcinogenesis and closely associated with the prognoses of various malignant tumors in the digestive tract such as colorectal cancer. The present study evaluated correlations between mucin and p53 expression and prognosis of gallbladder cancer using surgically resected tissue specimens from 26 patients with gallbladder carcinoma surgically treated at our hospital. Immunohistochemical staining was performed using MUC 1, MUC2, and p53 monoclonal antibody. The level of antigen expression in the lesion was classified into four stages: none(-), slight(+), moderate (++), and severe (+ + +). According to the UICC classification, histopathological grading, levels of T, N, and M factors, and tumor stages were compared with regard to the correlations with mucin and p53 expression. All cases were classified into two groups according to the results of mucin immunohistochemistry: group A (MUC1, > or = ++; and MUC2, < or = +) and group B (MUC1, < ++; or MUC2, > +). Postoperative survival periods were compared between the two groups and p53-positive and -negative groups. Neither histological grading nor T factor correlated with mucin or p53 expression, respectively. Moreover, neither N factor nor M factor correlated with mucin or p53 expression. Furthermore, stage grouping did not correlate with mucin or p53 expression. However, when the correlation between the postoperative survival period and mucin expression was evaluated, the mean postoperative surgical period was significantly shorter in Group A than in Group B (1.02 years in Group A vs 2.92 years in Group B; P = 0.016). There was no relationship between postoperative survival period and p53 positivity. Mucin expression was independent of various tumor growth factors and clearly reflected the prognosis of gallbladder cancer. Because the relative malignancy of gallbladder cancer could be evaluated by examining the level of glycoprotein expression in tumor tissue, mucin could be a more important marker than p53 for predicting prognosis in gallbladder carcinoma using surgically resected tissue specimens. (Keyword) gallbladder carcinoma / mucin / p53 / prognosis (Link to Publication Site) ● Publication site (DOI): 10.1007/s10620-005-2854-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16114133 ● Search Scopus @ Elsevier (PMID): 16114133 ● Search Scopus @ Elsevier (DOI): 10.1007/s10620-005-2854-8 (DOI: 10.1007/s10620-005-2854-8, PubMed: 16114133)
103.	Akemi Tsutsui, Seisuke Okamura, Naoki Muguruma, Koji Tsujigami, Soichi Ichikawa, Susumu Ito and Kazunori Umino : Three-Dimensional Reconstruction of ENdosonographic Images of Gastric Lesions: Preliminary Experience, Journal of Clinical Ultrasound, Vol.33, No.3, 112-118, 2005. (Summary) This study was conducted to assess the ability of the endoluminal sonographic probes to image upper gastrointestinal lesions detected with conventional endoscopy and to reconstruct 3-dimensional (3D) images. Sonographic images were obtained from 25 gastrointestinal lesions in 22 patients using a sonographic miniprobe manually drawn at a set speed across lesions detected during conventional endoscopy. 3D images were then reconstructed using an in-house software program. In 16 lesions (64%), the 3D sectional images were evaluated as good, and all 25 lesions (100%) could be visualized both transversely and longitudinally. In 12 lesions (48%), the 3D display of the endosonographic surface image corresponded to the endoscopic appearance. In all 11 cases of gastric cancer, the depth of tumor invasion measured using the 3D image was consistent with the histologic diagnosis (100% accuracy). When videotaped sonographic images were stored on a hard disk, it took an average of 3.5 minutes to obtain and display 3D images of the targeted area. 3D sonographic reconstructions of digestive lesions were useful in diagnosis, and we believe that further improvements should enhance the clinical usefulness of 3D endosonography. (Keyword) Adult / Aged / Aged, 80 and over / Artifacts / Endosonography / Female / Gastrectomy / Gastric Mucosa / Humans / Imaging, Three-Dimensional / Male / Middle Aged / Neoplasm Invasiveness / Neoplasm Staging / Retrospective Studies / Software / Stomach Neoplasms / Video Recording (Link to Publication Site) ● Publication site (DOI): 10.1002/jcu.20100 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15756663 ● Search Scopus @ Elsevier (PMID): 15756663 ● Search Scopus @ Elsevier (DOI): 10.1002/jcu.20100 (DOI: 10.1002/jcu.20100, PubMed: 15756663)
104.	Susumu Ito, Koichi Okamoto, Naoki Muguruma, T. Kimura, H. Yano, Y. Imoto, M. Kaji, R. Aoki and Seisuke Okamura : A Novel Diagnostic Method for Evaluation of Vascular Lesions in the Digestive Tract Using Infrared Fluorescence Endoscopy, Endoscopy, Vol.37, No.1, 52-57, 2005. (Summary) We have developed an infrared fluorescence endoscope to evaluate gastrointestinal vascular lesions. Infrared endoscopy (IRE) after intravenous administration of indocyanine green (ICG) is used at present to examine vascular lesions such as esophageal varices. However, no previous study has compared the sensitivity of infrared fluorescence endoscopy (IRFE) with that of IRE. In this study, we compared the usefulness of IRFE and IRE. For IRFE we used an infrared endoscope equipped with excitation and barrier filters and an intensified charge-coupled device camera. In preliminary experiments, the observable tissue depth was assessed by wrapping increasing numbers of layers of commercially available pork around a syringe containing a uniform concentration of ICG or by changing the concentration of ICG in a syringe covered by a piece of pork of uniform thickness. In the clinical part of the study, ICG was administered intravenously at different concentrations to patients with esophageal varices and the resulting infrared fluorescent images were evaluated. The preliminary experiments revealed that the depth of tissue that could be visualized was significantly greater in IRFE than it was in IRE (11.2 mm in IRFE vs. approximately 3.2 mm in IRE). Clear infrared fluorescence was obtained by IRFE at lower concentrations of ICG than the concentrations required to obtain clear images using IRE. In the clinical part of the study, clear infrared fluorescence was observed in a region where esophageal varices had been detected by conventional endoscopy when ICG was administered in doses of 0.005 mg/kg to 0.01 mg/kg, which was lower than the doses used in IRE. Compared with conventional IRE, IRFE facilitated the observation of deeper layers, and esophageal varices were observed by IRFE following the intravenous administration of a markedly reduced dose of ICG. IRFE, in combining the characteristics of reflected infrared light and fluorescence, may be a useful novel procedure in the diagnosis of vascular lesions in the gastrointestinal tract. (Keyword) Aged / Animals / Dose-Response Relationship, Drug / Endoscopy, Gastrointestinal / Esophageal and Gastric Varices / Female / Fluorescent Dyes / Gastric Mucosa / Humans / Indocyanine Green / Infrared Rays / Male / Middle Aged / Permeability / Swine / Tissue Culture Techniques (Link to Publication Site) ● Publication site (DOI): 10.1055/s-2004-826102 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15657859 ● Search Scopus @ Elsevier (PMID): 15657859 ● Search Scopus @ Elsevier (DOI): 10.1055/s-2004-826102 (DOI: 10.1055/s-2004-826102, PubMed: 15657859)
105.	Koichi Okamoto, Naoki Muguruma, Rika Aoki, Yasunori Sato, Jiro Nakamoto, Yoshitaka Imoto, Seisuke Okamura, Susumu Ito, Hiroshi Okitsu and Toshiaki Sano : A Treatment Using ST1571 for Jejunal Gastrointestinal Stromal Tumor (GIST) Accompanied with Liver Metastas and Peritoneal Dissemination, Internal Medicine, Vol.43, No.12, 1151-1156, 2004. (Summary) A 64-year-old man with a chief complaint of melena visited our emergency outpatient clinic. After several examinations, he was diagnosed as a gastrointestinal stromal tumor (GIST) with liver metastasis. Surgical resection of the jejunal lesion and postoperative adjuvant therapy with STI571 for one year was performed. Due to recent immunohistological studies and introduction of STI571, the diagnosis, treatment, and prognosis of GIST are about to change profoundly. Further accumulation of cases is necessary to investigate the diagnosis, treatment, and prognosis of GIST. (Keyword) Antineoplastic Agents / Gastrointestinal Stromal Tumors / Humans / Jejunal Neoplasms / Liver Neoplasms / Male / Middle Aged / Peritoneal Neoplasms / Piperazines / Pyrimidines / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.43.1151 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15645649 ● Search Scopus @ Elsevier (PMID): 15645649 ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.43.1151 (DOI: 10.2169/internalmedicine.43.1151, PubMed: 15645649)
106.	Masahiko Nakasono, Mitsuyoshi Hirokawa, Naoki Muguruma, Toshiya Okahisa, Seisuke Okamura, Susumu Ito, Hiroshi Miyamoto, Satoshi Wada, Tamotsu Fukuda and Toshiaki Sano : Colorectal xanthomas with polypoid lesion:report of 25 cases., APMIS, Vol.112, No.1, 3-10, 2004. (Summary) Little attention has been paid to colorectal xanthoma. To clarify the clinical and pathological features of colorectal xanthoma, we report 28 colorectal xanthomas biopsied from 25 patients. All were composed of typical xanthoma cells and showed polypoid configuration. Median age of the patients was 64 years and there were 15 men and 10 women. Diabetes mellitus, constipation, and hyperlipidemia were found in two, one, and seven patients, respectively. Seventeen (60.7%) of the 28 polyps were located in the sigmoid colon and the remaining 11 in the rectum. Twenty-three polyps (82.1%) were sessile. Twelve (60.0%) of twenty polyps that were recorded were reddish in color. Only two polyps revealed a yellowish tone. Microscopically, foamy cells were present in the lamina propria, but the submucosa did not contain foamy cells. Immunohistochemically, the foamy cells invariably expressed extensive positivity for CD68. The colonic glands showed a deformity in the case with moderate to intense density of the foamy cells. The surface epithelium showed a hyperplastic change in 22 (78.6%) xanthomas. The colonic glands in four xanthomas were also associated with hyperplastic changes. The basement membrane of the surface epithelium was often thickened. Cell debris and proliferation of the capillaries were observed just below the surface epithelium in 19 (67.9%) and 22 (78.6%) xanthomas, respectively. Previous mucosal minute injury was suggested as the pathogenesis of colorectal xanthomas. Colorectal xanthomas were not identical to gastric and esophageal xanthoma, endoscopically or microscopically. We prefer the term "xanthomatous polyp" rather than xanthoma in the colorectal region. They may be regarded as a novel type of colorectal non-neoplastic polyp. (Keyword) Adult / Aged / Aged, 80 and over / Biopsy / Colonic Diseases / Female / Humans / Immunohistochemistry / Male / Middle Aged / Rectal Diseases / Retrospective Studies / Xanthomatosis (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1600-0463.2004.apm1120102.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 14961968 ● Search Scopus @ Elsevier (PMID): 14961968 ● Search Scopus @ Elsevier (DOI): 10.1111/j.1600-0463.2004.apm1120102.x (DOI: 10.1111/j.1600-0463.2004.apm1120102.x, PubMed: 14961968)
107.	Masaya Tadatsu, Susumu Ito, Naoki Muguruma, Yoshihiro Kusaka, Kumi Inayama, Termi Bando, Yoko Tadatsu, Koichi Okamoto, Kunio Ii, Yoshimitsu Nagao, Shigeki Sano and Hiromi Taue : A New Infrared Fluorescent-Labeling Agent and Labeled Antibody for Diagnosing Microcancers, Bioorganic & Medicinal Chemistry, Vol.11, No.15, 3289-3294, 2003. (Summary) We have developed infrared fluorescent labeling agents and infrared-ray fluorescence endoscopes to establish a novel diagnostic technique. Since the fluorescence intensity of the initial labeled antibody (ICG-sulfo-OSu-labeled antibody) was not sufficient for practical use, we synthesized indocyanine green acylthiazolidinethione (ICG-ATT), which was expected to label various target molecules having amino groups efficiently. To confirm imaging of infrared fluorescence intensity of ICG-ATT- and ICG-sulfo-OSu-labeled anti-MUC1 antibodies, cotton thread was soaked in various concentrations of the antibody solution in 0.1M PBS, and observed under the epi-illumination infrared fluorescence microscope. Localization and the intensity of infrared fluorescence and DAB coloring was compared in paraffin sections of human gastric mucosa. In the study of cotton threads, both labeled antibodies showed relatively clear infrared fluorescence, and significant difference was not observed between the two antibodies. ICG-ATT-labeled anti-MUC1 antibody produced stronger staining than that by ICG-sulfo-OSu-labeled antibody. Localization pattern of infrared fluorescent staining was in good agreement with that by the conventional method with oxidized DAB staining. ICG-ATT is useful as a fluorescent-labeling agent for diagnosis of microcancers by infrared fluorescence endoscopes. (Keyword) Gastric Mucosa / Humans / Indocyanine Green / Microscopy, Fluorescence / Neoplasms / Spectrophotometry, Infrared / Staining and Labeling / Thiazolidinediones (Link to Publication Site) ● Publication site (DOI): 10.1016/S0968-0896(03)00239-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12837539 ● Summary page in Scopus @ Elsevier: 2-s2.0-10744220597 (DOI: 10.1016/S0968-0896(03)00239-6, PubMed: 12837539, Elsevier: Scopus)
108.	K Inayama, Susumu Ito, Naoki Muguruma, Yoshihiro Kusaka, T Bando, Y Tadatsu, M Tadatsu, Kunio Ii, S Shibamura and K Takesako : Basic study of an agent for reinforcement of near-infrared fluorescence on tumor tissue, Digestive and Liver Disease, Vol.35, No.2, 88-93, 2003. (Summary) An indocyanine green derivative (ICG-sulfo-OSu) and agents for reinforcement of infrared fluorescence, which can be used as an infrared fluorescent labeling substance suitable for detection of microlesions by an IR fluorescence endoscope, have been developed. The study aims were to confirm the ability of a reinforcement agent, as well as imaging processing, to intensify fluorescence from the labeled antibody on immunohistochemical staining. ICG-sulfo-OSu-labeled MUC1 antibody and an IR fluorescence imaging system were employed in the present study. Paraffin sections of gastric cancer were stained with anti-MUC1 antibody by the avidin-biotinylated peroxidase complex method. Among the positive specimens, three cases were used for IR imaging analysis. Octylglucoside was used as a reinforcement agent. The incubation of paraffin sections with ICG-sulfo-OSu-labeled MUC1 antibody resulted in positive staining of the tumor sites by an IR fluorescence imaging system, and the intensity of fluorescence was increased depending on the concentration of octylglucoside and grade of imaging processing. A reinforcement agent, and image processing, intensify a labeled antibody excitable by infrared fluorescence in tumor sections and can generate a strong enough fluorescent signal to detect small cancers when examined with an infrared fluorescence endoscope. (Keyword) endoscopic diagnosis / fluorescence marker / infrared fluorescence / infrared fluorescent endoscope / octylglucoside / ULTRAVIOLET-RADIATION / RAY EXCITATION / DNA / ANTIBODIES / DAMAGE (Link to Publication Site) ● Publication site (DOI): 10.1016/S1590-8658(03)00005-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12747626 ● Search Scopus @ Elsevier (PMID): 12747626 ● Search Scopus @ Elsevier (DOI): 10.1016/S1590-8658(03)00005-7 (DOI: 10.1016/S1590-8658(03)00005-7, PubMed: 12747626)
109.	Hiroko Matsunaga, Hirohito Honda, Kenichiro Kubo, Katsutaka Sannomiya, Xuezhi Cui, Yoshio Toyota, Toshifumi Mori, Naoki Muguruma, Toshiya Okahisa, Seisuke Okamura, Ichiro Shimizu and Susumu Ito : Clinical value of the determination of serum guanase activity in patients with chronic hepatitis type C, The Journal of Medical Investigation : JMI, Vol.50, No.1-2, 64-71, 2003. (Summary) The study examines the clinical significance of guanase (GU) measurement in patients with hepatitis C. 688 patients in whom either ALT was abnormal, or in whom HBsAg or HCVAb was detected in the serum, were enrolled into this study. The percentage of cases in which normal ALT while elevated GU was compared among the different disease groups. Then, the percentage of cases with normal ALT but elevated GU was compared between HBV and HCV groups. For the entire population, a significant correlation was observed between ALT and GU (r=0.872). The overall percentage of cases with normal ALT but elevated GU activity was 11.4%. In HCV group, 449 cases had normal ALT. Of these cases, 20.3% had elevated GU, while ALT was normal. Before 1989, no test to check donated blood for HCV antibody was available. However, screening of donated blood for high GU was associated with a reduced incidence of post-transfusion hepatitis. This is probably because following the screening, blood donated by patients with hepatitis C who had normal ALT but elevated GU was rejected. After the introduction of HCV antibody measurement, GU measurement is still useful to reveal the pathophysiological condition in-patients with chronic hepatitis type C. (Keyword) Alanine Transaminase / Biological Markers / Blood Donors / Comorbidity / Guanine Deaminase / Hepatitis B Surface Antigens / Hepatitis B, Chronic / Hepatitis C Antibodies / Hepatitis C, Chronic / Humans / Incidence / Japan / Mass Screening / Prospective Studies / Sensitivity and Specificity (Tokushima University Institutional Repository) ● Metadata: 110679 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12630570 ● CiNii @ National Institute of Informatics (CRID): 1050865122807436032 ● Summary page in Scopus @ Elsevier: 2-s2.0-0037762732 (Tokushima University Institutional Repository: 110679, PubMed: 12630570, CiNii: 1050865122807436032, Elsevier: Scopus)
110.	野山晏志, Masahiro Nomura, 伊賀彰子, 上村英子, 友兼優子, 蔭山徳人, 山下潤司, 近藤憲保, Naoki Muguruma, Toshiya Okahisa, Hiroshi Shibata, Seisuke Okamura, Hirohito Honda, Akiyoshi Nishikado, 矢野充保, Ichiro Shimizu and Susumu Ito : 消化器内視鏡下総胆管処置中における自律神経活動と心電図変化, Clinics in digestive tract, Vol.9, 57-62, 2003.
111.	Ichiro Shimizu, Masahiro Nomura, 青木利佳, 福野天, 居和城宏, 筒井朱美, Naoki Muguruma, Toshiya Okahisa, Seisuke Okamura, Hirohito Honda and Susumu Ito : 高齢者消化管癌検診時の循環動態モニタリングの重要性, 消化器科, Vol.37, 103-108, 2003.
112.	豊田敬生, Hirohito Honda, 板垣達三, 三宮勝隆, 久保謙一郎, 井本佳孝, Koichi Okamoto, Naoki Muguruma, Seisuke Okamura, Ichiro Shimizu and Susumu Ito : ラフチジンの胃粘膜防御能亢進作用についての検討, 消化器の臨床, Vol.6, No.5, 585-589, 2003.
113.	Yoshio Toyota, Hirohito Honda, Toshihiro Omoya, Kumi Inayama, Masaharu Suzuki, Kenichiro Kubo, Masahiko Nakasono, Naoki Muguruma, Seisuke Okamura, Ichiro Shimizu, Kunio Ii and Susumu Ito : Usefulness of a hemoglobin index determined by electronic endoscopy in the diagnosis of Helicobacter pylori gastritis, Digestive Endoscopy, Vol.14, No.4, 156-162, 2002. (Keyword) congestion / hyperemia / diffuse redness / endoscopy / helicobacter pylori / hemoglobin index (Link to Publication Site) ● Publication site (DOI): 10.1046/j.1443-1661.2002.00189.x (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1571698600794960000 ● Summary page in Scopus @ Elsevier: 2-s2.0-0036916449 (DOI: 10.1046/j.1443-1661.2002.00189.x, CiNii: 1571698600794960000, Elsevier: Scopus)
114.	Masako Kamamura, Hirohito Honda, Hiroshi Inoue, Hirohiko Shinomiya, Kenichiro Kobo, Akemi Tsutsui, Naoki Muguruma, Hiroshi Shibata, Ichiro Shimizu and Susumu Ito : Study of causes of higher mortality rates from chronic liver diseases in Tokushima Prefecture, The Journal of Medical Investigation : JMI, Vol.49, No.3-4, 163-171, 2002. (Summary) Mortality rates from chronic liver diseases (CLD) such as liver cirrhosis and hepatocellular carcinoma have been reported to be higher in Tokushima prefecture, although its causes remain unclear. To clarify the causes of CLD in Tokushima prefecture, we evaluated the positive rates of HBs antigen and anti-HCV antibody and the mortality rates from CLD in patients with liver diseases and blood donors after dividing the entire Tokushima prefecture into 8 district boundaries of health centers. In addition, to evaluate the causes of the higher frequency of CLD and the relationship between the development of CLD and viruses, medical examinations were performed in 2 mountain villages in Tokushima prefecture where the drift of population was limited and the mortality rates from CLD differed from each other. As a result, it was found that HCV infection was the major cause of the higher mortality rates from CLD in Tokushima prefecture. Although there were marked regional differences in the mortality rates from CLD, they were mainly due to different rates of HCV infection. (Keyword) Adult / Aged / Blood Donors / Carcinoma, Hepatocellular / Chronic Disease / female / Hepatitis B Antibodies / Hepatitis B Surface Antigens / Hepatitis B, Chronic / Hepatitis C Antibodies / Hepatitis C, Chronic / Humans / Japan / Liver Cirrhosis / Liver Diseases / Liver Function Tests / Liver Neoplasms / male / Middle Aged / Population Dynamics / Rural Population / Seroepidemiologic Studies (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12323006 ● CiNii @ National Institute of Informatics (CRID): 1050583647830737152 ● Search Scopus @ Elsevier (PMID): 12323006 (PubMed: 12323006, CiNii: 1050583647830737152)
115.	Terumi Bando, Naoki Muguruma, Susumu Ito, Yoko Musashi, Kumi Inayama, Yoshihiro Kusaka, Masaya Tadatsu, Kunio Ii, Tatsuro Irimura, Seiichi Shibamura and Kazuhiro Takesako : Basic studies on a labeled anti-mucin antibody detectable by infrared-fluorescence endoscopy, Journal of Gastroenterology, Vol.37, No.4, 260-269, 2002. (Summary) We developed a fluorescent dye, indocyanine green (ICG)-sulfo-OSu, which was excited by infrared rays and conjugated to various antibodies. We attempted to clarify the staining patterns of antisulfomucin and anti-MUC1 antibodies in gastrointestinal cancer. We then evaluated the potential of the dye as a fluorescent label for antibodies specific to cancer, to be used as a diagnostic method for microcancer, with infrared fluorescence endoscopy. Paraffin sections of samples collected from 10 patients with esophageal cancer, 30 patients with gastric cancer, and 20 patients with colorectal cancer were immunohistologically stained using an anti-sulfomucin antibody and an anti-MUC1 antibody, and the staining patterns were examined. If a section had a high staining intensity, it was reacted with the ICG-suflo-OSu-labeled antibody and evaluated with infrared fluorescence imaging. The staining patterns with the antibodies varied depending on the organs and the histological types and depth of the cancers, but the staining was generally good and the staining on the mucosal surface of cancer tissues was retained. Good images of cancer cells could be obtained by infrared fluorescence observation using the ICG-sulfo-OSu-labeled anti-MUC1 antibody. The anti-MUC1 antibody stained gastrointestinal cancer cells well, and nearly specific infrared fluorescence in cancer tissues was observed using the labeled anti-MUC1 antibody. The ICG-sulfo-OSu-labeled anti-MUC1 antibody has possible usefulness for the screening of cancer via infrared fluorescence endoscopy. (Keyword) infrared-fluorescence / mucin / labeled antibody / cancer imaging / vital immunostaining (Link to Publication Site) ● Publication site (DOI): 10.1007/s005350200033 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11993509 ● CiNii @ National Institute of Informatics (CRID): 1572824500087249536 ● Search Scopus @ Elsevier (PMID): 11993509 ● Search Scopus @ Elsevier (DOI): 10.1007/s005350200033 (DOI: 10.1007/s005350200033, PubMed: 11993509, CiNii: 1572824500087249536)
116.	S Ichikawa, Seisuke Okamura, K Tujigami, Y Kusaka, M Tadatsu, Y Okita, A Tsutsui, Naoki Muguruma, Toshiya Okahisa, Hiroshi Shibata, Ichiro Shimizu, Susumu Ito and K Umino : Quantitative Analysis of Red Color Sign in the Endoscopic Evaluation of Esophageal Varices, Endoscopy, Vol.33, No.9, 747-753, 2001. (Summary) Bleeding due to esophageal variceal rupture is associated with an extremely high mortality rate. Variceal bleeding is frequent in patients who have a red color sign on endoscopy. However, the red color sign is subjectively evaluated on the basis of color tone and the shape of the varices. To allow standardization and facilitate consensus, an objective method of assessing the red color sign is needed. In this study, a system was established for quantifying the red color sign during endoscopic evaluation. Between July 1995 and February 1997, 55 untreated patients with portal hypertension and esophageal varices identified on upper gastrointestinal endoscopy were enrolled in the study. Images obtained about 5 cm oral to the esophagogastric junction during endoscopy were stored on magnetic optical disks using an endoscopic image processor. The still images were transmitted to a computer and analyzed using computer software. The RGB components (R, red; G, green; B, blue) were measured at points showing flare consistent with the red color sign. The endoscopic assessment was based on the Japanese Research Society for Portal Hypertension's general rules for recording endoscopic findings in esophagogastric varices. The ratio of the red color area to the variceal area increased with increasing red color grade. There were significant positive correlations between the R and G, and G and B components. This suggests that comparing the R components alone would allow assessment of the color differences in the red color area and in the varices. The R value was significantly higher in the red color area (115 +/- 20) than in the varices (57 +/- 19). An R value of 90 was found at the boundary between the two parts (P < 0.001). The red color area can be automatically calculated and quantified using the analysis program. Improvements in data storage methods may allow real-time evaluation during endoscopy in the future. (Keyword) Aged / Color / Endoscopy, Digestive System / Esophageal and Gastric Varices / Female / Follow-Up Studies / Gastrointestinal Hemorrhage / Humans / Hypertension, Portal / Japan / Liver Cirrhosis / Male / Middle Aged (Link to Publication Site) ● Publication site (DOI): 10.1055/s-2001-16514 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11558027 ● Search Scopus @ Elsevier (PMID): 11558027 ● Search Scopus @ Elsevier (DOI): 10.1055/s-2001-16514 (DOI: 10.1055/s-2001-16514, PubMed: 11558027)
117.	Hitoshi Miyajima, Masahiro Nomura, Naoki Muguruma, Toshiya Okahisa, Seisuke Okamura, Hirohito Honda, Ichiro Shimizu, Masafumi Harada, Ken Saito, Yutaka Nakaya and Susumu Ito : Relationship among gastric motility,autonomic activity,and portal hemodynamics in patients with liver cirrhosis, Journal of Gastroenterology and Hepatology, Vol.16, No.6, 647-659, 2001. (Summary) We examined the effects of the autonomic nervous function and the volume of portal blood flow to clarify the mechanism of the abnormal gastric motility in patients with liver cirrhosis. Heart rate variability, electrogastrogram (EGG), and volume of portal blood flow were measured before and after a meal in 27 patients with liver cirrhosis (LC group) and in 20 normal subjects (N group). Autonomic nervous function was evaluated by using spectral analysis of heart rate variability. We used the cine phase-contrast (PC) method, using magnetic resonance imaging (MRI) to measure the portal flow, while the peak frequency and spectral power of the EGG were measured at pre- and postprandial change. The ratio of low frequency power to high frequency power (LF/HF) was significantly higher, and the HF power was significantly lower in the LC group than in the N group both before and after a meal. In both groups, the electrogastrographic peak power ratio before and after a meal showed a positive correlation with the HF ratio, and an inverse correlation with the LF/HF ratio. In addition, portal blood flow volume was significantly decreased in the LC group than in the N group. However, the increased rate of portal blood flow after a meal correlated positively with the increased rate of electrogastrographic peak power. Moreover, gastric motility was positively correlated with esophageal varices and coma scale with the use of multivariate analysis. Parasympathetic hypofunction, sympathetic hyperfunction and portal hemodynamics were closely related with gastric motility in cirrhotic patients. In addition, gastric motility was decreased, at least in part, by the ingestion of food in cirrhotic patients because of abnormalities in autonomic functions and portal blood flow following a meal. (Keyword) Aged / Autonomic Nervous System / Electrophysiology / Female / Gastrointestinal Motility / Heart Rate / Hemodynamics / Humans / Liver Cirrhosis / Magnetic Resonance Imaging / Male / Middle Aged / Portal System (Link to Publication Site) ● Publication site (DOI): 10.1046/j.1440-1746.2001.02493.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11422618 ● Summary page in Scopus @ Elsevier: 2-s2.0-0035722279 (DOI: 10.1046/j.1440-1746.2001.02493.x, PubMed: 11422618, Elsevier: Scopus)
118.	Naoki Muguruma, Seisuke Okamura, Soichi Ichikawa, Koji Tsujigami, Suzuki Masaharu, Masahiko Nakasono, Yoshihiro Kusaka, Masaya Tadatsu, Yoshio Okita and Susumu Ito : Asymptomatic case of congenital absence of the gallbladder, The Journal of Medical Investigation : JMI, Vol.48, No.1-2, 118-121, 2001. (Summary) Congenital absence of the gallbladder is rare among biliary abnormalities, and its preoperative diagnosis has been considered very difficult. We encountered a patient with congenital absence of the gallbladder and suggest a possible preoperative diagnosis of the abnormality, as well as reviewing the literature. (Keyword) Adult / Gallbladder / Humans / Male (Tokushima University Institutional Repository) ● Metadata: 29036 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11286013 ● Search Scopus @ Elsevier (PMID): 11286013 (Tokushima University Institutional Repository: 29036, PubMed: 11286013)
119.	Susumu Ito, Naoki Muguruma, Yoshiko Kusaka, Masaya Tadatsu, Mikio Yano, Terumi Bando, Hirohito Honda, Ichiro Shimizu and Kunio Ii : Detection of human gastric cancer of resected specimens using a novel infrared fluorescent anti-human carcinoembryonic antigen antibody with an infrared fluorescence endoscope in vitro., Endoscopy, Vol.33, No.10, 849-853, 2001. (Summary) An indocyanine green derivative (ICG-sulfo-OSu) that can be used as an infrared fluorescent labeling substance suitable for detecting microlesions with an infrared fluorescence endoscope has been developed. The aims of the present study were to develop an infrared fluorescence endoscope and to demonstrate its usefulness in detecting cancerous tissue using an antibody coupled with ICG-sulfo-OSu. ICG-sulfo-OSu-labeled mouse anti-human carcinoembryonic antigen (CEA) antibody and an infrared fluorescence endoscope were used in this study. Biopsy specimens of gastric cancer were stained with anti-CEA antibody using the avidin-biotinylated peroxidase complex method. The positive specimens used for the infrared imaging analysis were freshly resected stomachs from three patients. Treatment of freshly resected stomach specimens with ICG-sulfo-OSu-labeled-anti-CEA antibody complex resulted in positive staining of the tumor sites on infrared fluorescence endoscopy, and the infrared fluorescent images correlated well with the tumor sites. An anti-CEA antibody with affinity for cancerous lesions and labeled with ICG-sulfo-OSu can therefore be imaged using this infrared fluorescence endoscope. Specific antibodies tagged with ICG-sulfo-OSu can label cancer cells and can generate a strong enough fluorescent signal to detect small cancers when examined with an infrared fluorescence endoscope. (Keyword) Adenocarcinoma / Animals / Antibodies, Monoclonal / Carcinoembryonic Antigen / Endoscopy, Gastrointestinal / Female / Fluorescence / Fluorescent Antibody Technique / Fluorescent Dyes / Humans / Immunohistochemistry / Indocyanine Green / Infrared Rays / Male / Mice / Stomach Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1055/s-2001-17328 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11571680 ● Search Scopus @ Elsevier (PMID): 11571680 ● Search Scopus @ Elsevier (DOI): 10.1055/s-2001-17328 (DOI: 10.1055/s-2001-17328, PubMed: 11571680)
120.	柴田啓志, 筒井朱美, 四宮寛彦, 稲山久美, 中園雅彦, Naoki Muguruma, Toshiya Okahisa, Seisuke Okamura, Ichiro Shimizu and Susumu Ito : 肝細胞に対する経皮的ラジオ波熱焼灼療法(RFA)の検討, The Japanese journal of clinical and experimental medicine, Vol.78, No.7, 93-98, 2001.
121.	Ichiro Shimizu, 面家敏宏, Yajun Zhou, 糸永美奈, 豊田敬生, Naoki Muguruma, 柴田啓志, Hirohito Honda and Susumu Ito : 女性ホルモン·エストラジオールの肝発癌抑制作用, 性差医学, No.7, 69-72, 2001.
122.	Yoshihiro Kusaka, Susumu Ito, Naoki Muguruma, Masaya Tadatsu, Terumi Bando, Kunio Ii, Tatsuro Irimura and Seiichi Shibamura : Vital immunostaining of human gastric and colorectal cancers grafted intro nude mice : a preclinical assessment of a potential adjunct to videoendoscopy, Journal of Gastroenterology, Vol.35, No.10, 748-752, 2000.
123.	Susumu Ito, Naoki Muguruma, Shigehito Hayashi, Satoko Taoka, Terumi Bando, Yoshiko Kusaka, Soichi Ichikawa, Aya Hiasa, Toshihiro Omoya, Hirohito Honda, Ichiro Shimizu, Kunio Ii and Yoko Goto : Visualization of human gastric cancer with a novel infrared fluorescent labeling marker of anticarcinoembryonic antigen antibody in vitro., Digestive Endoscopy, Vol.12, No.1, 33-36, 2000. (Keyword) endoscopic diagnosis / fluorescence marker / infrared fluorescence / infrared fluorescent endoscope / vital immunohistochemical staining (Link to Publication Site) ● Publication site (DOI): 10.1046/j.1443-1661.2000.00007.x (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1570291225574088704 ● Summary page in Scopus @ Elsevier: 2-s2.0-0034115931 (DOI: 10.1046/j.1443-1661.2000.00007.x, CiNii: 1570291225574088704, Elsevier: Scopus)
124.	Masahiro Nomura, 宮島等, 名田智美, 森下智文, 木下桂午, 多田由恵, Naoki Muguruma, Toshiya Okahisa, Hiroshi Shibata, Seisuke Okamura, Hirohito Honda, Ichiro Shimizu, Susumu Ito and Yutaka Nakaya : 老年者における上部消化管内視鏡検査中の自律神経活動およびQTc dispersionの変動, 老年消化器病, Vol.12, No.3, 259-264, 2000.
125.	Masahiro Nomura, Ritsuko Kawaguchi, Michiko Yukinaka, 近藤幸, 宮島等, 名田智美, 多田由恵, Ken Saito, Naoki Muguruma, Toshiya Okahisa, Hiroshi Shibata, Seisuke Okamura, Hirohito Honda, Ichiro Shimizu, Susumu Ito and Yutaka Nakaya : 高齢者における食後低血圧の成因, 日本高齢者消化器医学会議会誌, Vol.1, No.2, 36-41, 1999.
126.	Shigehito Hayashi, Naoki Muguruma, Terumi Bando, Satoko Taoka, Susumu Ito and Kunio Ii : Vital immunohistochemical staining for a novel method of diagnosing micro-cancer-examination of immunohistochemical staining of non-fixed fresh tissue-, The Journal of Medical Investigation : JMI, Vol.46, No.3-4, 178-185, 1999. (Summary) It becomes possible to establish a novel diagnostic method for micro-cancer by modulating the signals from the lesion, if lesions can be labeled with substances which can be detected by video endoscopy. The authors have already succeeded in synthesizing indocyanine green (ICG) derivatives for a fluorescent labeling substance which emits near-infrared rays. Before the antibodies labeled by these substances can be used, it is necessary to establish a method of vital immunohistochemical staining. So, we investigated the responses of antibodies exposed to non-fixed fresh tissue specimens as a basic study on vital immunohistochemical staining. The responses of fresh esophageal and gastric specimens (biopsied or surgically resected) to immunohistochemical staining with anti-epithelial membrane antigen (EMA) antibodies under various conditions using the ABC method were examined. These tissue specimens were stained immunohistochemically, and incubated with anti-EMA antibodies for 10 and 30 minutes (esophagus), and for 60 and 120 minutes (stomach) at 37 degrees C. These results suggest that vital immunohistochemical staining is possible under optimum conditions. If an infrared fluorescent endoscopy catching this excited fluorescence can be developed, it will be possible to establish a new endoscopic diagnostic method on the basis of vital immunohistochemical staining. (Keyword) Adult / Esophageal Neoplasms / Humans / Immunohistochemistry / Mucin-1 / Staining and Labeling / Stomach Neoplasms / Tissue Fixation (Tokushima University Institutional Repository) ● Metadata: 83488 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10687313 ● Search Scopus @ Elsevier (PMID): 10687313 (Tokushima University Institutional Repository: 83488, PubMed: 10687313)
127.	Naoki Muguruma, Seisuke Okamura, Toshiya Okahisa, Hiroshi Shibata, Susumu Ito and Keiko Yagi : Endoscopic sonography in the diagnosis of xanthogranulomatous cholecystitis, Journal of Clinical Ultrasound, Vol.27, No.6, 347-350, 1999. (Summary) Xanthogranulomatous cholecystitis (XGC) is an unusual inflammatory disease of the gallbladder that may simulate gallbladder cancer. We report the findings with conventional sonography, endoscopic sonography (EUS), and CT in 3 cases of XGC. EUS could visualize hyperechoic nodules in the gallbladder wall, probably representing xanthogranulomas, but loss of the multilayered structure of the gallbladder wall and infiltration into adjacent organs make differentiating XGC from gallbladder cancer difficult with EUS alone. (Keyword) Aged / Cholecystitis / Diagnosis, Differential / Endosonography / Female / Gallbladder / Granuloma / Humans / Male / Tomography, X-Ray Computed / Ultrasonography (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10395132 ● Summary page in Scopus @ Elsevier: 2-s2.0-0033012672 (PubMed: 10395132, Elsevier: Scopus)
128.	Tatsuro Ogata, Ichiro Shimizu, Takahiro Horie, Koji Yamamoto, Arata Iuchi, Masaya Tadatsu, Naoki Muguruma, Toshiya Okahisa, Seisuke Okamura and Susumu Ito : A case of a giant lipoma of the duodenal bulb., Endosc, Vol.11, No.4, 345-349, 1999.
129.	Seisuke Okamura, Akemi Tsutsui, Naoki Muguruma, Soichi Ichkawa, Masahiro Sogabe, Yoshio Okita, Tamotsu Fukuda, Shigehito Hayashi, Toshiya Okahisa, Susumu Ito and Toshiaki Sano : The utility and limitations of an ultrasonic miniprobe in the staging of gastric cancer, The Journal of Medical Investigation : JMI, Vol.46, No.1, 49-53, 1999. (Summary) To determine the utility and limitations of an ultrasonic miniprobe (UMP) in the staging of gastric cancer, we evaluated 46 patients who underwent endoscopic ultrasonography (EUS) using an UMP and who were histologically determined to have gastric cancers. In every case, UMP findings were compared with histopathological findings after treatment. The total accuracy of UMP relative to the depth of tumor invasion was 71.7% (33/46 cases). Accuracy with respect to T1-m tumor diagnosis was 75.7% (22/29 cases), and for T1-sm, 76.9% (10/13 cases), but accuracy for T2 tumor diagnosis was low, due to ultrasound attenuation. When the analysis was carried out based on the size of tumor, the accuracy for UMP was 50.0% (9/18 cases) for all tumors over 20 mm and 85.7% (24/28 cases) for all tumors smaller than 20 mm. We conclude that UMP is suitable for investigation of tumor extension when the lesion is superficial and/or small gastric cancers which do not cause ultrasonic attenuation, but not when the tumor is large or located in certain sites, although conventional EUS is useful in some of these cases. (Keyword) Aged / Endosonography / Female / Humans / Male / Neoplasm Staging / Sensitivity and Specificity / Stomach Neoplasms (Tokushima University Institutional Repository) ● Metadata: 83262 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10408157 ● Search Scopus @ Elsevier (PMID): 10408157 (Tokushima University Institutional Repository: 83262, PubMed: 10408157)
130.	Naoki Muguruma, Susumu Ito, T Bando, S Taoka, Y Kusaka, S Hayashi, S Ichikawa, Y Matsunaga, Y Tada, S Okamura, K Ii, K Imaizumi, K Nakamura, K Takesako and S Shibamura : Labeled carcinoembryonic antigen antibodies excitable by infrared rays : a novel diagnostic method for micro cancers in the digestive tract, Internal Medicine, Vol.38, No.7, 537-542, 1999.
131.	Naoki Muguruma, Susumu Ito, Shigehito Hayashi, Satoko Taoka, Hiromasa Kakehashi, Kunio Ii, Seiichi Shibamura and Kazuhiro Takesako : Antibodies labeled with fluorescence-agent excitable by infrared rays, Journal of Gastroenterology, Vol.33, No.4, 467-471, 1998.
132.	Naoki Muguruma, Seisuke Okamura, Toshiya Okahisa, M Yasuda, S Hayashi, H Shibata and Susumu Ito : Electrohydraulic lithotripsy treatment for persimmon bezoars., Digestive Endoscopy, Vol.30, No.5, S60, 1998.
133.	Susumu Ito, Naoki Muguruma, Shigehito Hayashi, Satoko Taoka, Terumi Bando, Kumi Inayama, Masahiro Sogabe, Toshiya Okahisa, Seisuke Okamura, Hiroshi Shibata, Tatsuro Irimura, Kazuhiro Takesako and Seiichi Shibamura : Development of agents for reinforcement of fluorescence on near-infrared ray excitation for immunohistological staining, Bioorganic & Medicinal Chemistry, Vol.6, No.5, 613-618, 1998.
134.	Junya Inoi, Ichiro Shimizu, Yasuhiro Tsuji, Naoki Muguruma and Susumu Ito : Effect of administration of ursodeoxycholic acid at bedtime on cholesterol saturation of hepatic bile in Japanese patients with gallstone, The Journal of Medical Investigation : JMI, Vol.45, No.1,4, 115-122, 1998. (Summary) The administration of a single, daily 600 mg dose of ursodeoxycholic acid (UDCA) at bedtime and 3-200 mg doses per day at mealtime was conducted for 6 patients with gallstone and choledocholithiasis who were undergoing biliary drainage for the purpose of improving jaundice. Hepatic bile was collected from a drainage tube after a lapse of time in order to compare the bile acid compositions and cholesterol saturation index (SI) in bile for the 2 protocols. A significant increase in UDCA levels in hepatic bile was observed after both UDCA administration at bedtime and mealtime, but the effect of bedtime administration was significantly greater than that of mealtime administration. Whereas levels of cholic acid and chenodeoxycholic acid (CDCA) decreased for the case of bedtime administration, this was not detected for mealtime administration, although no significant differences among the mean interval values were observed. A significant in difference decreased SI was observed during UDCA bedtime administration, but not during mealtime administration, compared to the SI before administration. This suggests a decreased cholesterol excretion into the bile. Based on these findings and from the point of view of compliance, bedtime administration of UDCA appears to be an effective method. (Keyword) Adult / Aged / Bile / Bile Acids and Salts / Cholagogues and Choleretics / Cholelithiasis / Cholesterol / Drug Administration Schedule / Eating / Female / Gallstones / Humans / Male / Middle Aged / Ursodeoxycholic Acid (Tokushima University Institutional Repository) ● Metadata: 111632 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 9864972 ● Search Scopus @ Elsevier (PMID): 9864972 (Tokushima University Institutional Repository: 111632, PubMed: 9864972)
135.	Terukage Hirata, Hiromi Kogiso, Kenji Morimoto, Satoshi Miyamoto, Hiromi Taue, Shigeki Sano, Naoki Muguruma, Susumu Ito and Yoshimitsu Nagao : Synthesis and Reactivities of 3-Indocyanine-green-acyl-1,3-thiazolidine-2-thione (ICG-ATT) as a New Near-Infrared Fluorescent-labeling Reagent, Bioorganic & Medicinal Chemistry, Vol.6, No.11, 2179-2184, 1998.
136.	Susumu Ito, Naoki Muguruma, Shigehito Hayashi, Satoko Taoka, Akemi Tsutsui, Tamotsu Fukuta, Toshiya Okahisa, Yoshio Ohkita and Ichiro Shimizu : Development of an imaging system using fluorescent labeling substances excited by infrared rays., Digestive Endoscopy, Vol.9, No.4, 278-282, 1997.
137.	Ichiro Shimizu, Susumu Ito, Takeshi Takaoka, Naoki Muguruma, Toshimasa Fukuda, Tatsuhiko Okabe, Minoru Horikita, Singo Hibino, Hiroshige Hayashi and Hirohito Honda : Prevention of posttransfusional non-A, non-B hepatitis by a screen test for hepatitis C virus antibody of donor bloods., The Tokushima Journal of Experimental Medicine, Vol.38, No.1, 19-23, 1991.

Academic Paper (Unrefereed Paper):

1.	T Goji, Seisuke Okamura, H Takeuchi, Tetsuo Kimura, Shinji Kitamura, Katsuyoshi Tamaki, Koichi Okamoto, Masako Kaji, Naoki Muguruma, Toshiya Okahisa, J Shunto and Tetsuji Takayama : Migrated Endoclip and Stone Formation after Cholecystectomy: A Case Treated by Endoscopic Sphincterotomy, Internal Medicine, Vol.48, No.23, 2015-2017, 2009. (Summary) Endoclip migration into the common bile duct following laparoscopic cholecystectomy (LC) is an extremely rare complication. Migrated endoclip into the common bile duct can cause obstruction, serve as a nidus for stone formation, and cause cholangitis. We report a case of cholangitis due to a migrated endoclip and consequent choledocholithiasis 6 years after LC, which was successfully treated by endoscopic extraction. (Keyword) Aged / Cholecystectomy / Common Bile Duct / Foreign-Body Migration / Gallstones / Humans / Male / Postoperative Complications / Sphincterotomy, Endoscopic / Surgical Instruments (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.48.2634 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19952484 ● Search Scopus @ Elsevier (PMID): 19952484 ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.48.2634 (DOI: 10.2169/internalmedicine.48.2634, PubMed: 19952484)
2.	Naoki Muguruma, Seisuke Okamura, 木村哲夫, 板垣達三, 井本佳孝, 梶雅子, 宮本弘志, Susumu Ito, 吉川幸造 and Hiroo Takehara : 小児に対し安全に施行しえたERCPの1例, 医薬の門, Vol.46, No.5, 30-33, 2006.
3.	Ichiro Shimizu, Naoki Muguruma, Seisuke Okamura, 林重仁, 横井孝文, 安田貢, Toshiya Okahisa, Hiroshi Shibata, Susumu Ito, Nobuya Sano, 日比野真吾, 和田哲 and 林秀樹 : 内視鏡的粘膜切除を施行した十二指腸腺腫の1例, 消化管の臨床, Vol.2, 67-71, 1996.
4.	Ichiro Shimizu, Hiroshi Shibata, 横井孝文, Naoki Muguruma, 梯泰昌, 松永裕子, 福田保, 林重仁, 安田貢, 堀江貴浩, Toshiya Okahisa, Seisuke Okamura, 西條哲也 and Susumu Ito : 岡山医誌, Vol.108, No.3-6, 197-198, 1996.
5.	Ichiro Shimizu, Naoki Muguruma, Seisuke Okamura, Toshiya Okahisa, 梯泰昌, 林重仁, 横井孝文, 安田貢, Hiroshi Shibata, Susumu Ito, 松森保道, 梶川愛一郎, 広瀬隆則 and 林秀樹 : 大量下血をきたした空腸平滑筋腫の1例, 消化管の臨床, Vol.1, 99-103, 1995.
6.	Ichiro Shimizu, Hiroshi Shibata, Naoki Muguruma, 横井孝文, 堀江千昌, 堀北実, 安田貢, 梯泰昌, 林重仁, Toshiya Okahisa, Seisuke Okamura, Susumu Ito, 矢野勇人 and Nobuya Sano : 各種画像診断にて肝癌と鑑別困難であった肝内多発結節性病変の1例, Liver Cancer, Vol.1, No.1, 43-50, 1995.
7.	Ichiro Shimizu, Hiroshi Shibata, 矢野充保, Naoki Muguruma, Hirohito Honda, Seisuke Okamura, Toshiya Okahisa and 西條哲也 : UDCA就寝前1回投与による胆石溶解について, 消化器科, Vol.18, No.4, 407-412, 1994.
8.	Ichiro Shimizu, 柴昌子, Naoki Muguruma, Seisuke Okamura, Toshiya Okahisa, 矢野充保, 和田哲, 春藤譲治進 and Susumu Ito : 食道静脈瘤硬化療法が有効であった巨木型食道静脈瘤(pipeline varix)の1例, The Japanese journal of clinical and experimental medicine, Vol.69, No.3, 827-830, 1992.

Academic Letter:

1.	Naoki Muguruma and Tetsuji Takayama : Endoscopic Sclerotherapy with Aluminum Potassium Sulfate and Tannic Acid: An Effective and Less Invasive Strategy for Internal Hemorrhoids, Clinical Endoscopy, Vol.52, No.6, 521-522, 2019. (Tokushima University Institutional Repository) ● Metadata: 114220 (Link to Publication Site) ● Publication site (DOI): 10.5946/ce.2019.162 (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-85075872536 (Tokushima University Institutional Repository: 114220, DOI: 10.5946/ce.2019.162, Elsevier: Scopus)
2.	Susumu Ito and Naoki Muguruma : コリンエステラーゼについて, 内科診療Q&A, Vol.36, 1020-1021, 2003.
3.	Ichiro Shimizu, 面家敏宏, 瀏炎, 日浅亜弥, 豊田敬生, 多田由恵, Naoki Muguruma, Hiroshi Shibata, Hirohito Honda, Susumu Ito and Masayuki Shono : 脂質過酸化反応と肝繊維化, 岡山医誌, Vol.111, 131-132, 1999. (Keyword) 肝繊維化 / 脂質過酸化反応

Review, Commentary:

1.	Satoshi Teramae, Kumiko Tanaka, Koichi Okamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Cowden症候群(IV. 各論消化管ポリポーシス)., Nihon Rinsho. Japanese Journal of Clinical Medicine, Vol.80, No.7, 241-246, Jul. 2022.
2.	Satoshi Teramae, Kumiko Tanaka, Koichi Okamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 【小腸疾患-診断・治療の最新動向-】消化管ポリポーシス Cowden症候群, Nihon Rinsho. Japanese Journal of Clinical Medicine, Vol.80, 241-246, Jul. 2022. (Keyword) 胃腫瘍 *過誤腫症候群-多発性(診断) 食道腫瘍大腸腫瘍小腸腫瘍評価基準ヒト
3.	Takanori Kashihara, Naoki Muguruma, Shota Fujimoto, Yoshihiko Miyamoto, Yasushi Sato and Tetsuji Takayama : Recent Advances in Molecular Imaging of Colorectal Tumors., Digestion, Vol.102, No.1, 57-64, Dec. 2020. (Summary) Recent endoscopic studies have revealed that small colorectal tumors are often overlooked during colonoscopy, indicating that more sensitive detection methods are needed. Molecular imaging has received considerable attention as a new endoscopic technique with high sensitivity. It generally employs a fluorescence-labeled compound that specifically binds to a molecule on the tumor. Fluorescent probes for molecular imaging are largely classified as 2 types: a fluorescence-labeled antibody targeting a molecule specifically expressed on the tumor cell surface such as epidermal growth factor receptor or vascular endothelial growth factor (VEGF); and a fluorescence-labeled small molecule compound targeting a molecule specifically expressed in tumor cells including c-Met, glutathione S-transferase, γ-glutamyltranspeptidase, cathepsin, or endothelin A receptor. These probes successfully detected colorectal tumors in several animal studies. Moreover, 3 recent human clinical trials evaluating endoscopic molecular imaging for colorectal tumors have been reported. In one study, a Cy5-labeled synthetic peptide against c-Met was developed, and fluorescent endoscopic observation with this probe detected a greater number of colorectal adenomas than with white light observation. Another trial used IR800-labeled anti-VEGF antibody, which sensitively detected human colorectal adenomas by fluorescent endoscopy. Last, a fluorescent probe with synthetic peptide against BRAF-positive cells was able to visualize sessile serrated lesions. The fluorescent probes accumulated at very high levels in colorectal tumor cells but at lower levels in surrounding nonneoplastic mucosa. Key Messages: We expect that molecular imaging techniques with fluorescent probes will soon lead to the establishment of a highly sensitive endoscopic method for colorectal tumor detection. (Link to Publication Site) ● Publication site (DOI): 10.1159/000512168 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33271567 ● Summary page in Scopus @ Elsevier: 2-s2.0-85097827136 (DOI: 10.1159/000512168, PubMed: 33271567, Elsevier: Scopus)
4.	Tetsuji Takayama, 五十嵐正広, 大住省三, 岡志郎, 角田文彦, Yoshiaki Kubo, 熊谷秀規, 佐々木美香, 菅井有, 菅野康吉, 武田祐子, 土山寿志, 阪埜浩司, 深堀優, 古川洋一, 堀松高博, Naoki Muguruma, 石川秀樹, 岩間毅夫, 岡崎康司, 斎藤豊, 武藤倫弘, 冨田尚弘, 秋山卓士, 山本敏樹, 石田秀行 and 中山圭子 : 小児・成人のためのCowden症候群/PTEN過誤腫症候群診療ガイドライン(2020年版), Journal of Hereditary Tumors, Vol.20, No.2, 93-114, Sep. 2020. (Link to Publication Site) ● Publication site (DOI): 10.18976/jsht.20.2_93 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.18976/jsht.20.2_93 (DOI: 10.18976/jsht.20.2_93)
5.	Naoki Muguruma, 藤本将太, 樫原孝典, 三橋威志, 宮本佳彦, Koichi Okamoto, Michiyasu Nakao, Shigeki Sano and Tetsuji Takayama : Recent Advances in Endoscopic Molecular Imaging of Gastrointestinal Cancer, OPTRONICS, Vol.39, No.9, 117-121, Sep. 2020. (Tokushima University Institutional Repository) ● Metadata: 115746 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050302315064940288 (Tokushima University Institutional Repository: 115746, CiNii: 1050302315064940288)
6.	Jinsei Miyoshi, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 【消化器疾患のバイオマーカーの有用性と将来】食道癌の診断マーカーの将来, 消化器・肝臓内科, Vol.7, No.2, 105-110, Feb. 2020. (Keyword) Serpins 腫瘍抗原自己抗体腫瘍バイオマーカー(血液) 食道腫瘍(診断) 腺癌(診断) 変異扁平上皮癌(診断) 流血中腫瘍細胞 CA-19-9抗原 Keratin-19 循環腫瘍DNA(血液) 循環MicroRNA(血液) CYFRA21-1 p53抗体 SCC抗原ヒト
7.	Satoshi Teramae, Kumiko Tanaka, Koichi Okamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 【リンチ症候群と遺伝性消化管ポリポーシス】遺伝性消化管ポリポーシス Cowden症候群, Clinical Gastroenterology, Vol.34, No.6, 633-639, May 2019. (Summary) <文献概要>Cowden症候群は,皮膚・粘膜,消化管,乳腺,甲状腺など全身臓器に過誤腫性病変が多発する常染色体優性遺伝性疾患である.顔面小丘疹,口腔粘膜乳頭腫などの特徴的な皮膚病変を呈し,食道から直腸にいたる全消化管にポリポーシスを高率に合併する.食道に多発する白色扁平隆起は本症の特徴的な所見である.また乳癌などの悪性腫瘍を合併する例も多く,適切なサーベイランスが重要である.診断は,皮膚病変,悪性腫瘍,家族歴などを契機に行われる.有病率は20∼25万人に1人と推定されているが,見逃されている症例も少なくない.原因遺伝子の一つとしてPTEN遺伝子が同定されており,約80 (Keyword) 角化症(合併症) *過誤腫症候群-多発性(診断,病理学,合併症) 甲状腺腫瘍子宮内膜腫瘍集団サーベイランス変異消化器系内視鏡法乳頭腫乳房腫瘍腫瘍-第二原発遺伝学的検査丘疹(合併症) PTEN Phosphatase ヒト
8.	田中育太, 友兼毅, 樫原孝典, 小田修治, Jun Okazaki, Yasushi Sato and Naoki Muguruma : 維持透析患者に対する胃瘻造設とその後の管理, 高松市民病院雑誌, Vol.33, 3-6, Mar. 2018. (Keyword) 胃鏡法胃造瘻術血液透析術後管理 *腎不全-慢性(治療,合併症) 腹膜透析(有害作用) 栄養管理ヒト
9.	和田浩典, Naoki Muguruma and Tetsuji Takayama : 胃癌の内視鏡治療, The Japanese journal of clinical and experimental medicine, Vol.94, No.12, 39-44, Dec. 2017.
10.	Naoki Muguruma, 藤本将太, Yasuteru Fujino, Koichi Okamoto and Tetsuji Takayama : Endoscopic molecular imaging:current status and future perspectives, Gastroenterological Endoscopy, Vol.59, No.7, 1473-1481, Jul. 2017. (Tokushima University Institutional Repository) ● Metadata: 114218 (Link to Publication Site) ● Publication site (DOI): 10.11280/gee.59.1473 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390282679197803904 ● Summary page in Scopus @ Elsevier: 2-s2.0-85025103847 (Tokushima University Institutional Repository: 114218, DOI: 10.11280/gee.59.1473, CiNii: 1390282679197803904, Elsevier: Scopus)
11.	Koichi Okamoto, Tomoyuki Kawaguchi, Kaizoh Kagemoto, Daisaku Fujimoto, Naoki Muguruma and Tetsuji Takayama : 大腸癌の疫学と基礎大腸鋸歯状病変のメカニズム., 臨牀消化器内科, Vol.32, No.7, 818-824, May 2017.
12.	Naoki Muguruma, Shinji Kitamura, Koichi Okamoto, Tetsuo Kimura and Tetsuji Takayama : 内視鏡分子イメージング, G.I.Research, Vol.22, No.1, 31-36, Feb. 2014.
13.	Naoki Muguruma, Cirocco Maria and Marcon Norman : Dysplasiaを伴うBarrett食道に対する内視鏡診断および治療, 臨床消化器内科, Vol.25, No.3, 353-362, Mar. 2010.
14.	Naoki Muguruma and Marcon E Norman : Technique and emerging role of cryotherapy., Techniques in Gastrointestinal Endoscopy, Vol.12, No.1, 44-48, 2010. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.tgie.2010.02.002 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.tgie.2010.02.002 (DOI: 10.1016/j.tgie.2010.02.002)
15.	Susumu Ito, Naoki Muguruma, Tetsuo Kimura, Hiromi Yano, Yoshitaka Imoto, Koichi Okamoto, Masako Kaji, Shigeki Sano and Yoshimitsu Nagao : Principle and Clinical Usefulness of the Infrared Fluorescence Endoscopy, The Journal of Medical Investigation : JMI, Vol.53, No.1/2, 1-8, Feb. 2006. (Summary) Since there is no infrared fluorescence materials in the living body, infrared fluorescence labeling materials are very useful for making a diagnosis of a micro cancer. We have developed an infrared fluorescence endoscope (IRFE) and indocyanin green (ICG)-derivative as infrared fluorescence labeling materials to evaluate gastrointestinal neoplastic lesions. The study aims were to apply an IRFE and to demonstrate its usefulness in detecting cancerous tissue using an antibody coupled with ICG-derivative. IRFE consisted of an infrared endoscope equipped with excitation (710-790 nm) and barrier (810-920 nm) filters and an intensified CCD camera. We have developed ICG N-hydroxy sulfo succinimide ester (ICG-sulfo-OSu) and 3-ICG-acyl-1, 3-thiazolidine-2-thione (ICG-ATT) as an infrared fluorescent-labeling reagent. ICG-derivative-labeled mouse anti-human carcinoembryonic antigen (CEA) antibody and MUC1 antibody were employed in this study. Moreover, we examined the ability of a reinforcement agent, octylglucoside, to intensity fluorescence from the labeled antibody. Biopsy specimens of gastric cancer were stained with anti-CEA antibody by the avidin-biotinylated peroxidase complex method. Among the positive specimens, freshly resected stomach from three cases were used for the infrared (IR) imaging analysis. The incubation of freshly resected stomach specimens with ICG-anti-CEA antibody-complex resulted in positive staining of the tumor sites by IRFE, and the IR fluorescent images correlated well with the tumor sites. The immunohistochemical studies suggested that the intensity of IR fluorescence of ICG-ATT-MUC1 was stronger than that of ICG-sulfo-OSu. In tumor sections, the reinforcement agent intensified fluorescence, ever at low antibody concentrations. Therefore, we conclude that an anti-CEA (and/or MUC1) antibody with affinity for cancerous lesions and labeled with ICG-derivative can be imaged with this IRFE. Specific antibodies tagged with ICG-derivative with the reinforcement agent can label cancer cells and generate a strong enough fluorescent signal to detect small cancers when examined with an IR fluorescence endoscope. (Keyword) Animals / Antibodies, Neoplasm / Antigens, Neoplasm / Carcinoembryonic Antigen / Endoscopy, Gastrointestinal / Fluorescent Dyes / Gastrointestinal Neoplasms / Humans / Indocyanine Green / Infrared Rays / Mice / Mucin-1 / Mucins (Tokushima University Institutional Repository) ● Metadata: 110782 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.53.1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16537990 ● Search Scopus @ Elsevier (PMID): 16537990 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.53.1 (Tokushima University Institutional Repository: 110782, DOI: 10.2152/jmi.53.1, PubMed: 16537990)
16.	Susumu Ito, Naoki Muguruma, 林重仁, 日下至弘, 多田津昌也, 多田津陽子, Koichi Okamoto, 井本佳孝, 稲山久美, 板東輝実, 田岡聡子, 高川真由子, 矢野充保, 伊井邦雄, Yoshimitsu Nagao, Shigeki Sano, 芝村誠一, 島田典招, 石田和彦 and 中村一成 : 赤外線蛍光内視鏡の原理と応用, Biomedical THERMOLOGY, Vol.23, 77-97, 2003.
17.	Susumu Ito, Hirohito Honda, 日下至弘, Ichiro Shimizu, Naoki Muguruma and Seisuke Okamura : データ解説, Frontiers in Gastroenterology, Vol.6, No.3, 52-61, 2001.
18.	Susumu Ito, Ichiro Shimizu, 面家敏宏, Zhou Yajun, 糸永美奈, 豊田敬生, Naoki Muguruma, 柴田啓志 and Hirohito Honda : 女性ホルモン·エストラジオールの肝発癌抑制作用, 性差医学, No.7, 69-72, 2001.

Proceeding of International Conference:

1.	Tomoyuki Kawaguchi, Koichi Okamoto, shota fujimoto, Masahiro Bando, hironori wada, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Lansoprazole as an effective chemopreventive agent for serrated-neoplasia pathway; A comprehensive analysis using connectivity map., DDW2023, May 2023.
2.	Hiroyuki Ueda, Yasuhiro Mitsui, Makoto Takishita, Mitsuyasu Yano, Masanori Takehara, Akira Fukuya, Tomoyuki Kawaguchi, Kazuyoshi Noda, Shinji Kitamura, Koichi Okamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Clinicopathologial Analysis of Six Families with Gastric Adenocarcinoma and Proximal Polyposis of the stomach (GAPPS)., DDW2020, May 2020.
3.	Yasushi Sato, Kumiko Tanaka, Ishikawa Hideki, Satoshi Teramae, Fumika Nakamura, Yasuhiro Mitsui, Kagemoto Kaizo, Hiroshi Miyamoto, Koichi Okamoto, Naoki Muguruma, Ohmiya Naoki, Mutoh Michihiro and Tetsuji Takayama : Small- intestinal involvement in familial adenomatous polyposis: characteristics and genotype- phenotype correlation from a Japanese cohort study, DDW, May 2020.
4.	Yasushi Sato, Tetsu Tomonari, Hironori Tanaka, Takahiro Tanaka, Hirao Akihiro, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Kagiwada Harumi, Kitazawa Masashi, Fukui Kazuhiko, Horimoto Katsuhisa and Tetsuji Takayama : Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma beyond progression of sorafenib treatment: A real-world evidence and in vitro assessment with protein phosphorylation array, ASCO Gastrointestinal Cancers Symposium(ASCO-GI 2020), San Francisco, Jan. 2020. (Link to Publication Site) ● Publication site (DOI): 10.1200/JCO.2020.38.4_suppl.485 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2020.38.4_suppl.485 (DOI: 10.1200/JCO.2020.38.4_suppl.485)
5.	Naoki Muguruma, Daisaku Fujimot, Tomoyuki Kawaguchi, Kaizoh Kagemoto, Satoshi Teramae, Yoshifumi Kida, Hironori Wada, Fumika Nakamura, Yasuteru Fujino, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Toshihito Tanahashi, Hiroshi Miyamoto, Yasushi Sato and Tetsuji Takayama : Linked Color Imaging Improves Detection Rate of Sessile Serrated Adenoma/Polyp in the Colon: A Prospective Randomized Controlled Trial., UEG Week 2019, Barcelona, Oct. 2019.
6.	Shinji Kitamura, Mototsugu Kato, Kenro Kawada, Masanori Takehara, Kaizo Kagemoto, Fumika Nakamura, Hironori Wada, Naoki Muguruma, Osamu Dohi, Shoko Ono, Hideki Ishikawa and Tetsuji Takayama : Linked Color Imaging for the Detection of Gastric Neoplasm in High Risk Patients: A Prospective Multicenter Randomized Controlled Trial (LCI-FIND Trial)., UEG Week2019, Barcelona, Oct. 2019.
7.	Yasushi Sato, Tadahiko Nakagawa, Toshihito Tanahashi, Shinji Kitamura, Hiroshi Miyamoto, Koichi Okamoto, Naoki Muguruma and Tetsuji Takayama : JMJD2A is a novel epigenetic factor of chemotherapeutic susceptibility in gastric cancer., The ESMO Congress 2019, Barcelona, Sep. 2019. (Link to Publication Site) ● Publication site (DOI): 10.1093/annonc/mdz239.077 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1093/annonc/mdz239.077 (DOI: 10.1093/annonc/mdz239.077)
8.	Naoki Muguruma, Fujimoto Daisaku, Yasuteru Fujino, Kashihara Takanori, Kazuyoshi Noda, Fukuya Akira, Takehara Masanori, Hirao Akihiro, Hironori Tanaka, Takahiro Tanaka, Tetsu Tomonari and Tetsuji Takayama : Linked Color Imaging System in the Endoscopic Detection of Sessile Serrated Adenoma/Polyp, Korea International Digestive Endoscopy Congress 2019, Aug. 2019. (Keyword) Image-enhanced endoscopy / Linked color imaging / Sessile serrated adenoma/polyp
9.	Naoki Muguruma, Koichi Okamoto and Tetsuji Takayama : Advanced Endoscopic Imaging in Colorectal Lesions, Korea International Digestive Endoscopy Congress 2019, Aug. 2019. (Keyword) Colorectal cancer / Image-enhanced endoscopy / Molecular imaging
10.	Hironori Tanaka, Tetsu Tomonari, Takahiro Tanaka, Akihiro Hirao, Fumika Nakamura, Kumiko Tanaka, Koichi Okamoto, Yasushi Sato, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : Therapeutic efficacy of chemoradiotherapy with Miriplatin for hepatocellular carcinoma., digestive disease week2019, San Diego, May 2019.
11.	Jinsei Miyoshi, Noriaki Murayama, Kumiko Tanaka, Takahiro Tanaka, Fumika Nakamura, Yasuteru Fujino, Keiichiro Matsumura, Miwako Kagawa, Tetsu Tomonari, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Development of a Novel Mirna-Based Signature to Predict Invasion and Metastasis in Rectal Neuroendocrine Tumors., digestive disease week2019, Vol.156, No.6, 133, San Diego, May 2019. (Link to Publication Site) ● Publication site (DOI): 10.1016/S0016-5085(19)37123-9 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/S0016-5085(19)37123-9 (DOI: 10.1016/S0016-5085(19)37123-9)
12.	Jun Okazaki, Toshihito Tanahasi, Yasushi Sato, Jinsei Miyoshi, Tadahiko Nakagawa, Tetsuo Kimura, Hiroshi Miyamoto, Yasuteru Fujino, Fumika Nakamura, Masanori Takehara, Masahiro Bando, Shinji Kitamura, Koichi Okamoto, Naoki Muguruma, Masahiro Sogabe and Tetsuji Takayama : Interaction Between Pancreatic Cancer Cells and Adipocytes Promote Pancreatic Cancer Progression Through Overexpression of Saa1., digestive disease week2019, San Diego, May 2019.
13.	Tetsuji Takayama, Toshihito Tanahashi, Koichi Okamoto, Shota Fujimoto, Tadahiko Nakagawa, Kaizoh Kagemoto, Yasuyuki Okada, Fumika Nakamura, Yasuteru Fujino, Shinji Kitamura, Hiroshi Miyamoto, Yasushi Sato and Naoki Muguruma : S100P as a novel hypomethylation target in Sessile Serrated Adenoma(SSA/P)-cancer sequence: A genome-wide DNA methylation array analysis., UEG Week2018, Wien, Oct. 2018.
14.	Jinsei Miyoshi, Noriaki Murayama, Tadahiko Nakagawa, Tetsu Tomonari, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Mir-144-3P/451A as a Novel Biomarker for Predicting Recurrence and Metastasis in Rectal Neuroendocrine Tumors Through Targeting Pten/P19., Digestive Disease Week 2018, Washington, D.C., Jun. 2018.
15.	Fumika Nakamura, Koichi Okamoto, Kumiko Tanaka, Yasuteru Fujino, Jinsei Miyoshi, Shinji Kitamura, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Clinicopathological Analyses of Colorectal Polyps and Cancers in Serrated Polyposis Syndrome., DIgestive Disease Week2018, Washington, D.C., Jun. 2018.
16.	Shota Fujimoto, Naoki Muguruma, Michiyasu Nakao, Yoshihiko Miyamoto, Tatsuhiro Ishida, Shigeki Sano and Tetsuji Takayama : Near-Infrared Molecular Imaging of Gastrointestinal Stromal Tumors using a Novel Fluorescent Probe Indocyanine Green (ICG)-Labeled Dasatinib., Digetive Disease Week2018, Washington, D.C., Jun. 2018.
17.	Yasushi Sato, Tamotsu Sagawa, Yasuo Takahashi, Hiroyuki Ohnuma, Kyoko Hamaguchi, Masahiro Hirakawa, Koshi Fujikawa, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : A dose-escalation study of docetaxel, oxaliplatin and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer., 2018 Gastrointestinal Cancers Symposium, San Francisco, Jan. 2018.
18.	Daisaku Fujimoto, Kaizo Kagemoto, Yasuyuki Okada, Hironori Tanaka, Satoshi Teramae, Akihiro Hirao, Fumika Nakamura, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : Usefulness of Linked Color Imaging System in Endoscopic Diagnosis of Sessile Serrated Adenoma/Polyp: A Novel Image Enhanced Technique., Digestive Disease Week2017, Chicago, May 2017.
19.	Kaizo Kagemoto, Koichi Okamoto, Tohshi Takaoka, Yasuyuki Okada, Kumiko Tanaka, Akihiro Hirao, Shinji Kitamura, Tetsuo Kimura, Hiroshi Miyamoto, Naoki Muguruma, Toshiya Okahisa, Koichi Tsuneyama and Tetsuji Takayama : Detection of Aberrant Crypt Foci Using Image-Enhanced Endoscopy., Digestive Disease Week2017, Chicago, May 2017.
20.	Naoki Muguruma, Koichi Okamoto, Shota Fujimoto, Tadahiko Nakagawa, Katsutaka Sannomiya, Yasuhiro Mitsui, Tetsuo Kimura, Hiroshi Miyamoto, Mitsuo Shimada, Yoko Horino, Shinya Matsumoto, Kenjiro Hanaoka and Tetsuji Takayama : Optical Molecular Imaging of Aberrant Crypt Foci in the Human Colon by Glutathione S-Transferase-Activated Fluorogenic Probe., Digestive Disease Week2017, Chicago, May 2017.
21.	Shota Fujimoto, Naoki Muguruma, Koichi Okamoto, Misaki Miwa, Yoshihiko Miyamoto, Yoshifumi Takaoka, Koichi Tsuneyama and Tetsuji Takayama : A New Theranostic Combination of Fluorescent Molecular Imaging and Laser Therapy Targeting C-Kit in Gastrointestinal Stromal Tumors., Digestive Disease Week2017, Chicago, May 2017.
22.	Masanori Takehara, Naoki Muguruma, Koichi Okamoto, Kazuyoshi Noda, Kaizo Kagemoto, Yuri Matsumoto, Tadahiko Nakagawa, Shunsaku Takeishi, Jun Okazaki, Daisaku Fujimoto, Shinji Kitamura, Tetsuo Kimura, Hiroshi Miyamoto and Tetsuji Takayama : Endoscopic Resection is safe and effective for rectal carcinoid tumors., The First World Congress of Gastrointestinal Endoscopy,, Hyderabad, Feb. 2017.
23.	Tomoyuki Kawaguchi, Naoki Muguruma, Koichi Okamoto, Kumiko Tanaka, Satoshi Teramae, Yasuhiro Mitsui, Yoshifumi Takaoka, Tatsunao Sueuchi, Takahiro Goji, Shinji Kitamura, Masako Kimura, Tetsuo Kimura, Hiroshi Miyamoto and Tetsuji Takayama : Assessment of small bowel capsule endoscopy and APC gene mutation in familial adenomatous polyposis., The First World Congress of Gastrointestinal Endoscopy, Hyderabad, Feb. 2017.
24.	Masahiro Sogabe, Toshiya Okahisa, Tadahiko Nakagawa, Noriaki Murayama, Masanori Takehara, Kaizo Kagemoto, Yoshifumi Takaoka, Tetsu Tomonari, Tatsuya Taniguchi, Tetsuo Kimura, Naoki Muguruma and Tetsuji Takayama : Influence of Lifestyle and Lifestyle-Related Disease on Nonalcoholic Fatty Liver Disease in Japanese With Metabolic Syndrome, Digestive Disease Week2016, San Diego, May 2016.
25.	Tatsuya Taniguchi, Hironori Tanaka, Takahiro Tanaka, Tetsu Tomonari, Kazuhiro Kishi, Hiroshi Miyamoto, Naoki Muguruma, Masahiro Sogabe, Tadahiko Nakagawa and Tetsuji Takayama : Des-g-carboxy Prothrombin (DCP) Is Produced by Overexpression of Prothrombin Gene in Hepatocellular Carcinoma, Digestive Disease Week2016, San Diego, May 2016.
26.	Tetsu Tomonari, Shunsaku Takeishi, Tatsuya Taniguchi, Takahiro Tanaka, Hironori Tanaka, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : MRP3 As a Novel Resistance Factor for Sorafenib in Hepatocellular Carcinoma, Digestive Disease Week2016, San Diego, May 2016.
27.	Yoshihiko Miyamoto, Naoki Muguruma, Shota Fujimoto, Tadahiko Nakagawa, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Masahiro Sogabe, Toshiya Okahisa and Tetsuji Takayama : Molecular Imaging Targeting Epidermal Growth Factor Receptor in Detection and Evaluation of Therapeutic Efficacy for Colorectal Cancer, Digestive Disease Week2016, San Diego, May 2016.
28.	Tetsuji Takayama, Naoki Muguruma and Koichi Okamoto : Chemoprevention for Colorectal Cancer targeting Aberrant Crypt Foci, The 5th International Forum,The 102nd General Meeting of the Japanese Society of Gastroenterology, Tokyo, Apr. 2016.
29.	Naoki Muguruma, Yoshihiko Miyamoto, Shota Fujimoto, Tadahiko Nakagawa, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Kazuki Horikawa and Tetsuji Takayama : Endoscopic molecular imaging of colorectal cancer targeting epidermal growth factor receptor., APDW2015, Taipei, Dec. 2015.
30.	Tatsuya Taniguchi, Tetsu Tomonari, Hironori Tanaka, Takahiro Tanaka, Kazuhiro Kishi, Hiroshi Miyamoto, Naoki Muguruma, Masahiro Sogabe, Toshiya Okahisa, Tadahiko Nakagawa and Tetsuji Takayama : Des-G-Carboxy Prothrombin (DCP) Is Induced by PARP-1 in Hepatocellular Carcinoma, Digestive Disease Week 2015, Washington, D.C., May 2015.
31.	Kaizo Kagemoto, Atsushi Inoue, Koichi Okamoto, Yasuyuki Okada, Jun Okazaki, Yoshifumi Takaoka, Yoshihiko Miyamoto, Yasuhiro Mitsui, Jinsei Miyoshi, Kumiko Tanaka, Yasuteru Fujino, Shinji Kitamura, Tetsuo Kimura, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Toshiya Okahisa and Tetsuji Takayama : Proximal Aberrant Crypt Foci As Precursor Lesions of SSA/P-Cancer Sequence., Digestive Disease Week 2015, Washington, D.C., May 2015.
32.	Naoki Muguruma, Miyamoto Yoshihiko, Fujimoto Shota, Okada Yasuyuki, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto and Tetsuji Takayama : Optical Molecular Imaging and Assessment of Therapeutic Response of Colorectal Cancer Targeting Epidermal Growth Factor Receptor, World Congress of Molecular Imaging 2014, Sep. 2014.
33.	Kagawa Miwako, Toshiya Okahisa, Takaoka yoshifumi, Yasuteru Fujino, Jinsei Miyoshi, Takaoka Toshi, Tetsu Tomonari, Shinji Kitamura, Okada Yasuyuki, Kagemoto Kaizo, Takehara Masanori, Kumiko Tanaka, Matsumoto Sayo, Teramae Tomofumi, Hiroshi Miyamoto, Naoki Muguruma, Tetsuji Takayama and Takaoka Toshi : Angiogenesis-Related Factors At the Residual Inflammation in Patients With Ulcerative Colitis in Clinical Remission Stage, Digestive Disease Week2014, Chicago, May 2014.
34.	Akina Nakanishi, Toshiya Okahisa, Emi Umezu, Tadahiko Nakagawa, Miwako Kagawa, Toshi Takaoka, Takahiro Goji, Hiromi Yano, Shinji Kitamura, Takahiro Goji, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : Expression of Thymidline EMT via ERK 1/2 Signal Patway in Ulcerative Colitis, DDW2013,Orland, Orange County Convention Center, Orlando, May 2013.
35.	Yasuteru Fujino, Koichi Okamoto, Naoki Muguruma, Jun Okazaki, Yasuyuki Okada, Hironori Tanaka, Jinsei Miyoshi, Toshi Takaoka, Shinji Kitamura, Hiroshi Miyamoto, Toshiya Okahisa and Tetsuji Takayama : Usefulness of a new sphincterotome for the endoscopic submucosal dissection of colorectal neoplasms, DDW2013, Orlando, May 2013.
36.	Naoki Muguruma, Kwon Kwang-an, Al-Quarshobi Issa, Donnellan Fergal, Swan P. Michael, Streutker Catherine, Cirocco Maria, May R. Gary, Kandel Gabor, Kortan P. Paul and Marcon E. Norman : The Role of Endoscopic Resection in the Diagnosis and Treatment of Gastric Inflammatory Fibroid Polyp, DDW 2010, New Orleans, May 2010.
37.	H Takeuchi, Seisuke Okamura, T Kimura, T Itagaki, K Okamoto, M Kaji, H Miyamoto, Naoki Muguruma and Susumu Ito : Simple and appropriate pretreatment for nasal endoscopy: Usefulness of vasoconstrictor nose drop, Digestive disease Week 2007, Washington, D.C., May 2007.
38.	Masahiro Sogabe, Toshiya Okahisa, Koji Tsujigami, Yoshio Okita, Hirokazu Hayashi, Toshikatsu Taniki, Hiroshi Hukuno, Masahiko Nakasono, Naoki Muguruma, Seisuke Okamura and Susumu Ito : Ultrasonographic assessment of gastric motility in diabetic gastroparesis before and after attaining glycemic control., Journal of Gastroenterology, Vol.40, No.6, 583-590, Jul. 2005. (Summary) Glycemic control is important for maintaining gastric motility in diabetic patients, but gastric motility has not yet been studied ultrasonographically in relation to glycemic control. We made such observations before and after establishing glycemic control in diabetic patients with gastroparesis. We studied 30 diabetic patients with upper abdominal digestive symptoms who were hospitalized for correction of poor blood sugar control and who underwent upper digestive tract endoscopy to rule out structural causes such as gastric/duodenal lesions. Gastric motility was evaluated by transabdominal ultrasonography, using a test meal, before and after attainment of glycemic control (within 3 days after admission and 3 days before discharge). Also, upper abdominal digestive symptoms present on admission and at discharge were compared. After glycemic control was established, contractions of the antral region were more frequent than before the attainment of control (8.93 +/- 1.17/3 min vs 7.63 +/- 2.22/3 min, respectively; P < 0.001). Glycemic control also significantly improved gastric emptying (before glycemic control, 49.2 +/- 14.8%; after, 67.1 +/- 11.5%; P < 0.001). This was also true for the motility index, concerning antral gastric contractility (before control, 2.97 +/- 1.57; after, 3.75 +/- 1.09; P < 0.05). Upper abdominal symptom scores were also significantly lower after attainment of control than before (0.47 +/- 0.78 vs 3.17 +/- 2.00, respectively; P < 0.001). These findings suggest that attaining glycemic control improves gastric motility and attainments upper abdominal symptoms in diabetic patients with gastroparesis. (Keyword) Adult / Aged / Aged, 80 and over / Blood Glucose / Diabetes Mellitus, Type 1 / Diabetes Mellitus, Type 2 / Female / Follow-Up Studies / Gastric Emptying / Gastroparesis / Humans / Male / Middle Aged / Severity of Illness Index (Link to Publication Site) ● Publication site (DOI): 10.1007/s00535-005-1592-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16007392 ● Search Scopus @ Elsevier (PMID): 16007392 ● Search Scopus @ Elsevier (DOI): 10.1007/s00535-005-1592-1 (DOI: 10.1007/s00535-005-1592-1, PubMed: 16007392)
39.	U Eiko, Masahiro Nomura, Kohzou Uehara, Naoki Muguruma, Seisuke Okamura, Yutaka Nakaya and Susumu Ito : , Influence in gastrointestinal endoscopy on circulatory dynamics: Relation with pulse wave velocity, The 7th Asia/Oceania Regional Congress of Gerontology, Tokyo, 2003.
40.	Hitoshi Miyajima, Masahiro Nomura, Tomomi Nada, Naoki Muguruma, Toshiya Okahisa, Hiroshi Shibata, Seisuke Okamura, Hirohito Honda, Ichiro Shimizu, Susumu Ito and Yutaka Nakaya : Abnormal gastric motility in liver cirrhosis: Effect of autonomic nervous function and volume of portal blood flow, The 7th United European Gastroenterology Week, Roma,Italy, 1999.
41.	Ken Saito, Yutaka Nakaya, Masahiro Nomura, N Takeuchi, Naoki Muguruma, Fumiko Kishi, Hirokazu Miyoshi and Hiromu Nishitani : Study on the excitation process during ventricular depolarization in normal subjects by magnetocardiogram, The 9th International Conference on Biomagnetism, Wien, 1993.

Proceeding of Domestic Conference:

1.	Takanori Kashihara, Yutaka Kawano, takanori miyake, shota fujimoto, 平田光里, Koichi Okamoto, Naoki Muguruma and Tetsuji Takayama : 抗c-KIT抗体を用いた消化管間質腫瘍(GIST)の新しい蛍光内視鏡診断., 第3回日本抗体学会学術大会, Dec. 2024.
2.	Tomoyuki Kawaguchi, Koichi Okamoto, shota fujimoto, Hiroyuki Ueda, hironori wada, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : オルガノイド培養を用いたSessile serrated lesion の動物モデルの樹立とLansoprazole の⼤腸癌予防効果の検討., 第31回日本がん予防学会総会(日本がん予防学会学術大会2024徳島), Sep. 2024.
3.	Takanori Kashihara, takanori miyake, Koichi Okamoto, Yutaka Kawano, Naoki Muguruma, Yasushi Sato and Tetsuji Takayama : <ワークショップ>蛍光標識フラグメント化抗c-KIT抗体を用いた消化管間質腫瘍(GIST)の蛍光内視鏡診断の試み., 第110回日本消化器病学会総会, May 2024.
4.	Tomoyuki Kawaguchi, Koichi Okamoto, shota fujimoto, Hiroyuki Ueda, hironori wada, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Connectivity Mapによる大腸癌予防薬の網羅的解析とSessile serrated lesionのオルガノイドを用いた抑制効果の検討., がん予防学術大会2023金沢, Sep. 2023.
5.	Yasushi Sato, Koichi Okamoto, Tetsuji Takayama, Naoki Muguruma, 中山圭子, 大住省三, Yoshiaki Kubo, 内野眞也, 阪埜浩司 and 石川秀樹 : <作業部会委員会企画>Cowden症候群/PTEN hamartoma tumor syndrome (PHTS)の前向き登録コホート研究の概要., 第29回日本遺伝性腫瘍学会学術集会, Jun. 2023.
6.	Tomoyuki Kawaguchi, Koichi Okamoto, shota fujimoto, Hiroyuki Ueda, hironori wada, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 前癌病変Sessile serrated lesionのオルガノイドを用いたLansoprazoleの抑制効果およびその機序の検討., 第40回サイトプロテクション研究会, Mar. 2023.
7.	Tomoyuki Kawaguchi, Koichi Okamoto, Hironori Wada, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 前癌病変 Sessile serrated lesion のオルガノイドを用いた Lansoprazole の抑制効果およびその機序の検討., 第19回日本消化管学会総会学術集会, Feb. 2023.
8.	Kumiko Tanaka, Koichi Okamoto, Yasushi Sato, Tetsuji Takayama, Naoki Muguruma, 石川秀樹, 竹内洋司 and 武藤倫弘 : 家族性大腸腺腫症における小腸病変の形態学的解析., 第10回日本家族性大腸腺腫症研究会学術集会, Sep. 2022.
9.	Akihiro Hirao, Yasushi Sato, Hironori Tanaka, Takahiro Tanaka, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Naoki Muguruma, Kensei Nishida and Tetsuji Takayama : 肝細胞癌においてmiR-125b-5pは上皮間葉転換を引き起こし，ソラフェニブに対して耐性を獲得する, 第19回日本臨床腫瘍学会学術集会, Feb. 2022.
10.	Yasuyuki Okada, Yasuhiro Mitsui, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : LAMC2 is a novel predictive biomarker for gemcitabine-based therapy in pancreatic ductal adenocarcinoma., 第19回日本臨床腫瘍学会学術集会, Feb. 2022.
11.	shota fujimoto, Naoki Muguruma, Michiyasu Nakao, Hidenori ANDO, takanori miyake, 樫原孝典, Tatsuhiro Ishida, Shigeki Sano and Tetsuji Takayama : 消化管間質腫瘍(GIST)に対する新たな内視鏡診断法の確立に向けた蛍光分子イメージング技術の開発, 第18回日本消化管学会学術集会, Feb. 2022.
12.	Tomoyuki Kawaguchi, Koichi Okamoto, Masahiro Bando, hiroyuki ueda, 和田浩典, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 前癌病変Sessile serrated lesionのオルガノイドを用いた大腸癌予防薬の開発∼Connectivity Mapを用いた網羅的な分析∼, 第18回日本消化管学会学術集会, Feb. 2022.
13.	Shinji Kitamura, Naoki Muguruma and Tetsuji Takayama : 自己免疫性胃炎に合併した早期胃癌の臨床病理学的検討., JDDW2021(第29回日本消化器医関連学会週間), Nov. 2021.
14.	Noriaki Murayama, Koichi Okamoto, Jinsei Miyoshi, Tomoyuki Kawaguchi, Shinji Kitamura, beibei ma, Hiroshi Miyamoto, Naoki Muguruma, Yasushi Sato and Tetsuji Takayama : miR-144-3p/miR-451aは，PTEN/p19を介して直腸カルチノイド(NET-G1)の浸潤に関与する., 第59回日本癌治療学会学術集会, Oct. 2021.
15.	Hironori Tanaka, Tetsu Tomonari, kaizo kagemoto, Yasuyuki Okada, hironori wada, Fumika Nakamura, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 免疫チェックポイント阻害薬投与中の肝障害., 第59回日本癌治療学会学術集会, Oct. 2021.
16.	Akinari Kasai, Jinsei Miyoshi, Akihiro Haga, Takashi Kawanaka, Koichi Okamoto, Naoki Muguruma, Yasushi Sato and Tetsuji Takayama : CT-based AI radiomics model for predicting complete response and progression free survival of chemoradiothearapy in ESCC., 第80回日本癌学会学術総会, Oct. 2021.
17.	Beibei Ma, Hiroyuki Ueda, Naoki Muguruma, Koichi Okamoto, Tomoyuki Kawaguchi, Akira Fukuya, Yoshifumi Kida, Yasuyuki Okada, Tatsuya Taniguchi, Yasushi Sato and Tetsuji Takayama : Activation of EGFR signaling pathway in the left-side colorectal cancerLeft-side vs. right-side cancer organoids., 第80回日本癌学会学術総会, Sep. 2021.
18.	Tomoyuki Kawaguchi, Naoki Muguruma and Tetsuji Takayama : 内視鏡生検組織を用いたSessile serrated lesion(SSL)のオルガノイド培養とSSL動物モデルの樹立., 第101回日本消化器内視鏡学会総会, May 2021.
19.	田中育太, 友兼毅, 門田美由香, 多田早織, 小田修治, Yasushi Sato and Naoki Muguruma : 当院における進行再発胃癌に対しFOLFOX療法を施行した症例の検討., 第107回日本消化器病学会総会, Apr. 2021.
20.	矢野庄悟, Fumika Nakamura, Yasushi Sato, akira fukuya, Yasuteru Fujino, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : 消化管悪性腫瘍における免疫チェックポイント阻害薬の効果と免疫関連副作用の関連性について., 第17回日本消化管学会総会学術集会, Feb. 2021.
21.	Fumika Nakamura, Koichi Okamoto, 影本開三, Yoshifumi Kida, Kumiko Tanaka, Shinji Kitamura, Yasushi Sato, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : Serrated polyposis syndrome に合併した大腸癌の臨床病理学的特徴ならびに発癌機序の検討., 第17回日本消化管学会総会学術集会, Feb. 2021.
22.	和田浩典, Koichi Okamoto, Masahiro Bando, Naoki Muguruma and Tetsuji Takayama : 新規大腸癌予防薬の開発―大腸腺腫オルガノイドを用いて―., 第17回日本消化管学会総会学術集会, Feb. 2021.
23.	上田浩之, Yasuhiro Mitsui, 滝下誠, 矢野充保, 福家慧, Tomoyuki Kawaguchi, Yoshifumi Kida, Shinji Kitamura, Koichi Okamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Clinicopathological analysis of six families with Gastric Adenocarcinoma and Proximal Polyposis of the Stomach(GAPPS)., 第18回日本臨床腫瘍学会学術集会, Feb. 2021.
24.	矢野庄悟, Satoshi Teramae, Kumiko Tanaka, Yasuteru Fujino, Koichi Okamoto, Yasushi Sato, Naoki Muguruma, Tetsuji Takayama, 佐々木悠, 八島一夫, 大瀬戸久美子 and 石川秀樹 : 本邦におけるCowden症候群の実態調査., 第7回消化管ポリポーシス研究会学術集会, Jan. 2021.
25.	芳川明奈, Jinsei Miyoshi, akinari kasai, 松本れいか, 宮城愛, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma, Kenji Kita and Tetsuji Takayama : AI-based ESCC miRNA diagnosis model: retro-prospective multinational cohort study., 第74回日本食道学会学術集会, Dec. 2020.
26.	Tadahiko Nakagawa, Sayaka Takeuchi, Haruki Yamada, Naoki Igata, 板東直紀, 緒方良輔, 佐藤翔平, Tetsu Tomonari, Hiroshi Miyamoto, Naoki Muguruma, Tetsuji Takayama, Masahiro Sogabe and Toshiya Okahisa : 胸腹水の循環式濾過濃縮処理時の物理刺激によるサイトカイン濃度の上昇., 第58回日本人工臓器学会大会, Nov. 2020.
27.	多田理香, 竹内彩郁薫, 山田青季, 井形直紀, Masaki Oono, Masami Shishibori, Masao Fuketa, Kenji Terada, Yoshifumi Kida, Tomoyuki Kawaguchi, Yasuhiro Mitsui, Tatsunao Sueuchi, Naoki Muguruma, Tetsuji Takayama, Masahiro Sogabe and Toshiya Okahisa : 睡眠中の腸蠕動音の解析に適した腸音図システムの試作開発., 第58回日本人工臓器学会大会, Nov. 2020.
28.	Shinji Kitamura, Naoki Muguruma and Tetsuji Takayama : 自己免疫性胃炎に合併した胃癌33病変の臨床病理学的検討., 第28回日本消化器関連学会週間(JDDW2020), Nov. 2020.
29.	Yasushi Sato, Toshihito Tanahashi, Tadahiko Nakagawa, Shinji Kitamura, Hiroshi Miyamoto, Koichi Okamoto, Naoki Muguruma and Tetsuji Takayama : JMJD2Aヒストン脱メチル化酵素はCCDC8と協調し胃癌に対する化学療法感受性を制御する., 第58回日本癌治療学会学術集会, Oct. 2020.
30.	横山怜子, Fumika Nakamura, Yasushi Sato, Kazuhiro Kishi, 和田浩典, Tetsu Tomonari, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Toshiya Okahisa and Tetsuji Takayama : 胃癌におけるICI治療の効果予測因子としてのirAEの意義とその後治療への影響., 第58回日本癌治療学会学術集会, Oct. 2020.
31.	Jinsei Miyoshi, Shusuke Toden, Daisuke Izumi, Mitsuro Kanda, Yasushi Sato, Naoki Muguruma, Hideo Baba, Yasuhiro Kodera, Ajay Goel and Tetsuji Takayama : Circulating miRNA signature of esophageal squamous cell carcinoma diagnosis: retro-prospective multinational cohort study., 第79回日本癌学会学術総会, Oct. 2020.
32.	Tomoyuki Kawaguchi, shota Fujimoto, Masahiro Bando, 上田浩之, 和田浩典, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Connectivity Map とsessile serrated lesion オルガノイドを用いた網羅的な大腸癌予防薬の検索., がん予防学術大会2020米子, Sep. 2020.
33.	Shota Fujimoto, Naoki Muguruma and Tetsuji Takayama : 大腸微小病変Aberrant cypt fociの新規イメージング技術開発., 第99回日本消化器内視鏡学会総会, Sep. 2020.
34.	藤井祥平, Fumika Nakamura, Yasushi Sato, 岸和弘, Sumiko Yoshida, Yasuhiro Mitsui, Yasuteru Fujino, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : <第23回若手奨励賞>胃癌における免疫チェックポイント阻害薬の効果と免疫関連副作用(irAE)との関連性についての検討., Shikoku Acta Medica, Vol.76, No.3-4, 173-178, Aug. 2020. (Summary) Recently, immune checkpoint inhibitors(ICI)have been approved for use in advanced gastric cancer(AGC)based on the positive results of ATTRACTION‐2 trial in Japan. There has been accumulating evidence that the development of immune-related adverse events(irAE)may be associated with a response to ICI therapy, particularly in lung cancer, although little is known about these correlations in gastrointestinal cancer. To investigate the efficacy and irAE of ICI treatment and their correlation in AGC, we retrospectively examined 29 patients with AGC who received nivolumab therapy in our departments. Among them, 15 patients(52%)developed irAEs including 4 patients(14%)for grade 3 irAEs ; liver dysfunction(n＝2), type 1 diabetes mellitus(n＝2) and adrenal insufficiency(n＝1). The median overall survival was12．0months in the irAE group and 3．25 months in the non-irAE group(p＝0．164), which suggested the relationship between the effects and irAEs in ICI treatment of AGC. Further research is required to understand the implications of irAE characteristics on ICI response in GCA patients. (Keyword) Immune-checkpoint inhibitors / Gastric cancer / Immune-related adverse events / Nivolumab (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050865265018642176 (CiNii: 1050865265018642176)
35.	Takanori Kashihara, Yoshihiko Miyamoto, Shota Fujimoto, 和田浩典, Tomoyuki Kawaguchi, Yoshifumi Kida, Fumika Nakamura, Kumiko Tanaka, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 大腸腫瘍に発現するepidermal growth factor receptor in colorectal tumors., 第16回日本消化管学会総会学術集会, Feb. 2020.
36.	Fumika Nakamura, Koichi Okamoto, Kaizoh Kagemoto, Kumiko Tanaka, Yasuteru Fujino, Shinji Kitamura, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Serrated polyposis syndrome の臨床病理学的特徴ならびに発癌機序の検討., 第16回日本消化管学会総会学術集会, Feb. 2020.
37.	Tomoyuki Kawaguchi, Masanori Takehara, Kaizoh Kagemoto, Satoshi Teramae, Fumika Nakamura, Takahiro Tanaka, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 胸腺を含む5臓器にわたって10個の同時性多発重複癌を呈したLynch症候群の一例 ., 第57回日本癌治療学会学術集会, Oct. 2019.
38.	Masanori Takehara, Yasushi Sato, Tomoyuki Kawaguchi, Kazuyoshi Noda, Akira Fukuya, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : 癌関連脂肪細胞は膵癌のSAA1発現を誘導し，転移・浸潤を促進する., 第57回日本癌治療学会学術集会, Oct. 2019.
39.	Tetsuji Takayama, Koichi Okamoto and Naoki Muguruma : Surrogate marker for chemoprevention study on colorectal cancer Molecular imaging of aberrant crypt foci., 第78回日本癌学会学術総会, Sep. 2019.
40.	Tadahiko Nakagawa, Toshihito Tanahashi, yoshihiko miyamoto, Jun Okazaki, masanori takehara, noriaki murayama, Jinsei Miyoshi, Tatsuya Taniguchi, Yoshimi Bando, Koichi Okamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : JMJD2A (KDM4A) sensitizes metastatic gastric cancer to chemotherapy by cooperating CCDC8., 第78回日本癌学会学術総会, Sep. 2019.
41.	yoshihiko miyamoto, Naoki Muguruma, yasuyuki okada, Hironori Tanaka, Jun Okazaki, Koichi Okamoto, Yasushi Sato and Tetsuji Takayama : EGFR-targeted molecular imaging for detection and treatment evaluation of colorectal tumors in animal model., 第78回日本癌学会学術総会, Sep. 2019.
42.	Hironori Tanaka, Koichi Okamoto, 岡田泰行, 宮本佳彦, Yasuhiro Mitsui, Fumika Nakamura, Jinsei Miyoshi, Yasuteru Fujino, Takahiro Tanaka, Tetsu Tomonari, Shinji Kitamura, Hiroshi Miyamoto, Naoki Muguruma, Yasushi Sato and Tetsuji Takayama : Therapeutic efficacy of miriplatin in combination with radiotherapy for advanced hepatocellular carcinoma., 第17回日本臨床腫瘍学会学術集会, Jul. 2019.
43.	Jinsei Miyoshi, 村山典聡, Satoshi Teramae, 宮本佳彦, Hironori Tanaka, 岡田泰行, Yasuhiro Mitsui, Yasuteru Fujino, Takahiro Tanaka, Kumiko Tanaka, 松村圭一郎, Miwako Kagawa, Tetsu Tomonari, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 直腸NETのmicroRNA網羅的発現解析を用いた転移機序の解明と新規転移予測バイオマーカーの探索., 第17回日本臨床腫瘍学会学術集会, Jul. 2019.
44.	Yoshihiko Miyamoto, Naoki Muguruma and Tetsuji Takayama : 大腸腫瘍に発現する EGFR を標的とした内視鏡分子イメージングの試み., 第97回日本消化器内視鏡学会総会, Jun. 2019.
45.	Shota Fujimoto, Naoki Muguruma, Michiyasu Nakao, Hidenori ANDO, Yoshihiko Miyamoto, Koichi Okamoto, Yasushi Sato, Tatsuhiro Ishida, Shigeki Sano and Tetsuji Takayama : 新規蛍光プローブIndocyanine green (ICG) 標識Dasatinibを用いた消化管間質腫瘍 (GIST) の近赤外蛍光イメージング., 第14回日本分子イメージング学会総会・学術集会, May 2019.
46.	Yasuhiro Mitsui, Shinji Kitamura, Koichi Okamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Clinicopathological characteristics of Gastric adenocarcinoma with proximal polyposis of the stomach., 第91回日本胃癌学会総会, Mar. 2019.
47.	Jinsei Miyoshi, 村山典聡, Tadahiko Nakagawa, Koichi Okamoto, Yasushi Sato, Naoki Muguruma, Kensei Nishida, Koichi Tsuneyama, 藤盛孝博 and Tetsuji Takayama : 直腸NETのmiRNA-Gene-Pathwayを介した転移機序の解明とmiR-144-3p/451aの転移予測マーカーとしての意義., 第15回日本消化管学会総会学術集会, Feb. 2019.
48.	Shota Fujimoto, Naoki Muguruma, Koichi Okamoto, Yasushi Sato, Yoshihiko Miyamoto, Shinji Kitamura, Hiroshi Miyamoto and Tetsuji Takayama : 近赤外蛍光標識c-KIT抗体を用いた消化管間質腫瘍(GIST)に対する新たな内視鏡診断治療法(Theranostics)の開発., 第15回日本消化管学会総会学術集会, Feb. 2019.
49.	Yasuhiro Mitsui, Kumiko Tanaka, Satoshi Teramae, Shinji Kitamura, Koichi Okamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Gastric adenocarcinoma with proximal polyposis of the stomach(GAPPS)家系における若年罹患者へのアプローチ., 第5回日本消化管ポリポーシス研究会(日本消化器病学会関連研究会), Jan. 2019.
50.	Shota Fujimoto, Naoki Muguruma, Koichi Okamoto, Yasushi Sato, Yoshihiko Miyamoto, Michiyasu Nakao, Shinji Kitamura, Hiroshi Miyamoto, Shigeki Sano, Tatsuhiro Ishida, Koichi Tsuneyama and Tetsuji Takayama : Theranostics理論に基づく消化管間質腫瘍(GIST)の新規診断治療法の開発., 第26回日本消化器関連学会週間(第96回日本消化器内視鏡学会総会), Nov. 2018.
51.	taro mizutani, ju nishioka, naoki igata, kazuhide iwasa, tetsuya honda, Tomoyuki Kawaguchi, Yasuhiro Mitsui, Jinsei Miyoshi, Tatsunao Sueuchi, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Tetsuji Takayama, Masahiro Sogabe and Toshiya Okahisa : 携帯型小型腸音図システムの試作による腸蠕動音測定時間の最適化., 第56回日本人工臓器学会大会, Nov. 2018.
52.	Tetsuya Honda, Kazuhide Iwasa, Naoki Igata, Taro Mizutani, Junji Nishioka, Kazuyoshi Noda, 宮城愛, 山本加奈子, 新居徹, 津保友香, Akira Fukuya, Masanori Takehara, Satoshi Teramae, Yasuteru Fujino, Hiroshi Miyamoto, Naoki Muguruma, Tetsuji Takayama, Masahiro Sogabe and Toshiya Okahisa : 潰瘍性大腸炎における内視鏡画像解析による腫瘍の診断., 第56回日本人工臓器学会大会, Nov. 2018.
53.	Naoki Igata, Kazuhide Iwasa, Junji Nishioka, Tetsuya Honda, Kazuyoshi Noda, Yoshifumi Kida, Tatsunao Sueuchi, Miwako Kagawa, Tetsu Tomonari, Shinji Kitamura, Naoki Muguruma, Tetsuji Takayama, Masahiro Sogabe and Toshiya Okahisa : 腹水濾過濃縮再静注法(CART)の濾過濃縮処理による腹水中物質の濃度変化., 第56回日本人工臓器学会大会, Nov. 2018.
54.	西岡潤司, 水谷太郎, 井形直紀, 岩佐一秀, 本多哲也, Kazuyoshi Noda, 高岡慶史, Tatsunao Sueuchi, Miwako Kagawa, Tetsu Tomonari, Shinji Kitamura, Naoki Muguruma, Tetsuji Takayama, Masahiro Sogabe and Toshiya Okahisa : Multiple Point Bowel-sound Analysis System(MPBAS)の試作による腸蠕動音測定部位の最適化, 第56回日本人工臓器学会大会, Nov. 2018.
55.	和田浩典, Shinji Kitamura, Fumika Nakamura, Akira Fukuya, Masanori Takehara, Yasuyuki Okada, Yasuhiro Mitsui, Jinsei Miyoshi, Yasuteru Fujino, Kumiko Tanaka, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : CRT後咽頭狭窄を伴う表在型食道癌に対して細径内視鏡を用いたPDTが有効であった一例., 第56回日本癌治療学会学術集会, Oct. 2018.
56.	Akira Fukuya, Yasushi Sato, 佐川保, 高橋康雄, 大沼啓之, 濱口京子, 平川昌宏, 藤川幸司, Yasuteru Fujino, Koichi Okamoto, Naoki Muguruma and Tetsuji Takayama : 切除不能進行胃癌に対するドセタキセル/オキサリプラチン/S-1 3剤併用療法の第1相試験., 第56回日本癌治療学会学術集会, Oct. 2018.
57.	Jun Okazaki, Toshihito Tanahashi, Hironori Tanaka, Yasuyuki Okada, Yoshihiko Miyamoto, Jinsei Miyoshi, Tatsuya Taniguchi, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : miR-296-5p inhibits apoptosis and enhances invasion through the down-regulated BOK in unresectable pancreatic cancer., 第77回日本癌学会学術集会, Sep. 2018.
58.	Yoshihiko Miyamoto, Hironori Tanaka, Jun Okazaki, Yasuyuki Okada, Tatsuya Taniguchi, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Molecular imaging of colorectal tumor targeting epidermal growth factor receptor (EGFR)., 第77回日本癌学会学術集会, Sep. 2018.
59.	Tadahiko Nakagawa, Toshihito Tanahashi, Yoshihiko Miyamoto, Masanori Takehara, Noriaki Murayama, Hironori Tanaka, Jinsei Miyoshi, Tatsuya Taniguchi, Yoshimi Bando, Koichi Okamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : ヒストン脱メチル化酵素JMJD2Aは切除不能進行胃癌においてCCDC8の発現調節を介して抗癌剤感受性を制御する., 第77回日本癌学会学術総会, Sep. 2018.
60.	Satoshi Teramae, Kumiko Tanaka, 三橋威志, Yasuhiro Mitsui, Fumika Nakamura, Yasuteru Fujino, Jinsei Miyoshi, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 新規APC遺伝子変異(C.1626+1G>A)を認めた家族性大腸腺腫症の一例., 第6回日本家族性大腸腺腫症研究会学術集会, Sep. 2018.
61.	Masanori Takehara, Yasushi Sato, 津保友香, Akira Fukuya, 岡田泰行, 宮本佳彦, Yasuhiro Mitsui, Yasuteru Fujino, Fumika Nakamura, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : 膵癌と脂肪細胞の相互作用はSAA1の発現を誘導することにより膵癌の浸潤を促進させる., 第16回日本臨床腫瘍学会学術集会, Jul. 2018.
62.	津保友香, Yasuhiro Mitsui, Akira Fukuya, Masanori Takehara, 岡田泰行, Jinsei Miyoshi, Yasuteru Fujino, Fumika Nakamura, Kumiko Tanaka, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 切除不能進行神経内分泌癌に対するIrinotecan+Cisplatin併用療法の後方視的検討., 第16回日本臨床腫瘍学会学術集会, Jul. 2018.
63.	福家慧, Yasushi Sato, 佐川保, 高橋康雄, 大沼啓之, 濱口京子, 平川昌宏, 藤川幸司, Yasuteru Fujino, Yasuhiro Mitsui, 岡田泰行, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : 切除不能進行胃癌に対するdocetaxel/ oxaliplatin/S-1(DOS)療法の第I相試験., 第16回日本臨床腫瘍学会学術集会, Jul. 2018.
64.	Tetsu Tomonari, 新居徹, 津保友香, Yoshihiko Miyamoto, Hironori Tanaka, Takahiro Tanaka, Koichi Okamoto, Hiroshi Miyamoto, Masahiro Sogabe, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 集学的治療奏功例を含む進行肝癌に対するRegorafenibの初期治療成績., 第54回日本肝癌研究会, Jun. 2018.
65.	Yasuhiro Mitsui, Kumiko Tanaka, 寺前智史, Shinji Kitamura, Koichi Okamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Gastric adenocarcinoma with proximal polyposis of the stomach(GAPPS)におけるAPC 遺伝子生殖細胞系列変異および臨床病理学的特徴., 第24回日本家族性腫瘍学会学術集会, Jun. 2018.
66.	Naoki Muguruma, Koichi Okamoto, 藤本将太, 宮本佳彦, Shinji Kitamura, Hiroshi Miyamoto, Mitsuo Shimada and Tetsuji Takayama : 分子解析に基づく大腸前癌病変 Aberrant crypt foci の新規イメージング技術開発., 第 13 回日本分子イメージング学会総会・学術集会, May 2018.
67.	藤本大策, Naoki Muguruma and Tetsuji Takayama : 大腸ポリープに対する Linked Color Imaging(LCI)の有用性の検討., 第95回日本消化器内視鏡学会総会, May 2018.
68.	Shinji Kitamura, Naoki Muguruma, Yasushi Sato and Tetsuji Takayama : New Traction Method with Endoloop for ESD., 第90回日本胃癌学会総会, Mar. 2018.
69.	Fumika Nakamura, Koichi Okamoto, Kaizoh Kagemoto, Noriaki Murayama, Kumiko Tanaka, Yasuteru Fujino, Shinji Kitamura, 三宮勝隆, Yasushi Sato, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : Serrated polyposis syndromeにおける遺伝性及び発癌機序の検討., 第14回日本消化管学会総会学術集会, Feb. 2018.
70.	Yasuteru Fujino, Koichi Okamoto, Naoki Muguruma, Yasuhiro Mitsui, Shinji Kitamura, 藤本大策, Masahiro Sogabe, Hiroshi Miyamoto, Yasushi Sato and Tetsuji Takayama : microRNA arrayを用いた大腸粘膜下層浸潤癌リンパ節転移に関わるバイオマーカーの同定及び機能解析, 第14回日本消化管学会総会学術集会, Feb. 2018.
71.	岡田泰行, Tetsuo Kimura, Koichi Okamoto, Fumika Nakamura, Yasuteru Fujino, Kumiko Tanaka, Jinsei Miyoshi, Yasuhiro Mitsui, Shinji Kitamura, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 抗EGFR抗体薬治療におけるEarly tumor shrinkage(ETS)とEGFR内在化の関連について, 第88回大腸癌研究会, Jan. 2018.
72.	Yasuteru Fujino, 野田和克, 村山典聡, Kumiko Tanaka, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma, Toshiya Okahisa, Tetsuji Takayama, Yoshiaki Kubo, Yoshimi Bando and Seisuke Okamura : 胃巨大ポリープから出血をきたしたCowden病の一例., 第4回消化管ポリポーシス研究会(日本消化器病学会関連研究会), Jan. 2018.
73.	Shota Fujimoto, Naoki Muguruma, Koichi Okamoto, Yasushi Sato, Yoshihiko Miyamoto, Shinji Kitamura, Hiroshi Miyamoto and Tetsuji Takayama : Gastrointestinal stromal tumorに対するC-KITを標的とした新規近赤外蛍光イメージング診断と光抗体療法の開発., 第3回G-PLUS, Dec. 2017.
74.	Yasuteru Fujino, 池田敬洋, Tetsu Tomonari, Yasuhiro Mitsui, 香川美和子, Momoko Sato, 仁木美也子, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Ipilimumab にて完全奏功が得られた転移性直腸悪性黒色腫の1例., 第 55 回日本癌治療学会学術集会,, Oct. 2017.
75.	高岡慶史, 影本開三, Yasuhiro Mitsui, Kumiko Tanaka, Fumika Nakamura, Yasuteru Fujino, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Masako Kimura, 仁木美也子, Hiroshi Miyamoto, Naoki Muguruma, 石川正志 and Tetsuji Takayama : 免疫チェックポイント阻害薬で加療した直腸肛門部悪性黒色腫の4例., 第55回日本癌治療学会学術集会, Oct. 2017.
76.	Shinji Kitamura, Naoki Muguruma and Tetsuji Takayama : 胃癌ハイリスク診断における胃黄色腫の意義., 第25回日本消化器関連学会週間(JDDW2017), Oct. 2017.
77.	藤本大策, Naoki Muguruma and Tetsuji Takayama : SSA/P診断におけるランダム化比較試験によるLinked Color Imaging(LCI)の有用性の検討., 第25回日本消化器関連学会週間(JDDW2017), Oct. 2017.
78.	Tadahiko Nakagawa, Toshihito Tanahashi, Tetsuo Kimura, Koichi Okamoto, Tatsuya Taniguchi, 村山典聡, Hironori Tanaka, Yoshimi Bando, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : ヒストン脱メチル化酵素JMJD2Aは切除不能進行胃癌において CCDC8の発現を調節することで薬剤感受性を制御している., 第76回日本癌学会学術総会, Sep. 2017.
79.	村山典聡, Koichi Okamoto, Tadahiko Nakagawa, Tetsuo Kimura, Tatsuya Taniguchi, Hironori Tanaka, Yasushi Sato, Naoki Muguruma, Koichi Tsuneyama, 藤盛孝博 and Tetsuji Takayama : miR-144-3p/miR-451a はPTEN/p19 を抑制することにより直腸カルチノイド(NET-G1)の浸潤・転移に関与する., 第76回日本癌学会学術総会, Sep. 2017.
80.	Kumiko Tanaka, 寺前智史, Yasuteru Fujino, Koichi Okamoto, Yasushi Sato, Naoki Muguruma, Tetsuji Takayama, 小倉俊郎, 石畝亨 and 石田秀行 : 胆管癌及び多発十二指腸癌を合併した家族性大腸腺腫症の一例., 第5回日本家族性大腸腺腫症研究会学術集会, Sep. 2017.
81.	Kumiko Tanaka, 寺前智史, Yasuteru Fujino, Koichi Okamoto, Yasushi Sato, Naoki Muguruma, 佐々木悠, 八島一夫, 大瀬戸久美子, 石川秀樹 and Tetsuji Takayama : 本邦におけるCowden病の実態調査., 第23回日本家族性腫瘍学会学術集会, Aug. 2017.
82.	岡田泰行, 福家慧, Takahiro Goji, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Toshiya Okahisa, 辻靖 and Tetsuji Takayama : 大腸癌における抗 EGFR 抗体薬による EGFR の lysosome への誘導と治療効果との関連について., 第15回日本臨床腫瘍学会学術集会, Jul. 2017.
83.	Yasuteru Fujino, Kumiko Tanaka, Fumika Nakamura, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 大腸粘膜下層浸潤癌リンパ節転移に関わるmicroRNAの網羅的解析., 第87回大腸癌研究会, Jul. 2017.
84.	影本開三, Koichi Okamoto, 岡田泰行, 高岡慶史, Yasuhiro Mitsui, 藤本大策, Shinji Kitamura, Tetsuo Kimura, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 画像強調内視鏡(IEE)によるヒト Aberrant crypt foci (ACF)の観察∼従来のメチレンブルー散布法と比較して∼., がん予防学術大会2017, Jun. 2017.
85.	Shota Fujimoto, Naoki Muguruma and Tetsuji Takayama : KIT を標的とした Gastrointestinal stromal tumor の新しい光分子イメージングと光抗体療法の開発., 第93回日本消化器内視鏡学会総会, May 2017.
86.	Shota Fujimoto, Naoki Muguruma, Yoshihiko Miyamoto, Michiyasu Nakao, Shigeki Sano, Hidenori ANDO, Tatsuhiro Ishida and Tetsuji Takayama : KIT分子を標的としたGISTの分子イメージング, 第103回日本消化器病学会総会, Apr. 2017.
87.	藤本大策, Naoki Muguruma and Tetsuji Takayama : 大腸SSA/Pに対するLinked Cokor Imaging(LCI)の有用性を調べるランダム化比較試験, 第103回日本消化器病学会総会, Apr. 2017.
88.	藤本大策, 岡田怜子, 福家慧, 影本開三, Yasuhiro Mitsui, Takahiro Goji, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : 大腸サーベイランスにおけるSSA/P検出率の上昇を目指して―LCIの有用性の検討―, 第13回日本消化管学会総会学術集会, Feb. 2017.
89.	村山典聡, 寺前智史, Yasuhiro Mitsui, Yasuteru Fujino, Kumiko Tanaka, Tetsuo Kimura, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : Serrated polyposis syndromeにおけるポリープ，大腸癌の性状と発癌機序の検討., 第13回日本消化管学会総会学術集会, Feb. 2017.
90.	Mayu Uyama, Masahiro Sogabe, Toshiya Okahisa, 平田光里, Tadahiko Nakagawa, 村山典聡, 武原正典, 松本友里, 岡崎潤, 高岡慶史, Yasuteru Fujino, 香川美和子, 田中貴大, Tetsu Tomonari, Tatsuya Taniguchi, Takahiro Goji, Tetsuo Kimura, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : 胸腹水濾過濃縮再静注法の施行状況と今後の課題, 第37会日本アフェレシス学会学術大会, Nov. 2016.
91.	笠井嘉人, 玉井瑠人, 谷直也, 田中大基, Tatsunao Sueuchi, 高岡慶史, 香川美和子, Tadahiko Nakagawa, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Tetsuji Takayama, Mayu Uyama, Masahiro Sogabe and Toshiya Okahisa : 携帯型腸蠕動音収集解析システムの試作開発., 第54回日本人工臓器学会大会, Nov. 2016.
92.	寺前智史, Kumiko Tanaka, Koichi Okamoto, Naoki Muguruma, 石川秀樹, 竹内洋司 and Tetsuji Takayama : 家族性大腸腺腫症における小腸病変について, 第54回小腸研究会, Nov. 2016.
93.	Daisaku Fujimoto, Naoki Muguruma and Tetsuji Takayama : Usefulness of linked color imaging in endoscopic diagnosis of SSA/P: A novel image enhancment technique., 第24回日本消化器関連学会週間, Nov. 2016.
94.	岡田泰行, Tetsuo Kimura, Takahiro Goji, Shinji Kitamura, Hiroshi Miyamoto, Naoki Muguruma, 辻靖 and Tetsuji Takayama : 大腸癌における抗EGFR抗体薬のEGFR内在化誘導と治療効果の検討., 第54回日本癌治療学会学術集会, Oct. 2016.
95.	松本早代, Koichi Okamoto, Naoki Muguruma, Tadahiko Nakagawa, 関崚太, 武原正典, 影本開三, 高岡慶史, 岡崎潤, 藤本大策, Tetsuo Kimura, Shinji Kitamura, Hiroshi Miyamoto, Toshiya Okahisa and Tetsuji Takayama : 10mm以下の直腸カルチノイド(NET-G1)に対する内視鏡的治療の有用性の検討., 第54回日本癌治療学会学術集会, Oct. 2016.
96.	武原正典, Tetsuo Kimura, Tadahiko Nakagawa, Tatsuya Taniguchi, Naoki Muguruma and Tetsuji Takayama : 膵癌と脂肪組織の相互作用によるSAA1発現亢進は癌の転移・浸潤を促進する., 第75回日本癌学会学術総会, Oct. 2016.
97.	Tadahiko Nakagawa, Tetsuo Kimura, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Yoshimi Bando, Naoki Muguruma, Toshiya Okahisa and Tetsuji Takayama : ヒストン脱メチル化酵素JMJD2Aは切除不能進行胃癌における新しい治療効果予測因子である., 第75回日本癌学会学術総会, Oct. 2016.
98.	寺前智史, Kumiko Tanaka, Naoki Muguruma, 石川秀樹, 竹内洋司 and Tetsuji Takayama : 家族性大腸腺腫症における小腸病変の検討, 第4回日本家族性大腸腺腫症研究会学術集会, Sep. 2016.
99.	Naoki Muguruma, Koichi Okamoto, Shota Fujimoto, Yasuteru Fujino, Tadahiko Nakagawa, Shinji Kitamura, Tetsuo Kimura, Mitsuo Shimada, Hiroshi Miyamoto and Tetsuji Takayama : 分子解析に基づいたAberrant crypt fociの新規イメージング技術開発, がん予防学術大会2016, Jul. 2016.
100.	寺前智史, Kumiko Tanaka, Naoki Muguruma, 高岡慶史, 岡崎潤, 村山典聡, Tatsunao Sueuchi, Yasuhiro Mitsui, 藤本大策, Takahiro Goji, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, 江副康正, 石川秀樹, 竹内洋司 and Tetsuji Takayama : 家族性大腸腺腫症における小腸病変についての検討, 第85回大腸癌研究会, Jul. 2016.
101.	寺前智史, Koichi Okamoto, Naoki Muguruma, Kumiko Tanaka, Yasuteru Fujino, 香川美和子, Shinji Kitamura, Tetsuo Kimura, Hiroshi Miyamoto, Mitsuo Shimada and Tetsuji Takayama : 若年で原発性十二指腸癌を合併したSTK11全欠失型Peutz–Jeghers症候群の1例, 第22回日本家族性腫瘍学会学術集会, Jun. 2016.
102.	山尾雅美, 西尾進, 平田有紀奈, 鳥居裕太, Seiji Iwamoto, Naoki Muguruma, Hirotsugu Yamada, Masataka Sata, 藤崎由紀子 and 渡辺滋夫 : 膵臓原発性悪性リンパ腫の1例, 日本超音波医学会第89回学術集会, May 2016.
103.	Shinji Kitamura, Naoki Muguruma and Tetsuji Takayama : 胃黄色腫の除菌後胃粘膜における胃癌バイオマーカーとしての意義, 第91回日本消化器内視鏡学会総会, May 2016.
104.	Shinji Kitamura, 竹内尚, 影本開三, 岡田泰行, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : 経鼻内視鏡検診における送水装置(AF-WP1)の有効性の検討, 第91回日本消化器内視鏡学会総会, May 2016.
105.	松本早代, Koichi Okamoto, Naoki Muguruma, 野口拓樹, Tadahiko Nakagawa, 武原正典, 影本開三, 宮本佳彦, 高岡慶史, 岡崎潤, 岡田泰行, Yasuteru Fujino, Kumiko Tanaka, 香川美和子, Tetsuo Kimura, Shinji Kitamura, Hiroshi Miyamoto, Toshiya Okahisa and Tetsuji Takayama : 10mm以下の直腸カルチノイド(NET-G1)に対する内視鏡的治療の有用性の検討, 第12回日本消化管学会総会学術集会, Feb. 2016.
106.	Naoki Muguruma, Koichi Okamoto, Shota Fujimoto, Yasuteru Fujino, Tadahiko Nakagawa, Shinji Kitamura, Tetsuo Kimura, Hiroshi Miyamoto, Mitsuo Shimada and Tetsuji Takayama : GST 活性型新規蛍光プローブによる大腸前癌病変 ACF の in vivo 分子イメージング, 第1回G-PLUS, Dec. 2015.
107.	長瀬襟加, 鳥居裕太, 西尾進, 平田有紀奈, 山尾雅美, Seiji Iwamoto, Hirotsugu Yamada, Naoki Muguruma and Masataka Sata : 好酸球性胆管炎の1例, 日本超音波検査学会第19回中国・四国第23回合同地方会学術集会, Nov. 2015.
108.	武原正典, Hiroshi Miyamoto, 岡田泰行, Yasuhiro Mitsui, Yasuteru Fujino, Kumiko Tanaka, Tetsuo Kimura, Shinji Kitamura, Koichi Okamoto, 仁木美也子, Masako Kimura, Naoki Muguruma, Toshiya Okahisa, Yoshimi Bando and Tetsuji Takayama : 化学療法により長期生存が得られた脾臓原発血管肉腫の一例, 第53回日本癌治療学会学術集会, Oct. 2015.
109.	中川忠彦, Masahiro Sogabe, 岡崎潤, 松本早代, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Tetsuji Takayama, Takahiro Emoto, Masatake Akutagawa and Toshiya Okahisa : 腹水濾過濃縮再静注法の濾過工程の物理刺激が腹水中サイトカイン濃度に及ぼす影響第2報:培養癌細胞を用いた検討, 第36回日本アフェレシス学会学術総会, Oct. 2015.
110.	影本開三, Tatsunao Sueuchi, Yasuhiro Mitsui, Kumiko Tanaka, 香川美和子, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Masako Kimura, 仁木美也子, Hiroshi Miyamoto, Naoki Muguruma, 石川正志 and Tetsuji Takayama : Nivolumabにて加療した直腸肛門部悪性黒色腫の2例, 第53回日本癌治療学会学術集会, Oct. 2015.
111.	中川忠彦, Shinji Kitamura, 岡田泰行, Tatsuya Taniguchi, 田中貴大, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Toshiya Okahisa and Tetsuji Takayama : ヒストン脱メチル化酵素 JMJD2A は切除不能胃癌に対する化学療法の新しい治療効果予測因子である, 第74回日本癌学会学術総会, Oct. 2015.
112.	Kumiko Tanaka, Naoki Muguruma, 岡崎潤, 岡田泰行, 高岡慶史, 田中宏典, 宮本佳彦, 松本早代, 田中貴大, Yasuteru Fujino, 香川美和子, Tetsu Tomonari, Tatsuya Taniguchi, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Toshiya Okahisa, 石川秀樹 and Tetsuji Takayama : 家族性大腸腺腫症における小腸病変の検討 -形態学的，病理組織学的解析を含めて-, 第23回消化器関連学会週間(第57回日本消化器病学会大会), Oct. 2015.
113.	西尾進, 鳥居裕太, 平田有紀奈, 山尾雅美, Shin-ichiro Yamada, Seiji Iwamoto, Hirotsugu Yamada, Naoki Muguruma, Mitsuo Shimada and Masataka Sata : 正常肝に発症した巨大肝細胞癌の1例, 日本超音波医学会第25回四国地方会学術集会, Oct. 2015.
114.	岡田泰行, Yasuteru Fujino, Shinji Kitamura, Tetsuo Kimura, Masako Kimura, Hiroshi Miyamoto, Kazuhiro Kishi, Naoki Muguruma, 辻靖 and Tetsuji Takayama : 大腸癌に対する抗EGFR抗体薬の効果予測因子の解析., 第13回日本臨床腫瘍学会学術集会, Jul. 2015.
115.	Jun Okazaki, Tetsuo Kimura, Hiroshi Miyamoto, Yasuhiro Mitsui, Yasuteru Fujino, Shinji Kitamura, Masako Kimura, Koichi Okamoto, Naoki Muguruma and Tetsuji Takayama : S-1/oxaliplatin/irinotecan (SOXIRI) for advanced unresectable pancreatic cancer : A dose-finding study, 第13回日本臨床腫瘍学会学術集会, Jul. 2015.
116.	Yasuteru Fujino, Koichi Okamoto, Naoki Muguruma and Tetsuji Takayama : ACF-SSA/P-cancer sequenceにおけるメチル化遺伝子の網羅的解析, 第83回大腸癌研究会, Jul. 2015.
117.	Koichi Okamoto, Yasuteru Fujino, 中川忠彦, 井上篤, 松本早代, Kumiko Tanaka, 三宮勝隆, Shinji Kitamura, Naoki Muguruma, Toshiya Okahisa and Tetsuji Takayama : SSA/P-cancer sequenceにおけるACFの前癌病変としての意義―右側大腸癌のバイオマーカーとしてのACF―, がん予防学術大会2015さいたま, Jun. 2015.
118.	Yasuhiro Mitsui, Naoki Muguruma, Kumiko Tanaka, 高岡慶史, Yasuteru Fujino, Koichi Okamoto, Shinji Kitamura, Tetsuo Kimura, Hiroshi Miyamoto and Tetsuji Takayama : 異なる胃病変を呈する家族性大腸腺腫症(FAP)の1家系, 第21回日本家族性腫瘍学会学術集会, Jun. 2015.
119.	岡崎潤, 福家慧, 影本開三, 高岡慶史, 宮本佳彦, 岡田泰行, 松本早代, Yasuhiro Mitsui, Tatsunao Sueuchi, Kumiko Tanaka, Yasuteru Fujino, 高岡遠, Shinji Kitamura, Hiroshi Miyamoto, Naoki Muguruma, Toshiya Okahisa and Tetsuji Takayama : EUS-FNAで確定診断し得た小型退形成性膵管癌の1例., 第89回日本消化器内視鏡学会総会, May 2015.
120.	Tetsuo Kimura, 武原正典, 岡崎潤, 高岡慶史, 岡田泰行, 宮本佳彦, 松本早代, 三井康裕, Tatsunao Sueuchi, Kumiko Tanaka, Yasuteru Fujino, 髙岡遠, Shinji Kitamura, Masako Kimura, Hiroshi Miyamoto, Naoki Muguruma, Tetsuya Ikemoto, Mitsuo Shimada and Tetsuji Takayama : 非典型的な画像所見を呈する膵神経内分泌腫瘍(膵NET)の治療方針, 第101回日本消化器病学会総会, Apr. 2015.
121.	高岡慶史, Toshiya Okahisa, 岡崎潤, 岡田泰行, 松本早代, Tatsunao Sueuchi, 三井康裕, Yasuteru Fujino, Kumiko Tanaka, 藤本大策, Tetsuo Kimura, Shinji Kitamura, Hiroshi Miyamoto, Naoki Muguruma, 河野正樹, 難波和樹, 赤田茂甫規, Takahiro Emoto and Tetsuji Takayama : 過敏性腸症候群の客観的診断と病態評価のための腸音図システムの開発, 第101回日本消化器病学会総会, Apr. 2015.
122.	Yasuteru Fujino, 松本早代, 佐藤勝哉, 藤本大策, Kumiko Tanaka, Tatsunao Sueuchi, 三井康裕, Tetsuo Kimura, Shinji Kitamura, Hiroshi Miyamoto, Naoki Muguruma, Toshiya Okahisa and Tetsuji Takayama : Serrated polyposis syndromeの前癌病変としての意義―病理所見，発癌，遺伝子異常の解析―, 第101回日本消化器病学会総会, Apr. 2015.
123.	田中育太, 友兼毅, 多田早織, 吉野すみ, 小田修治, Naoki Muguruma and Tetsuji Takayama : ヘリコバクターピロリ感染に伴う胃十二指腸炎を認め加療を行った11歳女児の1例, 第11回日本消化管学会総会学術集会, Feb. 2015.
124.	藤本大策, 佐藤勝哉, 松本早代, Yasuteru Fujino, 末内辰尚, 三井康裕, 岡田泰行, 岡崎潤, 宮本佳彦, 高岡慶史, 田中宏典, Shinji Kitamura, Tetsuo Kimura, Hiroshi Miyamoto, Toshiya Okahisa, Shunsaku Takeishi, Naoki Muguruma and Tetsuji Takayama : Serrated polyposisの前癌病変としての意義, 第11回日本消化管学会総会学術集会, Feb. 2015.
125.	Shinji Kitamura, 岡田泰行, 福家慧, 岡崎潤, 高岡慶史, 宮本佳彦, 末内辰尚, 松本早代, 三井康裕, Kumiko Tanaka, Yasuteru Fujino, 藤本大策, Tetsuo Kimura, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : ヨード染色後に病変の大部分が消失した表在型食道癌の一例, 第11回日本消化管学会総会学術集会, Feb. 2015.
126.	Kumiko Tanaka, Naoki Muguruma, Tetsuji Takayama, Yasushi Sato and 加藤淳二 : 家族性大腸線種症における小腸病変の検討, 第2回日本家族性大腸線種症研究会学術集会, Nov. 2014.
127.	Kumiko Tanaka, Naoki Muguruma and Tetsuji Takayama : 家族性大腸腺腫症における小腸内視鏡検査の有用性の検討, 第88回日本消化器内視鏡学会総会(JDDW2014), Oct. 2014.
128.	宮本佳彦, Naoki Muguruma, Shinji Kitamura, 影本開三, 岡田泰行, 岡崎潤, 松本早代, 末内辰尚, 三井康裕, Kumiko Tanaka, Yasuteru Fujino, Tetsuo Kimura, Hiroshi Miyamoto and Tetsuji Takayama : 大腸癌におけるEpidermal Growth Factor Receptor(EFGR)をターゲットとした分子イメージングと薬効評価, 第88回日本消化器内視鏡学会総会, Oct. 2014.
129.	Tetsuo Kimura, Naoki Muguruma and Tetsuji Takayama : Suppressive effect of the farnesyltransferase inhibitor for aberrant crypt foci as a precursor of colorectal cancer., 第56回日本消化器病学会大会(JDDW2014), Oct. 2014.
130.	山尾雅美, 西尾進, 鳥居裕太, 平田有紀奈, 笹田倫子, Shoichiro Takao, Naoki Muguruma, Hirotsugu Yamada, Mitsuo Shimada and Masataka Sata : 内部に嚢胞性変化を伴った肝過形成結節の1例, 第24回日本超音波医学会四国地方会学術集会, Oct. 2014.
131.	鳥居裕太, 西尾進, 山尾雅美, 平田有紀奈, 笹田倫子, 松本早代, Shoichiro Takao, Naoki Muguruma, Hirotsugu Yamada and Masataka Sata : 胃壁内膿瘍穿通による肝膿瘍の1例, 第24回日本超音波医学会四国地方会学術集会, Oct. 2014.
132.	Tatsuya Taniguchi, 影本開三, 田中宏典, 田中貴大, Tetsu Tomonari, 三宮勝隆, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : 肝細胞癌におけるPIVKA-Ⅱの発現機序の解明―PARP1の役割―, 第73回日本癌学会学術総会, Sep. 2014.
133.	Tetsuo Kimura, Takahiro Goji, Jinsei Miyoshi, Yasuteru Fujino, Shinji Kitamura, Momoko Sato, Masako Kimura, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : The prospective study of S-1+gemcitabine and concurrent radiotherapy for unresectable locally advanced pancreatic cancer, 第12回日本臨床腫瘍学会学術集会, Jul. 2014.
134.	Kumiko Tanaka, Naoki Muguruma and Tetsuji Takayama : PTEN exon 2に胚細胞性変異を認めたCowden病の1例, 第20回日本家族性腫瘍学会学術集会, Jun. 2014.
135.	Shinji Kitamura, Naoki Muguruma, 松本友里, 松本早代, 岡崎潤, 髙岡遠, 村山典聡, 香川美和子, Yasuteru Fujino, Jinsei Miyoshi, Fumika Nakamura, 大塚加奈子, Hiroshi Miyamoto, Toshiya Okahisa and Tetsuji Takayama : 内視鏡切除された直腸カルチノイド(NET-G1)の臨床経過に関する検討, 第87回日本消化器内視鏡学会総会, May 2014.
136.	宮本佳彦, Naoki Muguruma, Shinji Kitamura, 松本友里, 松本早代, Fumika Nakamura, 髙岡遠, Yasuteru Fujino, Jinsei Miyoshi, Kumiko Tanaka, Takahiro Goji, Hiromi Yano, 香川美和子, Hiroshi Miyamoto, Toshiya Okahisa and Tetsuji Takayama : 大腸癌に対する内視鏡分子イメージング技術の開発, 第87回日本消化器内視鏡学会総会, May 2014.
137.	Shinji Kitamura, Naoki Muguruma, 松本友里, 松本早代, 岡崎潤, 髙岡遠, 香川美和子, Yasuteru Fujino, Jinsei Miyoshi, Fumika Nakamura, Kumiko Tanaka, Hiroshi Miyamoto, Toshiya Okahisa and Tetsuji Takayama : バレット食道癌における欧米と日本のマネジメントの相違に関する検討, 第87回日本消化器内視鏡学会総会, May 2014.
138.	鳥居裕太, 西尾進, 山尾雅美, 平田有紀奈, Junko Hotsuchi, Takayuki Ise, Shoichiro Takao, Naoki Muguruma, Hirotsugu Yamada and Masataka Sata : 門脈圧亢進症および門脈・左胃静脈内血栓による巨大脾動脈瘤の1症例, 第87回日本超音波医学会学術集会, May 2014.
139.	Naoki Muguruma, 田中久美子, 高岡慶史, 松本早代, 藤野泰輝, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto and Tetsuji Takayama : 家族性大腸腺腫症における胃小腸病変に関する検討, 第100回日本消化器病学会総会附置研究会消化管ポリポーシス研究会, Apr. 2014.
140.	Shinji Kitamura, Naoki Muguruma and Tetsuji Takayama : 早期胃癌に対する経胃瘻的ESD, 第100回日本消化器病学会総会, Apr. 2014.
141.	田中宏典, Tatsuya Taniguchi, Tetsuji Takayama, 田中貴大, 友成哲, 原田利枝, Momoko Sato, 三宮勝隆, Hiroshi Miyamoto, Naoki Muguruma and Toshiya Okahisa : 高度進行肝細胞癌に対するミリプラチンを用いた放射線併用動注化学療法の有用性, 第100回日本消化器病学会総会, Apr. 2014.
142.	藤野泰輝, 大塚加奈子, 田中久美子, Fumika Nakamura, 三好人正, 香川美和子, Takahiro Goji, 髙岡遠, Hiromi Yano, Shinji Kitamura, Hiroshi Miyamoto, Naoki Muguruma, Toshiya Okahisa and Tetsuji Takayama : Sessile serrated adenoma/polyp(SSA/P)の前病変としてのAberrant crypt foci(ACF)の解析, 第10回日本消化管学会総会学術集会, Feb. 2014.
143.	松本早代, Naoki Muguruma, 松本友里, 岡崎潤, 田中久美子, Fumika Nakamura, 藤野泰輝, 三好人正, 香川美和子, Takahiro Goji, 髙岡遠, 村山典聡, Hiromi Yano, Shinji Kitamura, Hiroshi Miyamoto, Toshiya Okahisa and Tetsuji Takayama : 内視鏡治療された直腸カルチノイド(NET-G1)の臨床経過に関する検討, 第80回大腸癌研究会, Jan. 2014.
144.	藤野泰輝, Koichi Okamoto, Naoki Muguruma and Tetsuji Takayama : 大腸発癌におけるACF-SSA/P-cancer sequenceの検証, 第21回浜名湖シンポジウム, Dec. 2013.
145.	高岡遠, 藤野泰輝, 平尾章博, 宮本佳彦, 岡田泰行, 三井康裕, 田中貴大, 高場梓, 香川美和子, 友成哲, 津田美穂, Tatsuya Taniguchi, Takahiro Goji, Hiromi Yano, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Toshiya Okahisa and Tetsuji Takayama : SSA/PのLASSEREO Blue LASER Imaging併用拡大内視鏡診断, 第21回日本消化器関連学会週間JDDW2013,第86回日本消化器内視鏡学会総会, Oct. 2013.
146.	Naoki Muguruma, 宮本佳彦, 藤野泰輝, 高岡遠, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Toshiya Okahisa and Tetsuji Takayama : 大腸癌における分子イメージング, 第21回日本消化器関連学会週間JDDW2013,第86回日本消化器内視鏡学会総会, Oct. 2013.
147.	香川美和子, Toshiya Okahisa, 中川忠彦, 高場梓, Takahiro Goji, Hiromi Yano, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : Thymidine Phosphorylaseを標的とした潰瘍性大腸炎治療薬の開発, 第21回日本消化器関連学会週間JDDW2013,第55回消化器病学会大会, Oct. 2013.
148.	鳥居裕太, 西尾進, 山尾雅美, 平田有紀奈, 笹田倫子, Takayuki Ise, Shoichiro Takao, Naoki Muguruma, Hirotsugu Yamada and Masataka Sata : 巨大脾動脈瘤の1症例, 第23回日本超音波医学会四国地方会学術集会, Oct. 2013.
149.	平田有紀奈, 西尾進, 山尾雅美, 鳥居裕太, 笹田倫子, 大塚加奈子, Shoichiro Takao, Naoki Muguruma, Hirotsugu Yamada and Masataka Sata : 十二指腸壁内血腫の1例, 第23回日本超音波医学会四国地方会学術集会, Oct. 2013.
150.	山尾雅美, 西尾進, 鳥居裕太, 平田有紀奈, 藤岡啓介, Yumiko Kotani, Shoichiro Takao, Naoki Muguruma, Hirotsugu Yamada and Masataka Sata : カテーテル感染を契機に巨大脾腫をきたした一例, 第23回日本超音波医学会四国地方会学術集会, Oct. 2013.
151.	藤野泰輝, Naoki Muguruma, Koichi Okamoto, Shinji Kitamura, Hiromi Yano, 高岡遠, 岡崎潤, Takahiro Goji, Hiroshi Miyamoto, Toshiya Okahisa, Mitsuo Shimada and Tetsuji Takayama : 多発性小腸重積を生じたPeutz-Jeghers syndromeの1例, 第19回日本家族性腫瘍学会学術集会, Jul. 2013.
152.	高岡遠, 藤野泰輝, Koichi Okamoto, Shinji Kitamura, Naoki Muguruma and Tetsuji Takayama : SSA/P症例におけるAberrant crypt foci(ACF)の解析, 第79回大腸癌研究会, Jul. 2013.
153.	Shinji Kitamura, Naoki Muguruma and Tetsuji Takayama : 壮年者鳥肌胃炎の胃癌リスク-若年者と壮年者を比較して-, 第85回日本消化器内視鏡学会総会, May 2013.
154.	三好人正, Hiroshi Miyamoto, 三井康裕, Takahiro Goji, Hiromi Yano, Shinji Kitamura, Koichi Okamoto, Naoki Muguruma, Toshiya Okahisa and Tetsuji Takayama : DAO活性による抗癌剤投与時の消化管粘膜障害と栄養の関連, 第110回日本内科学会総会・講演会, Apr. 2013.
155.	宮本佳彦, Naoki Muguruma and Tetsuji Takayama : EGFRを標的とした大腸癌分子イメージング-蛍光標識抗EGFR抗体による診断と治療戦略-, 第9回日本消化管学会総会学術集会, Jan. 2013.
156.	岡田泰行, Hiroshi Miyamoto, Hiroshi Miyamoto, Tetsuo Kimura, Naoki Muguruma and Tetsuji Takayama : 大腸癌細胞におけるEGFR数及び各種遺伝子変異とcetuximabの有効性に関する検討, 第9回日本消化管学会総会学術集会, Jan. 2013.
157.	高岡遠, Toshiya Okahisa, 香川美和子, 岡田泰行, 宮本佳彦, 田中貴大, 津田美穂, 友成哲, Takahiro Goji, Hiromi Yano, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Tetsuji Takayama and Takahiro Emoto : 腸蠕動音測定による簡便かつ非侵襲的腸運動機能評価法の確立, 第9回日本消化管学会総会学術集会, Jan. 2013.
158.	Naoki Muguruma, Koichi Okamoto and Tetsuji Takayama : 大腸癌細胞のEpidermal Growth Factor Receptor (EGFR)を標的とした分子イメージング-抗EGFR抗体薬の効果予測と効果判定を含めて-, 第20回日本消化器関連学会週間, Oct. 2012.
159.	津田美穂, Koichi Okamoto, 高岡遠, Shinji Kitamura, 三宮勝隆, 青柳えりこ, 梶本真弓美, Naoki Muguruma, Toshiya Okahisa and Tetsuji Takayama : RAS阻害剤における大腸発癌予防効果の検討, 第71回日本癌学会学術総会, Sep. 2012.
160.	末内辰尚, Seisuke Okamura, 井本佳孝, 有田加奈子, 竹内尚, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, 藤本浩史, 廣瀬隆則 and Tetsuji Takayama : 胃perineuriomaの1例, 第83回日本消化器内視鏡学会総会, May 2012.
161.	Shinji Kitamura, Seisuke Okamura, Tetsuo Kimura, Tetsuo Kimura, Hiroshi Miyamoto, Naoki Muguruma, Toshiya Okahisa and Tetsuji Takayama : シュミレーターを用いたESDトレーニングシステムの試み, 第8回日本消化管学会総会学術集会, Feb. 2012.
162.	Jinsei Miyoshi, Hiroshi Miyamoto, 松本早代, Yasuteru Fujino, Takahiro Goji, Hiromi Yano, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Naoki Muguruma, Toshiya Okahisa, Seisuke Okamura, 山口想太郎, Yutaka Nakaya and Tetsuji Takayama : 消化管癌化学療法における血清Diamine Oxidase(DAO)活性と栄養障害に関する検討, 第8回日本消化管学会総会学術集会, Feb. 2012.
163.	Naoki Muguruma, Marcon Norman and Tetsuji Takayama : バレット食道がんにおける日本と欧米の違い-カナダでの臨床経験を中心に-, 第8回日本消化管学会総会学術集会, Feb. 2012.
164.	郷司敬洋, Tetsuo Kimura, 松本早代, 藤野泰輝, 三好人正, Shinji Kitamura, 矢野弘美, Koichi Okamoto, Hiroshi Miyamoto, 仁木美也子, Naoki Muguruma, Toshiya Okahisa, Seisuke Okamura and Tetsuji Takayama : CPT11+CDDP療法を施行した胃原発神経内分泌癌(NEC)の4例, 第49回日本癌治療学会学術集会, Oct. 2011.
165.	Shinji Kitamura, 青柳えり子, Takahiro Goji, Tetsuo Kimura, Hiromi Yano, Hiroshi Miyamoto, Naoki Muguruma, Toshiya Okahisa, Seisuke Okamura and Tetsuji Takayama : DNAマイクロアレイを用いたdocetaxel+cisplatin+S-1併用化学療法の治療効果予測, 第49回日本癌治療学会学術集会, Oct. 2011.
166.	Shinji Kitamura, 青柳えりこ, Tetsuo Kimura, Koichi Okamoto, 木村雅子, 矢野弘美, Hiroshi Miyamoto, Naoki Muguruma, Toshiya Okahisa, 仁木美也子 and Tetsuji Takayama : 進行胃癌に対するdocetaxel+cisplatin+S-1併用化学療法の効果予測因子の開発, 第9回日本臨床腫瘍学会学術集会, Jul. 2011.
167.	Naoki Muguruma : 消化管がん診断における光分子イメージングの現状と展望, 「医工連携をめざした生体光計測」フォーラム, Mar. 2011.
168.	Naoki Muguruma and Susumu Ito : 消化器領域における内視鏡的分子イメージング, 第28回日本レーザー医学会シンポジウム6「PDD&PDTをめぐる新たな展開」, Sep. 2007.
169.	井上尚兵, 木下陽子, 青柳えり子, Naoki Muguruma, Susumu Ito, Shigeki Sano and Yoshimitsu Nagao : 新規ICG-ATT誘導体を用いた蛋白質標識モデル実験, 日本薬学会第127年会, Mar. 2007.
170.	Seisuke Okamura, Naoki Muguruma, Hiroshi Miyamoto, 木村哲夫, 井本佳孝, 友兼毅, 梶雅子 and Susumu Ito : 第71回日本消化器内視鏡学会総会, Oct. 2006.
171.	井上尚兵, 木下陽子, Shigeki Sano, Naoki Muguruma, Susumu Ito and Yoshimitsu Nagao : 新規な蛋白質標識試薬の合成開発研究, 第7回長井長義記念シンポジウム, Sep. 2006.
172.	Seisuke Okamura, 木村哲夫, 板垣達三, 井本佳孝, 梶雅子, Hiroshi Miyamoto, Naoki Muguruma, Susumu Ito, 西岡将規 and Mitsuo Shimada : 輪状潰瘍瘢痕によるイレウス症状を呈した小腸結核の一例, 第85回日本消化器病学会四国支部例会, Jun. 2006.
173.	Seisuke Okamura, Naoki Muguruma, Hiroshi Miyamoto, 木村哲夫, 井本佳孝, 友兼毅, 梶雅子 and Susumu Ito : 把持鉗子を用いたマルチベンディング2CHスコープによるESD, 第85回日本消化器病学会四国支部例会, Jun. 2006.
174.	木村哲夫, Seisuke Okamura, 板垣達三, 井本佳孝, 梶雅子, 宮本弘志, Naoki Muguruma, Susumu Ito, 西岡将機規 and 島田光生 : 輪状潰瘍瘢痕によるイレウス症状を呈した小腸結核の1例, Jun. 2006.
175.	井本佳孝, Naoki Muguruma, 木村哲夫, 板垣達三, 梶雅子, 宮本弘志, Seisuke Okamura, Susumu Ito, 佐藤孝宣, 宮崎かつし and 中川伸一 : 甲状腺を貫通した魚骨による食道異物の1例, Jun. 2006.
176.	Seisuke Okamura, Hiroshi Miyamoto and Naoki Muguruma : よりスムーズなERCPを目指して, 第71回日本消化器内視鏡学会総会, May 2006.
177.	伊賀彰子, Masahiro Nomura, Naoki Muguruma, Toshiya Okahisa, Hiroshi Shibata, Seisuke Okamura, Hirohito Honda, Ichiro Shimizu, Susumu Ito and 和田哲 : 21世紀の高齢化社会に対応する消化器病診断·治療手技，(合同シンポジウム)高齢者における消化器内視鏡検査時の循環動態の検討, 第76回日本消化器病学会四国支部例会, 2001.

Et cetera, Workshop:

1.	梶雅子, Naoki Muguruma, 矢野弘美, 木村哲夫, 井本佳孝, 青木利佳, 佐藤康紀, 宮本弘志, 福野天, Seisuke Okamura and Susumu Ito : 完全内臓逆位症に併存した閉塞性黄疸に対し内視鏡的胆管ステント留置術を施した1例, Gastroenterological Endoscopy, Vol.48, No.3, 341-345, Jan. 2006.
2.	上村英子, Masahiro Nomura, 上原康三, 澤優子, 伊賀彰子, Naoki Muguruma, Seisuke Okamura, Hirohito Honda, Susumu Ito and 矢野充保 : 上部消化管内視鏡中における動脈硬化の循環動態への影響, 第45回日本老年学会, Jun. 2003. (Summary) 上部消化器内視鏡検査中の循環動態とPWVとの関連性を検討し，年齢よりもPWVによる動脈硬化の診断が，検査中の循環動態の変動の予測因子である．
3.	上村英子, Masahiro Nomura, 澤優子, 伊賀彰子, Naoki Muguruma, Toshiya Okahisa, Hiroshi Shibata, Seisuke Okamura, Hirohito Honda, Ichiro Shimizu, Susumu Ito and 矢野充保 : 上部消化器内視鏡検査における循環動態への影響:脈波伝播速度との関連性, 第65回日本消化器内視鏡学会総会, May 2003. (Summary) 上部消化器内視鏡検査中の循環動態とPWVとの関連性を検討し，年齢よりもPWVによる動脈硬化の診断が，検査中の循環動態の変動の予測因子である．
4.	上原康三, Masahiro Nomura, 上村英子, 澤優子, 伊賀彰子, 原田顕治, Naoki Muguruma, Toshiya Okahisa, Hiroshi Shibata, Seisuke Okamura, Hirohito Honda, Akiyoshi Nishikado, Ichiro Shimizu, Susumu Ito and 矢野充保 : 脈波伝播速度と上部内視鏡検査中の循環動態との関連性, 第5回日本高齢消化器医学会, Jan. 2003. (Summary) 上部消化器内視鏡検査中の循環動態とPWVとの関連性を検討し，年齢よりもPWVによる動脈硬化の診断が，検査中の循環動態の変動の予測因子である．
5.	伊賀彰子, Masahiro Nomura, 和田哲, Hiroshi Miyamoto, 久次米佐映, Naoki Muguruma, Toshiya Okahisa, Hiroshi Shibata, Seisuke Okamura, Hirohito Honda, Ichiro Shimizu and Susumu Ito : 消化器内視鏡下総胆管処置中の循環動態の検討, 第63回日本消化器内視鏡学会総会, Apr. 2002. (Summary) 内視鏡下総胆管処置中は自律神経活動のアンバランスとQT dispersionの増大がみられ，この自律神経活動が引き金となり偶発症へ進展する可能性が示唆された．
6.	Masahiro Nomura, 伊賀彰子, Naoki Muguruma, Toshiya Okahisa, Hiroshi Shibata, Seisuke Okamura, Ichiro Shimizu and Susumu Ito : 亜硝酸薬投与による胃運動および自律神経活動の反応:胃電図および血圧·心拍変動スペクトル解析による検討, DDW-Japan 2001, Oct. 2001. (Summary) 亜硝酸薬は，食後の胃運動機能の低下および副交感神経活動の低下および交感神経の増加をきたし，自律神経活動の点からも消化管運動を抑制する．
7.	森下智文, Masahiro Nomura, Naoki Muguruma, Seisuke Okamura, Hirohito Honda, Ichiro Shimizu and Susumu Ito : 老年者における内視鏡的逆行性胆管膵管造影検査時の自律神経活動の変動, 第43回日本老年医学会, Jun. 2001. (Summary) 老年者において内視鏡的逆行性胆管膵管造影検査時には，副交感神経の抑制と交感神経の亢進があり，心事故発生に注意すべきである．
8.	Masahiro Nomura, 森下智文, 名田智美, Naoki Muguruma, Toshiya Okahisa, Hiroshi Shibata, Seisuke Okamura, Hirohito Honda, Ichiro Shimizu and Susumu Ito : エパルレスタットの糖尿病性胃運動機能障害への効果:胃電図および心拍変動解析による評価, 第87回日本消化器病学会総会, Apr. 2001. (Summary) エパルレスタットは糖尿病性胃麻痺への詳細な効果は報告されてない．本薬剤により胃電図の3cpm波の増大および自律神経の改善がみられた．
9.	Masahiro Nomura, 名田智美, 加藤寛正, Naoki Muguruma, Toshiya Okahisa, Hiroshi Shibata, Seisuke Okamura, Hirohito Honda, Ichiro Shimizu, Susumu Ito, 多田由恵 and 矢野充保 : 上部消化管内視鏡検査により不整脈の発生素地は形成されるか?心電図QTc dispersionによる検討, DDW-Japan, Oct. 2000. (Summary) 上部消化管内視鏡検査中の心電図QTc dispersionの変動を測定した．内視鏡中，特に十二指腸挿入中にその変動が大きく，不整脈の発生素地は形成される．
10.	加藤寛正, Masahiro Nomura, 名田智美, Naoki Muguruma, Toshiya Okahisa, Hiroshi Shibata, Seisuke Okamura, Hirohito Honda, Ichiro Shimizu and Susumu Ito : 慢性消化性潰瘍におけるH. pylori除菌前後の自律神経機能の検討, DDW-Japan, Oct. 2000. (Summary) 消化性潰瘍の発生にはH. pyloriが重要であるが，除菌後も交感·副交感神経亢進が残存しており，潰瘍形成には自律神経異常も関与している．
11.	Masahiro Nomura, 宮島等, 名田智美, 森下智文, 木下桂午, 多田由恵, Naoki Muguruma, Toshiya Okahisa, Hiroshi Shibata, Seisuke Okamura, Hirohito Honda, Ichiro Shimizu, Susumu Ito and Yutaka Nakaya : 老年者における上部消化管内視鏡検査中の自律神経活動およびQTc dispersionの変動, 第25回老年消化器病研究討論会, Jun. 2000. (Summary) 老年者の上部消化管内視鏡検査中には副交感神経の抑制およびQTc dispersionの増大が壮年者より大きく老年者の検査中は循環動態に注意すべきである．
12.	宮島等, Masahiro Nomura, 名田智美, Naoki Muguruma, Toshiya Okahisa, Hiroshi Shibata, Seisuke Okamura, Hirohito Honda, Ichiro Shimizu and Susumu Ito : 老年者における上部消化管内視鏡検査中の心電図QT dispersionの推移, 第42回日本老年医学会, Jun. 2000. (Summary) 老年者の上部消化管内視鏡検査中に12誘導心電図を連続記録してQT dispersionを検討した．12指腸検査中は，著明に延長して不整脈に注意すべきである．
13.	宮島等, Masahiro Nomura, 名田智美, 近藤幸, 多田由恵, Naoki Muguruma, Toshiya Okahisa, Hiroshi Shibata, Seisuke Okamura, Hirohito Honda, Ichiro Shimizu, Susumu Ito, Masafumi Harada, Hiromu Nishitani and Yutaka Nakaya : 肝硬変症における胃運動機能の検討:食道静脈瘤と門脈血流との関連性について, 第2回国際消化管運動研究会, Apr. 2000. (Summary) 肝硬変症では，摂食による門脈血流量の増加率の減少がみられ，摂食による胃運動機能低下の成因の一つとして門脈血流異常が考えられた．
14.	宮島等, Masahiro Nomura, 名田智美, 多田由恵, Naoki Muguruma, Toshiya Okahisa, Hiroshi Shibata, Seisuke Okamura, Hirohito Honda, Ichiro Shimizu and Susumu Ito : 胃運動は食道静脈瘤の有無により影響をうけるのか?胃電図による検討, 第86回日本消化器病学会総会, Apr. 2000. (Summary) 食道静脈瘤のある肝硬変例では，門脈血流量が低下して，側副血行が増加しているため，胃電図で観察した胃運動の低下がみられた．
15.	宮島等, Masahiro Nomura, 近藤幸, 名田智美, 多田由恵, Naoki Muguruma, Toshiya Okahisa, Hiroshi Shibata, Seisuke Okamura, Hirohito Honda, Ichiro Shimizu, Susumu Ito, 山口康男 and Masafumi Harada : 肝硬変症における胃運動機能の検討:自律神経機能および門脈血流量との関連性について, DDW-Japan 1999, Oct. 1999. (Summary) 門脈MRA，胃電図および心拍変動解析で検討した．肝硬変では，交感神経活動と門脈血流の低下による側副血流の増加により胃運動が低下すると思われた．
16.	川口律子, Masahiro Nomura, 宮島等, 名田智美, 多田由恵, Naoki Muguruma, Toshiya Okahisa, Hiroshi Shibata, Seisuke Okamura, Hirohito Honda, Ichiro Shimizu and Susumu Ito : 胃電図および心拍変動解析を用いた高齢者の食後低血圧の検討:若年者との比較, DDW-Japan 1999, Oct. 1999. (Summary) 食後低血圧の発生機序を胃電図により検討した．老年者では若年者よりも胃運動が低下していたが，自律神経の変動に対応できないため低血圧がおこる．
17.	多田由恵, Masahiro Nomura, 多田津昌也, 日下至弘, 大喜田義雄, 筒井朱美, Naoki Muguruma, Toshiya Okahisa, Seisuke Okamura, Ken Saito and Susumu Ito : 内視鏡的逆行性胆管膵管造影検査施行時における自律神経活動, 第57回日本消化器内視鏡学会総会, May 1999. (Summary) 内視鏡的逆行性胆管膵管造影検査施行時において，胆道内圧の亢進による副交感神経の抑制がみられ，循環動態の変動がみられやすいと考えられた．

Report:

1.	長瀬襟加, 鳥居裕太, 西尾進, 平田有紀奈, 山尾雅美, Seiji Iwamoto, Hirotsugu Yamada, Naoki Muguruma and Masataka Sata : 好酸球性胆管炎の1例, 超音波検査技術, Vol.41, No.1, 128, Feb. 2016.
2.	Seisuke Okamura, 木村哲夫, 矢野弘美, 井本佳孝, 梶雅子, 青木利佳, 佐藤康紀, Hiroshi Miyamoto, Naoki Muguruma, Susumu Ito, Michiko Yamashita, Toshiaki Sano, 池本哲也, Masahiko Fujii and Hidenori Miyake : 膵管内発育を主とし特異な形態を呈した膵腺房細胞癌の1例, 消化器画像, Vol.9, No.1, 41-46, Jan. 2007.
3.	Seisuke Okamura, Toshiaki Sano, 木村哲夫, 矢野弘美, 井本佳孝, 梶雅子, 青木利佳, 佐藤康紀, Hiroshi Miyamoto, Naoki Muguruma, Susumu Ito, Atsushi Umemoto, 下田忠和 and 春藤譲治 : 嚢胞変性により特異な形態を呈した胃GISTの1例, 胃と腸, Vol.41, No.5, 844-850, Tokyo, 2006.
4.	Seisuke Okamura, Koji Tsujigami, Naoki Muguruma, Susumu Ito, Shingo Wakatsuki, Toshiaki Sano, Atsushi Umemoto and Yoshihito Urakami : Jejunal extramedullary plasmacytoma, GASTROINTESTINAL ENDOSCOPY, Vol.61, No.1, 107-108, Jan. 2005.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

鋸歯状ポリポーシス症候群の左側及び右側大腸癌の分子生物学的差異の解析 (Project/Area Number: 22K07986 )
プロテインアレイを用いた肝細胞癌に対するレンバチニブの新たなバイオマーカーの解明 (Project/Area Number: 21K07964 )
Photoimmunotherapy targeting pancreatic cancer stem cell (Project/Area Number: 20K08387 )
Elucidation of carcinogenic mechanism for serrated polyposis syndrome (Project/Area Number: 19K08471 )
Significance of EGR1 as the new response predictors of chemotherapy for gastric cancer (Project/Area Number: 18K08006 )
Immunophoto therapy targeting cancer stem cell in colorectal cancer (Project/Area Number: 17K09385 )
Development of chemopreventive agents using Connectivity Map analysis (Project/Area Number: 17H04163 )
Development of new colorectal cancer treatment targeting p62 (Project/Area Number: 16K09313 )
大腸がんリンパ節転移の分子機構の解明及びリンパ節転移術前予測マーカーの開発 (Project/Area Number: 15K09059 )
Development of a novel high sensitivity molecular imaging for ACF (Project/Area Number: 26293176 )
In vivo molecular imaging targeting epidermal growth factor receptor in detection for colorectal cancer developed in ulcerative colitis (Project/Area Number: 25461034 )
赤外線蛍光内視鏡診断のための赤外蛍光増強剤の開発 (Project/Area Number: 15659173 )
Study on the vascular structure of esophagial varices using infrared fluorescent endoscopy (Project/Area Number: 12670492 )
Search by Researcher Number (90325283)